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Abstract 
Breast cancer is the most common cancer in the UK with the second highest cancer 
mortality rate for women. Primary tumours can be successfully treated locally 
through surgery and adjuvant chemotherapy or hormone therapy. However, it is 
the recurrence of, often chemoresistant, metastatic tumours at distant sites in the 
body that are the leading cause of breast cancer mortality.  Breast cancers 
preferentially metastasise to bone.  Once in the skeleton, breast cancer cells 
produce factors that influence the cells of the bone including osteoclasts and 
osteoblasts inducing osteolytic lesions.  Due to the high mortality rate observed in 
metastatic breast cancer, there is a real need to identify the molecular mechanisms 
through which tumour cells escape the primary tumour and to establish novel drug 
targets for the prevention and  treatment of metastatic breast cancer. IκB kinase 
subunit epsilon (IKKε), a key component of NFκB and IRF signalling, has been 
shown to act as a breast cancer oncogene However, its role in the development and 
progression of breast cancer osteolytic metastasis has yet to be elucidated.  Here, 
I have shown  breast cancer specific knockdown in triple negative human MDA-
MB-231-BT cells reduced skeletal tumour growth and subsequent osteolytic bone 
damage, similarly the IKKε/TBK-1 inhibitor, Amlexanox reduced tumour growth 
and osteolysis in the 4T1 mouse model of breast cancer. I have demonstrated 
through functional and mechanistic studies that IKKε/TBK-1contribute to the 
ability of osteotropic MDA-MB-231 cells to proliferate, move and enhance 
osteoclast formation through the activation of the IRF3 and NFκB signalling 
pathways. Furthermore, combined treatment of Amlexanox and Docetaxel in the 
neo-adjuvant setting in mice reduced primary breast tumour growth of syngeneic 
breast cancer cells and inhibited metastasis and prolonged metastasis-free 
survival. Thus IKK/TBK-1 inhibition shows great promise for the treatment of 
primary and skeletal tumour burden in advanced breast cancer  
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Figure 1. Targeting of IKKε, alone and in combination with conventional chemotherapies, may show promise for all stages of breast cancer.  
Therapeutic targeting of IKKε in the bone microenvironment using knockdown or Amlexanox reduces skeletal tumour growth of breast cancer cells, 
osteolysis and reduces osteoclast formation. Combined administration of Amlexanox and Docetaxel in the neoadjuvant setting reduces primary 
growth, metastasis and improves survival. Targeting of IKKε, alone and in combination with conventional chemotherapies, may show promise for 
all stages of breast cancer.   
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1 Introduction 
1.1 Breast cancer  
Breast cancer is the most common cancer in the United Kigdom (UK) (Office for 
National Statistics, 2014). It is estimated that 1 in 8 women will develop breast 
cancer throughout their lives.  Despite improved methods of early detection and 
treatment, breast cancer represents the second most common cause of cancer death 
in women, with 12,000 deaths in the UK associated with the disease in 2010 
(Office for National Statistics, 2014).  
 
1.1.1 Breast Cancer Risk Factors 
Several studies carried out over the past few decades have identified various risk 
factors associated with initial breast cancer development, reviewed extensively by 
(Ciriello et al., 2013, Kerlikowske et al., 2017). These risk factors can be broadly 
divided into intrinsic and extrinsic factors that influence the disease. Intrinsic 
factors include sex, age, genetic background and age at onset of menarche and 
menopause, whereas extrinsic risk factors include high fat diet, high alcohol 
consumption and intake of exogenous sex hormones. Many of said factors are 
linked to estrogen exposure, a class of female sex hormones associated with 
disease initiation and progression. Estrogen binding to its receptor induces cellular 
proliferation and thus may drive mammary epithelial cells through the cell cycle 
to continue dividing (Hilakivi-Clarke et al., 2002).  
 
1.1.2 Pathology of Invasive Breast Cancer 
Invasive breast cancer is not regarded as a singular disease but in fact a diverse 
group of lesions with varying molecular characteristics, prognoses and treatment 
options.  Breast cancers are mostly carcinomas, specifically adenocarcinomas 
arising from the mammary glandular epithelia. Breast carcinomas usually start as 
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a local hyperplastic disease known as carcinoma in situ. Division of breast 
carcinomas in to histological classifications is based upon both growth and 
cytological features whereas further subdivisions are assigned by molecular 
characteristics. Specific classifications have been devised in order to predict 
progression and response to treatment (Malhotra et al., 2010). 
 
1.1.3 Histological Grading of Tumours  
Following recognition of a histological type, breast cancers are assigned a 
histological grade. The Nottingham Prognostic Index (NPI) is the most 
widespread system in use in the clinic (Rakha et al., 2014). The NPI assigns a 
value of one to three, to three characteristics of normal breast tissue: tubule 
formation, nuclear grade and mitotic rate. Breast tissue is arranged as tubular 
glands, thus tumours with loss of this structure are given higher scores. Nuclear 
grade considers changes in cell size and uniformity, less uniformity in the cells is 
related to higher grades. Mitotic rate is defined by the number of mitotic figures 
in ten high power fields, where mitotic figures are the chromosomes seen as a dark 
threadlike tangle.  More mitotic figures correlate with a higher grade. The overall 
values are calculated and those with scores of three to five are described as grade 
1, scores of six and seven are grade 2 and grade 3 tumours have a score of eight or 
nine. The grading of tumours is indicative of prognosis, whereby a higher grade 
has a less favourable outcome.  
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1.1.4 Estrogen Receptor, Progesterone Receptor and HER2 Protein Status 
Standard practice in the assessment of breast tumours is the screening of tumours 
for expression of oestrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2).  This is due to the development of 
targeted treatments against these proteins (Allison, 2012). ER and PR are 
expressed in up to 70% and 65% of all breast carcinomas respectively. Although 
they are not necessarily strong prognostic markers, tumours that express ER/PR 
have the best response to hormone therapy such as tamoxifen and aromatase 
inhibitors. HER2 is an oncogene that codes for a tyrosine kinase receptor, which 
regulates processes involved in proliferation, survival and invasion of cells. 
Identification of HER2 overexpression led to the development of HER2-targeted 
treatment, Herceptin. The combined treatment of Herceptin with  standard 
chemotherapy (doxorubicin) improved survival rates of patients by 8.8% above 
doxorubicin alone after 10 years (Perez et al., 2011). A third histological type of 
breast cancer is represented by those lacking the aforementioned receptors known 
as triple negative breast cancers. As such, these breast cancers lack known 
druggable targets and such have a poor prognosis (Negi et al., 2016). Moreover, 
recent evidence indicates that a triple negative breast cancer subtype exists that 
expresses the androgen receptor and as such has been deemed the luminal 
androgen receptor (LAR) subtype (Lehmann et al., 2011).  Patients with LAR 
breast cancer exhibit decreased relapse-free survival, however on-going clinical 
trials suggest that these patients benefit from anti-androgen therapy (Barton et al., 
2016). The development of new targeted treatments for triple negative breast 
cancers is an unmet clinical need.  
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1.1.5 Molecular Subtypes of Invasive Breast Cancer 
With the development of gene profiling technologies, six molecular subtypes of 
invasive breast carcinoma have been identified with varying outlooks, treatments 
options and overall rate of survival (Perou et al., 2000, Prat and Perou, 2010, 
Yersal and Barutca, 2014). These classifications were deemed as: luminal-A, 
luminal-B, HER2 enriched, normal breast-like, basal-like and claudin-low (Table 
1). It should be noted that, there is some disagreement over the existence of 
normal-like breast cancers; some researchers have stated that this classification is 
actually an artefact due to high contamination of normal tissue in tumour samples 
(Weigelt et al., 2010). The characterisation of breast carcinomas into molecular 
subtypes improves the definition of prognostic signatures and tumour specific 
treatments. 
Table 1. Molecular taxonomy of invasive breast cancer and their characteristics  
(Malhotra et al., 2010) 
Subtype Prevalence Molecular profile 
Prognosis 
Luminal-A ~40% ERhigh, HER2low 
Good prognosis. 
Luminal-B ~20% 
ERlow, HER2low, 
high proliferation 
Favourable 
prognosis 
HER2 
enriched 
10-15% HER2high, ER/PR- 
Poor prognosis 
Normal like 8% 
Increased adipose gene signature, ER-, 
PR-, HER2-, 
Poor prognosis 
Basal-like 15-20% 
ER-, PR-, HER2-, 
cytokeratin5/14+, laminin+, EGFR+ 
Poor prognosis 
Claudin-Low 12-14% 
ER-, Claudins 3/4/7low, vimentin+, E-
cadherinlow, occludinslow, Zeb1+ 
Poor prognosis 
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1.1.6 Metastatic Breast Cancer 
The vast majority of deaths from breast cancer are not due to the primary tumour 
but to the development of metastasis at distal sites in the body. Around 10-15% of 
breast cancer patients develop metastases within 3 years of initial disease detection 
(Weigelt et al., 2005). Furthermore, it is not uncommon for patients to develop 
secondary metastases 10 or more years after initial diagnoses (Weigelt et al., 
2005). Breast cancer metastases have been recorded in all organs of the body with 
secondary tumours developing concomitantly at multiple locations. Breast cancers 
appear to preferentially metastasise to bone followed by the liver, pleura, lung, 
adrenal glands and brain (Coleman and Rubens, 1987). Many breast cancer 
patients will always be at risk of secondary cancers, thus it is necessary to identify 
targets within the tumour and the new niche that drive metastasis in order to 
develop new potential therapies.  
 
1.1.7 The Metastatic Process 
The idea that cancers spread to  specific secondary sites has been around since the 
turn of the  19th century, in which Stephen Paget suggested the ‘seed and 
soil ’hypothesis (Paget, 1989). This hypothesis denotes that  in certain cancers, the 
seeds, are  primed to metastasise to  particular  organs, the soil,  due to their ‘fertile’ 
conditions that permit them to proliferate.  
Progression to metastasis and the subsequent development of secondary tumours 
can be considered as a stepwise set of events (Nguyen et al., 2009). Genomic 
instability in cancer cells may lead to the expression of gene sets that ensure 
metastatic competence of certain cells and progression through the metastatic 
steps: invasion of local tissues; intravasation and survival in the circulation; 
extravasation of the circulation followed by organ-specific colonisation (Figure 2). 
   
Metastasis initiating genes are those that facilitate cell motility and extracellular 
matrix degradation, epithelial-to-mesenchymal transition (EMT – the process by 
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which cells change from a epithelial-like cell to an invasive mesenchymal-like 
cell) and evasion of the immune system (Nguyen and Massagué, 2007). For 
example, in breast carcinoma gain of metadherin and N-cadherin, induce EMT and 
thus enhances invasion (Li et al., 2011). Metastasis progression genes enable 
extravasation and aid survival in a new niche. Examples of such in breast cancer 
include COX2, LOX, MMP1, and epiregulin (Gupta et al., 2007).  The third class 
of metastatic genes has been deemed metastatic virulence genes (Nguyen and 
Massagué, 2007). These types of genes provide disseminated cancer cells with the 
ability to colonize specific organs. Additionally recent evidence suggests that 
tumour derived exosomes, 30-50nm membranous vesicles that contain protein, 
RNA, DNA and lipids are able to prime the metastatic niche and determine 
organotropism of cancers. Hoshino and colleagues (2015) demonstrated that 
exosomes from cancer cells with specific organotropism were specifically taken 
up by cells in their respective preferential secondary sites. Furthermore, they 
showed that pretreatment of mice with exosomes could redirect cancer cells to 
organs that they were unable to previously colonise. In addition, it was established 
that exosomal expression of integrins facilitated their organotropism, as 
knockdown of integrin β4 reduced lung metastasis of cancer cells. Exosomes once 
in the metastatic niche activated the Src-S100 pathway to induce an inflammatory 
environment and promote metastasis (Hoshino et al., 2015). 
 
Following a period of latency, in which cancer cells survive, often undetected as 
single cells or micrometastases, in the new niche, the disseminated tumour cells 
reacquire an aggressive proliferative phenotype and reinitiate growth such that 
clinically detectable metastases are visible (Nguyen et al., 2009). In addition, it is 
often the case that metastatic disease is associated with resistance to therapeutics 
and increased morbidity. 
  
8 
 
Figure 2. Schematic diagram of tumourigenesis and the metastatic process. 
Cancer cells gain a proliferative advantage over healthy cells. Enhanced proliferation leads to growth of primary tumour Hypoxia and inflammation 
induce cytokine production and angiogenesis. Gain of metastasis initiating genes leads to EMT and increase invasive capacity. Invasion is promoted 
by cytokines and facilitated by ECM remodelling proteins. Release of exosomes from the primary tumour promote organotropism. Circulating 
tumour cells (CTCs) survive in the vasculature through expression of metastasis progression gene sets. Upon arrival and arrest in the vasculature of 
the secondary organ. CTCs may undergo a period of dormancy and upon reactivation and the expression of metastasis virulence genes colonize the 
secondary organs. See text in section 1.1.7.  
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1.1.8 Patterns of  breast cancer metastasis 
Breast cancers with particular molecular patterns have characteristic sites to which 
they metastasise.  Characteristics that have been shown to affect the pattern of 
disseminated disease include hormone receptor status, tumour grade and 
histological type. A lower histological grade has been associated with the 
increased frequency of pleural metastatic lesions, whereas a higher grade is 
associated with a shorter metastasis-free survival and lesions in the lung and liver. 
In addition, it has been shown that different subgroups of breast cancer have 
different patterns of spread (Wu et al., 2017)(Figure 3).  ER+ disease (Luminal 
A/B) have the highest skeletal involvement (A – 58.52%, B- 47.28%) and the 
lowest brain involvement (A - 4.30%; B - 5.89%).  HER2-enriched tumours 
metastasise more frequently to the skeleton and the liver (34.49% and 31.72%) 
followed by lung and brain (25.48% and 8.31%).  Triple negative breast cancers 
metastasise commonly to bone followed by lung and liver (36.39%, 32.09% and 
22.40%). TNBCs also have the highest proportion of breast cancer patients 
developing brain metastases at 9.12% (Wu et al., 2017).  
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Figure 3. Patterns of breast cancer metastatic dissemination. 
Localised primary breast cancer has a favourable prognosis if caught at an early stage. However, breast cancer cells can enter the circulatory or the lymphatic 
systems and metastasise to the lymph nodes (yellow nodes) Breast cancers also metastasise to distant sites, primarily bone, liver, lung and brain, which, at this stage 
is incurable. Breast cancers frequently metastasise to the bone. This is more commonly associated with ER+ disease. TNBCs more frequently metastasise to lung 
followed by bone. Data taken from (Wu et al., 2017).  
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1.2 Bone  
The skeleton has a multitude of functions in vertebrates, which includes: acting 
as a scaffold for muscles; protection for organs and marrow; storage and release 
of ions and growth factors from its matrix; and regulation and release of 
haematopoietic cells. The skeleton is a dynamic organ that is constantly broken 
down and replaced by the cells of the bone. Many of the cells in the bone are 
derived from either mesenchymal or haemopoeitic progenitor cells. The 
mesenchymal progenitors can give rise to osteoblasts, chondrocytes, 
adipocytes, myocytes and endothelial cells. The osteoclast is formed following 
the fusion of bone marrow resident macrophages and are derived from myeloid 
progenitor cells of the haematopoietic lineage (Figure 4).  
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Figure 4. Cells of the bone and their lineage. 
Mesenchymal progenitor cells differentiate into various cells including myocytes, chondrocytes, adipocytes, endothelial cells and osteoblasts. Osteoblasts, 
the bone forming cells, lay down osteoid and then can become embedded in the bone matrix and become osteocytes. Osteoclasts, the cells that remove bone, 
are formed following the fusion of macrophage precursors of myeloid lineage. See section 1.2 for details.  
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1.2.1 Bone remodelling  
Much of the adult skeleton is covered by quiescent bone lining cells. These cells 
lie over a layer of mineralised and generally quiescent bone. Following micro-
damage or mechanical stress, osteoclast precursors and mature osteoclasts 
travel to the area where resorption is required. This process of bone remodelling 
serves to remove and replace old or damaged bone in the adult skeleton. Bone 
resorption phase has a median duration of 30 days whereas bone formation last 
for up to 3 months (Eriksen, 2010). 
This process is initiated by the removal of old/damaged bone by mature 
resorbing osteoclasts. Mature osteoblasts migrate to these resorption pits and 
lay down layers of unmineralised bone, known as osteoid, after around seven 
days this matrix becomes mineralised following the influence of Vitamin D-3 
and other factors. A fraction of these osteoblasts become implanted within the 
osteoid matrix and remain there as osteocytes. Osteocytes have dendritic 
extensions on their surface, which interconnect through channels within the 
bone. Through these connections, the osteocytes/osteoblasts sense mechanical 
strains, which regulates bone remodelling. 
1.2.1.1 Bone resorption 
The initial phase of the bone remodelling cycle involves a multitude of cells in 
the bone marrow including osteocytes, osteoblasts and lining cells. (Hadjidakis 
and Androulakis, 2006). Many researchers have suggested that osteocytes 
embedded within the mineralised matrix instruct osteoblasts and lining cells to 
secrete MMPs, collagenases and gelatinases that in turn break down the 
mineralised layer, thereby facilitating the migration of osteoclasts and their 
precursors to the remodelling site. (Lerner, 2000; Suda et al., 1997; Manolagas, 
2000; Troen, 2003). In addition, osteoclast precursors are drawn to the site of 
resorption by bone-derived factors such as TGFβ, type-1 collagen and 
osteocalcin (Suda et al., 1997). 
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The proliferation of osteoclast precursors and their subsequent fusion into 
multinucleated active osteoclasts is controlled by the main osteoclastic factors, 
RANKL and MCSF (Weir et al., 1993; Sarma and Flanagan, 1996; Morohashi 
et al., 1994 and the decoy RANKL receptor, osteoprotegerin (OPG), produced 
by osteocyte sand osteoblasts and lining cells (Nakashima et al., 2011 Proff and 
Romer, 2009; Boyce and Xing, 2008, Hsu et al., 1999).  
In response to these factors, osteoclasts utilise proteins of the integrin 
superfamily, specifically  the αVβ3 vitronectin receptor  to attach to  proteins 
such as vitronection, collagen type I and fibronectin exposed on the mineralised 
bone surface (Lakkakorpi et al., 1991). Following adhesion to the extracellular 
matrix of the bone, the osteoclast membrane becomes polarised in order to form 
specialised organelles known as podosomes. This allows the formation of an 
actin ring (Lakkakorpi et al., 1991; Hill, 1998).The structure of the actin ring 
allows for an intimate binding of the active osteoclast to the surface of the bone, 
surrounding an isolated region of bone called  Howship’s lacuna or the sealing 
zone (Roodman, 1996). Inside the sealing zone, the ruffled border of the 
osteoclast allows for the secretion of protons and chloride ions (Teti et al., 1989; 
Schaller et al., 2005). This creates a localised low pH environment which aids 
the demineralisation and degradation of the bone matrix. Hydroxyapatite 
crystals are then converted in to Ca2+, HPO4
2- and water in the process (Bar-
Shavit, 2007). Subsequently, the organic bone matrix is exposed, which is 
degraded following the release of vesicles containing cathepsin K, active at low 
pH, which digest collagen type I, thus removing the organic component of bone 
(Teitelbaum, 2000; Blair et al., 1989;(Garnero et al., 1998). Additionally, 
MMP9 removes organic bone matrix outside the acidic ruffled border (Everts 
et al., 1992). Once degraded, the organic and inorganic components of the bone 
are endocytosed at the ruffled border membrane, transported through the cell in 
vesicles and then secreted in to the extracellular space (Vaananen and Laitala-
Leinonen, 2008).  Once the bone resorption process is complete, osteoclasts 
undergo apoptosis and are subsequently and readily removed by phagocytes.  
(Hill, 1998).  
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1.2.1.2 Bone formation 
In the latter stage of the bone remodeling cycle, osteoblast precursors are 
recruited to the site of resorption in which new bone is deposited.  The release 
of chemotactic agents, such as osteocalcin (OCN), TGF-β, IGF-1 and collagen 
type I  are released from the bone matrix during resorption which promotes the 
migration of pre-osteoblasts to the site of resorption. (Mundy et al., 1982, 
Lerner, 2006). On arrival at the resorbed site, the osteoblast progenitors 
proliferate and differentiate in to mature osteoblasts. The maturation process is 
also mediated by bone-derived factors released during resorption including 
IGF-1 and 2, FGFs, TGFβ, Bone morphogenic protein 2 (BMP2), and platelet-
derived growth factors (PDGFs) (Hill, 1998). Mature osteoblasts produce 
collagen type I along with OCN, osteopontin (OPN), bone sialoprotein (BSP), 
osteonectin (OSN) and proteoglycans which collectively form the 
unmineralised bone matrix known as osteoid (Ducy, 2000; Mackie, 2003; 
Katagiri and Takahashi, 2002). Alkaline phosphatase (ALP), is also produced 
and secreted by osteoblasts, which functions to degrade  proteins such as 
pyrophosphate that inhibit mineralisation. In addition to these factors, 
osteoblasts also release matrix vesicles at sites within the osteoid. Matrix 
vesicles are membrane bodies which contain proteins, acidic phospholipids, 
phosphate and calcium that prompt the formation of hydroxyapatite crystals. 
One such highly phosphorylated protein that regulates the formation of 
hydroxyapatite is BSP. Expression of BSP is limited to actively mineralising 
bone and has been shown to nucleate hydroxyapatite crystals at nano-molar 
concentration under steady-state conditions (Hunter and Goldberg, 1993, Tye 
et al., 2003). Deposition of hydroxyapatite induces the conversions of osteoid 
into mineralised matrix, thus ensuring bones rigidity and strength (Katagiri and 
Takahashi, 2002; Murray J.Favus, 2006).  
Currently, the mechanisms by which bone deposition is terminated are not fully 
understood. Thus far two mechanisms have been hypothesised. One postulated 
mechanism involves the release of sclerostin (SOST) by osteocytes. SOST is a 
negative regulator of bone formation. It inhibits osteoblast activity whilst also 
inducing the transition of osteoblasts in to quiescent lining cells (Sutherland et 
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al., 2004). A second mechanism may be that bone deposition is terminated 
following the osteoblasts apoptosis initiated by bone-derived factors. In humans 
the bone formation phase lasts around three months and ends with up to 65% 
of osteoblasts undergoing apoptosis (Jilka et al., 1998).  
The remaining osteoblasts are either converted in to lining cells that cover the 
majority of the quiescent bone  or they become buried within the new bone 
matrix and become osteocytes (Murray J.Favus, 2006).  
1.2.2 Metastasis to Bone 
Approximately, 70% of all advanced breast cancer cases develop metastases in 
one or more bone sites (Manders et al., 2006) .  Breast cancer bone metastases 
are coupled with osteolysis (breakdown of the bone), bone pain, fragility, 
hypercalcaemia and deformity (Guise, 2000). The osseous microenvironment 
provides a unique setting in which a plethora of cell types from multiple 
lineages exist. The bone contains cells of a mesenchymal lineage; 
chondrocytes, endothelial cells, adipocytes osteoblasts and osteocytes, in 
addition to cells of the haemopoeitic lineage such as macrophages, osteoclasts, 
T- and B-cells and also cells of a vascular nature such as pericytes and endosteal 
cells (Krzeszinski and Wan, 2015). Cancer cells influence cells of the bone in 
two main ways (Yin et al., 2005).  Arrival of cancer cells within the bone leads 
to the formation of osteolytic lesions following an increase in the formation and 
activity of osteoclasts, resulting in bone resorption. In normal physiological 
conditions, there is no net difference in bone formation and bone resorption. 
However, in osteolytic bone metastases, increased cancer cell induced-
osteoclastic bone resorption exceeds inherent bone remodelling by osteoblasts 
resulting in the loss of mineralised tissue (Krzeszinski and Wan, 2015). 
Comparatively, cancer cells can also enhance the bone forming abilities of 
osteoblasts culminating in osteoblastic metastatic lesions. These lesions, 
although occuring through the enhanced formation of bone and are weak, due 
to the disorganised bone growth, which leads to fracture development. The 
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development of osteolytic or osteoblastic metastases is not mutually exclusive 
and individuals with bone metastases may possess both.  
 
1.2.2.1 Tumour cell dormancy 
Dissemination of tumour cells to the bone microenvironment is believed to 
occur early in the metastatic process (Braun et al., 2000). Disseminated tumour 
cells (DTCs) compete with haematopoietic stem cells (HSCs) to adhere to the 
endosteal niche (Shiozawa et al., 2011), the perivascular niche or the HSC 
niche . DTCs have been shown to remain in the bone marrow for years and even 
decades (Braun et al., 2000). Evidence suggests DTCs remain in the pre-
metastatic niche in a dormant quiescent state resistant to cytotoxic therapies 
(Shiozawa et al., 2010). 
 
1.2.2.2  Osteolytic Metastases 
Tumour cells that have colonised the bone induce the formation of osteolytic 
lesions through the secretion of factors that act directly on osteoclasts and their 
precursors or indirectly on osteoblasts to enhance osteoclastogenesis and later 
activity.  These factors include a plethora of cytokines including ILs, TNFα, 
MCS-F, VEGF, MMPs, IGF-1, TGF-β and parathyroid hormone related protein 
(PTHrP)(Ibrahim et al., 2010; Rose and Siegel, 2006). A number of these 
secreted factors induce osteoclast formation directly by stimulating osteoclast 
precursors and mature resorbing osteoclasts (e.g. TNFα and MCS-F) whilst 
others act on osteoblasts to enhance the production of RANKL and other 
osteoclastic cytokines and reduce the production of factors that inhibit 
osteoclast formation (Thomas et al., 1999; Ohshiba et al., 2003  IL-1, IL-8, IL-
11, TNFα and M-CSF all directly promote osteoclast differentiation, function 
and survival whereas other factors such as IL-1, IL-6 and TGFβ indirectly 
induce osteoclast formation by stimulating the release of factors such as PTHrP 
and  (PGE) that enhance RANKL production by osteoblasts (Guise, 2002). 
PTHrP is a highly studied secreted factor and has been demonstrated to induce 
osteolysis by increasing the production of RANKL by osteoblasts whilst 
simultaneously reducing the production of OPG (Thomas et al., 1999; Karaplis 
and Goltzman, 2000). 
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Arrival of malignant cancer cells, disturbs the normal bone remodelling process 
and ultimately leads to osteolysis and bone loss. As a consequence of the 
increased bone resorption stored growth factors such as IGFs, TGF-β and BMPs 
are freed from the bone matrix into the tumour-bone microenvironment. These 
factors act on the tumour cells to enhance survival, proliferation and migration 
(Guise et al., 2006). The high levels of extracellular calcium, coupled with the 
hospitable acidic local environment stimulate the growth of tumour cells 
through activation of the MAP kinase pathways (Guise et al., 2006) and 
augment the cancer cell production and secretion of PTHrP. Additionally, the 
reduction in trabecular bone enhances tumour burden by providing the tumour 
cells the space to grow (Guise et al., 2006). 
 
Collectively, the vicious cycle involves the tumour cells entering the bone 
microenvironment and after a period of dormancy, perturbing the balance of 
bone remodelling, in favour of destruction of the bone (Figure 5). The enhanced 
bone resorption  releases factors stored within the bone matrix and induces the 
proliferation of the tumour cells. Ultimately, the growth of the tumour cells 
leads to more osteoclast formation and destruction of the bone until 
progressively more and more bone is lost and the tumour burden worsens.  The 
observation that breast carcinomas are highly bone tropic and osteolytic in 
nature is well documented, thus it is necessary to identify cancer-specific 
drivers of metastases in order to significantly reduce the development of 
metastatic disease. 
1.2.2.3 Osteoblastic bone metastasis 
 Osteoblastic lesions are induced by the excessive stimulation of osteoblast 
activity that culminates in the formation of disorganized and weak new bone 
(Guise et al., 2006). Many osteoblastic bone metastases have areas of both 
osteoblastic and osteolytic lesions with recent evidence from the clinic 
indicating that both processes contribute to the phenotype in the same patient 
(Mundy, 2002; Keller and Brown, 2004). Osteoblasts produce the main 
osteoclastic cytokines RANKL and MCSF and a significant increase in the 
number of mature osteoblasts leads to an increase in osteoclast number with a 
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resulting increase in bone resorption with bone formation. The development 
and regulation of bone is modulated by a number of complex endocrine and 
paracrine factors such as urokinase plasminogen activator (uPA), Wnt 
signalling factors and endothelin-1 (ET-1).  These factors are involved in the 
regulation of osteoblasts by modulating their proliferation, differentiation and 
activity. These same factors that regulate normal bone physiology are also 
involved in the development of osteoblastic lesions (Guise et al., 2006; Mundy, 
2002; Logothetis and Lin, 2005).  Cancer cells that metastasise to bone produce 
these factors that directly stimulate the proliferation and enhanced activity of 
osteoblasts or these cancer cells can indirectly influence bone formation by 
modifying the bone matrix and microenvironment.  
ET-1 and IGF-1 are two heavily studied factors in the process of osteoblastic 
metastases. Both of which are known to directly stimulate the proliferation and 
function of osteoblasts. Additionally ET-1 has been shown to reduce osteoblast 
apoptosis (Van et al., 2007).  The exact mechanisms through which ET-1 
stimulates bone formation is unknown, however, some studies have shown ET-
1 leads to the nuclear translocation of the pro-survival factor NFATc1 (Van 
Sant et al., 2007). Moreover, ET-1 has previously shown to both reduce 
osteoclast formation and motility (Alam et al., 1992). BMPs and TGF-β directly 
stimulate osteoblast activity, whilst uPA activates TGF-β and IGF-1 release 
from IGF binding proteins ultimately stimulates osteoblasts activity (Guise et 
al., 2006; Guise, 2002; Papachristou et al., 2012). IGF-1 has been shown to 
stimulate both the MAPK and PI3K/AKT signalling pathways in osteoblasts 
and increase the expression of RUNX2, the master regulator of 
osteoblastogenesis, in osteoblast precursors. Selective inhibition of the IGF-1 
receptor with the pharmacological inhibitor, PQIP was shown to reduce 
RANKL/OPG ratio in IGF-1 stimulated osteoblasts, prevent their ability to 
induce osteoclast formation and also reduced breast cancer induced osteolysis 
in vivo (Logan et al., 2013). Additionally, tumour derived VEGF has been 
shown to promote osteoblast activity and osteoblastic lesions (Dai et al., 2004). 
Furthermore, recent phase III clinical trials indicate that inhibition of VEGFR2 
and c-Met with the dual inhibitor cabozantinib modestly improved overall 
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survival in previously treated metastatic prostate cancer patients (Pond et al., 
2018).  
Overall, the effect of cancer-induced osteoblast activity  results in enhanced 
bone formation and osteoclastic bone resorption. Tumour and osteoblast 
released factors such as RANKL enhance osteoclast bone resorption and in turn 
cytokines and bone-derived factors in the osteolytic lesions enhance tumour 
growth further enhancing the vicious cycle (Ibrahim et al., 2010) .  
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Figure 5. The bone metastatic process. 
Diagram of the bone metastatic process and vicious cycle.  Colonisation of the bone by disseminated tumour cells follows a period of dormancy. Upon reactivation, 
tumour cells secrete factors that influence osteoblasts to produce weak ectopic bone and RANKL which stimulates osteoclast formation and osteolysis. Growth factors in 
the bone lead to tumour cell proliferation. See section 1.2.2 for details.  
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1.3 IKK 
Inhibitor of nuclear factor kappa-B kinase subunit epsilon, also known as IB 
kinase epsilon, IKKε or IKK-inducible (IKK-i), is a protein encoded by the 
gene IKBKE. Through an integrative genomics approach that utilised RNA 
interference (RNAi) screens, overexpression screens and comparative 
genomics, IKBKE was identified as a breast cancer oncogene (Boehm et al., 
2007). It was demonstrated that IKBKE is overexpressed and amplified in 
16.3% of breast cancer cell lines and in 30% of breast cancer patient samples. 
In addition, they showed that IKKε-transformed breast epithelial cells  into 
tumour cells and up-regulated NFκB response genes, thus implicating the NFκB 
pathway in the tumourigenesis and survival of some breast carcinomas.  
1.3.1 The NFκB Pathway 
The NFκB pathway is a key regulator of many vital biological process including 
innate immunity, inflammation, cell proliferation and survival. These processes 
have been implicated in cancer development and progression, whether through 
aberrant cancer-intrinsic NFκB signalling activation or through deregulation of 
the pathway in cells of the microenvironment leading to inflammation 
(Hanahan and Weinberg, 2011).  
 
The NFκB family are a group of five transcription factors consisting of 
RelA(p65), RelB, c-Rel, p52 (p100 precursor) and p50 (p105 precursor) 
reviewed extensively by (Hayden and Ghosh, 2004). The NFκB transcription 
factors all contain a shared Rel homology domain (RHD), which enables 
specific DNA binding and subsequent transcription of target genes.  
 
In the cytosol of unstimulated cells, the NFκB transcription factors remain 
bound to the inhibitors of κB (IκB) proteins preventing their nuclear 
translocation. The IκB family consists of seven proteins with different binding 
affinities for NFκB proteins (Hayden and Ghosh, 2004). The seven family 
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members include IκB, IκB, IκBε, the REL-precursory p100 and p105 
proteins and the atypical IκBζ and Bcl-3. Phosphorylation of the IB proteins 
on two conserved serine residues (-32 and -36) by members of the inhibitor of 
IB (IKK) family results in their subsequent ubiquitin-directed proteasomal 
degradation. This is a prerequisite to NFB activation (Hayden and Ghosh, 
2004). 
 
The members of the IKK family are a collection of serine/threonine kinases 
compromised of IKK/IKK1, IKK/IKK2, IKK/IKK-i, TANK-binding 
kinase-1 (TBK-1) and the regulatory IKK/NEMO.  The distinct ways in which 
the IKKs are regulated by upstream proteins enable the strict control of the 
NFB response by various stimuli. 
 
1.3.2 Canonical versus Non-Canonical NFB Activation 
The canonical NFB pathway involves the assembly of the classical IKK 
complex consisting of IKK,,. This complex phosphorylates IB proteins 
leading to the release of NFB proteins, their nuclear translocation and 
transcription of NFB-related genes (Figure 6)(Hayden and Ghosh, 2004).  The 
classical pathway is activated by numerous cytokines and through their 
receptors including the Toll-like receptors (TLRs), interleukin-1 receptor -1 
(IL1R1) and the tumour necrosis factor- receptor (TNFR). When these 
receptors are stimulated by their respective ligands, a signalling cascade ensues 
and converges upon the IKK complex through phosphorylation and activation 
of IKK. Adaptor proteins such as the TNFα receptor associated factors 
(TRAFs) and certain kinases such as TGF-β activated kinase-1 (TAK1) are 
brought into close proximity upon stimulation by distinct ligands leading to 
IKK phosphorylation. Once activated the IKK complex in turn phosphorylates 
IB at serine-32 and serine-36 leading to its ubiquitination and destruction by 
the proteasome. This allows liberation of the p65/p50 heterodimers to 
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translocate to the nucleus where it activates the transcription of various NFκB 
target genes (Hayden and Ghosh, 2004).  
 
The non-canonical pathways are believed to be IKK independent. The best 
characterised is the activation of IKK homodimer by a subset of receptors 
(Figure 6). In an unstimulated cell, NFB inducing protein (NIK) is subject to 
constant proteosomal degradation. However, following stimulation, NIK is 
stabilised allowing it to phosphorylate the IKK homodimer. In turn the IKKα 
homodimer phosphorylates p100 such that it is undergoes ubiquitin-mediate 
proteosomal degradation. The catalytically active p52 protein is free to 
translocate as a heterodimer with RelB to the nucleus and induce gene 
transcription (Hayden and Ghosh, 2004). 
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Figure 6. Canonical and non-canonical NFκB activation. 
NFB transcription factors remain catalytically inactive in the cytoplasm bound to IB proteins. Upon 
stimulation IB proteins are phosphorylated by IKK complexes and undergo lysine-48 linked 
ubiquitin dependent proteosomal degradation allowing NFB proteins to translocate to the nucleus 
and induce gene transcription. See text for details.  
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1.3.3  The IKK-related Kinases - IKK and TBK-1 
The discovery of IKK occurred simultaneously by two separate groups and 
was named IKK and IKK-inducible (IKK-i). IKK was discovered through a 
database search for proteins similar to IKK and IKK and was shown to 
activate NFB upon stimulation of Jurkat T-cells with phorbol esters (Peters et 
al., 2000). IKK-i was discovered by Shimada and colleagues who showed IKK-
i expression was induced following lipopolysaccharide stimulation of murine 
macrophages and its mRNA could be induced by other proinflammatory signals 
including TNF, IL-1, IL-6 and IFNγ (Shimada et al., 1999). TBK-1 was 
initially identified, through a yeast two-hybrid system, as a protein that binds 
to TANK (Pomerantz and Baltimore, 1999). IKK and TBK-1 share 33% and 
31% kinase sequence similarity to IKK and IKK, respectively, whereas they 
share 65% sequence similarity to one another (Clément et al., 2008). In 
addition, TBK-1 and IKKε both contain multimerisation domains allowing 
them to from homo-dimers and heterodimers with each other. In addition, 
TBK-1, similarly to IKK and IKK, is a constitutively expressed protein and 
knockout of TBK-1 in mice leads to embryonic lethality due to liver apoptosis 
(Bonnard et al., 2000). However, IKK protein is undetectable in almost all 
tissues and is only expressed constitutively in certain tissues such as the 
pancreas, thymus, spleen and also peripheral blood leukocytes (Shimada et al., 
1999). Furthermore, IKK deficient mice are viable, yet are hyper-susceptible 
to viral infection due to deficient IFN signalling (Hemmi et al., 2004, Tenoever 
et al., 2007). 
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1.3.4 The role of IKK  and TBK-1 in NFB Signalling 
IKK and TBK-1 were initially deemed IB kinases through their ability to 
phosphorylate IB when overexpressed and both proteins were shown to only 
phosphorylate IB on serine 36, which is insufficient to result in IB 
degradation (Peters et al., 2000, Shimada et al., 1999). Comparatively, IKK 
phosphorylates IB on both serine-36 and serine-32, which leads to its 
subsequent degradation. Knockout of IKK and TBK-1 of mouse embryonic 
fibroblasts show no inherent deficiency in IB degradation and NFB 
activation in response to TNF and other inducers.  This suggests that IKK 
and TBK-1 do not activate NFB through direct phosphorylation of IB 
(Hemmi et al., 2004). Interestingly, IKK deficient MEFs show abrogation of 
NFB specific genes including MMP2, IL6, MCP1, COX2 and ICAM-1 
suggesting that phosphorylation of p65 by IKK is necessary for transcription 
of certain genes (Kravchenko et al., 2003).  Studies have revealed that NFB 
activation by IKK is a result of direct phosphorylation of NFB proteins (p65 
and c-Rel). IKK phosphorylates serine 468 and serine 536 on p65; post-
translational modifications necessary for proper transcription of specific NFB 
related genes (Buss et al., 2004). These modifications successively facilitate 
co-translocation of p65 and IKK to the nucleus and to DNA regions that 
contain NFB binding sites. Once at these sites, IKK phosphorylates c-Jun 
and initiates the clearance of nuclear receptor co-repressor proteins (nCOR) 
allowing for transcription of c-Jun specific genes (Huang et al., 2009). It is 
worth noting that such c-Jun specific genes include matrix remodelling 
enzymes matrix metalloproteinases (MMP). Furthermore, IKK-deficient 
murine fibroblast-like synoviocytes  do not up-regulate production of MMP3 
and MMP13 in response to classical inflammatory stimuli (Sweeney et al., 
2005). IKK and TBK-1 also phosphorylate c-Rel leading to its nuclear 
accumulation independently of IB serine-32 and serine-36 
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phosphorylations. However, these phosphorylation events do not suffice in 
potentiating c-Rel activation and subsequent induction of survival and 
proliferation gene expression suggesting the necessity of other post-
translational modifications (Harris et al., 2006). 
1.3.5 The role of IKK and TBK-1 in Interferon Regulatory Factor (IRF) 
Signalling 
The overlapping functions of NFB proteins and innate immunity is evidenced 
by the role of the IKK-related proteins in IRF signalling (Figure 7) (Clément et 
al., 2008). The IRF transcription factors regulate the expression of type-I 
interferons (IFNs), important pro-inflammatory cytokines involved in the 
innate immune response against viral infection. IFNα and IFNβ induce growth 
arrest and programmed cell death in virally infected cells. Both IKK and TBK-
1 phosphorylate IRF-3, -5 and -7 in response to a number of pathogen 
associated molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs) including LPS, double stranded RNA (dsRNA) and 
cytosolic DNA through TLR-dependant pathways. Activation of PAMP and 
DAMP sensing TLRs by their ligands leads to the recruitment of adaptor 
proteins such as TNFR-associated factors 2 (TRAF2), -3 and -6 leading to 
recruitment of scaffold proteins. IKK and TBK-1 form distinct complexes 
with TANK, NAK associated protein 1 (NAP-1) and the similar to NAP1 and 
TBK-1 adaptor (SINTBAD) (Chau et al., 2008). It is believed that these 
scaffold proteins assemble IKK and TBK-1 as hetero- and homodimers. 
Dimers form in response to specific upstream signals (i.e. PAMPs and DAMPs) 
that in turn phosphorylate IRF3 and IRF7 on specific serine residues to stabilise 
and activate IRF dimers leading to nuclear translocation and transcription of 
IRF target genes (Figure 7). Stringent controls are in place to prevent continued 
IRF signalling and prolonged IFN production (Chau et al., 2008). The 
deubiquitinating protein, CYLD negatively regulates IRF signalling (and NFB 
signalling) by deubiquitinating adaptor proteins and also IKK and TBK-1 to 
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diminish their activation. A20 is a ubiquitin ligase that adds K48 linked 
ubiquitin to various proteins within the NFκB and IRF signalling pathways 
leading to their proteolytic degradation. Another example is the suppressor of 
IKK (SIKE), a protein with high binding affinity for both TBK-1 and IKK. 
In unstimulated cells, SIKE is found bound to TBK-1 in the cytoplasm and 
inhibits its interaction with IRF3 thus diminishing the IRF3 dependant response 
but not NFB signalling (Huang et al., 2005). 
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Figure 7. IKKε/TBK-1 signalling pathways in innate immunity.  
 IKKε and TBK-1 functions as homo- and heterodimers to phosphorylate a number of adaptor proteins (TRAFs), kinases (IKKs) and transcription 
factors (NFκB, IRFs, STATs, p38, JNK and ERK) to maintain a pro-inflammatory and anti-viral state in response to cytokines, PAMPs and DAMPs, 
see text in sections 1.3.4 to 1.3.7. 
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1.3.6 The role of IKK and TBK-1 in JAK-STAT signalling 
The signal transducers and activators of transcription (STAT) proteins are 
important for the induction of genes involved in an anti-viral IFN-induced state.  
IKK has recently been shown to phosphorylate STAT1, a protein that forms 
part of the IFN-stimulated gene factor 3 complex (ISGF3) with STAT2 and 
IRF-9.  Phosphorylation of STAT-1 by IKK allows it to form a more stable 
heterodimer with STAT2 and bind to target gene sequences (Figure 7) 
(Tenoever et al., 2007). 
1.3.7 The role of IKK and TBK-1 in IL-17 Signalling 
IL-17 is an inflammatory cytokine produced by a subset of T-cells, immune 
cells and cancer cells including breast cancer which induces the activation of a 
variety of transcription factors leading to transcription and production of 
proinflammatory cytokines, MMPs and vascular endothelial growth factor 
(VEGF) (Welte and Zhang, 2015). Upon IL-17 binding to its receptor, NFB 
activator 1 (Act-1) is recruited and forms a complex with TRAF6 leading to 
NFB activation via the canonical pathway. At the same time, IKK and/or 
TBK-1 are recruited to IL-17R where it phosphorylates Act1 inducing a 
conformational change (Figure 7). This change decreases its binding affinity to 
TRAF6 and increases its affinity to a TRAF2/5 complex leading to activation 
of p38, JNK, and ERK transcription factors and inflammatory chemokine 
expression (Bulek et al., 2011) 
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1.4  The role of IKK in Breast Cancer  
The association between IKK and cancer was first established by Eddy and 
colleagues who implicated IKK overexpression in primary human breast 
cancer samples, breast cancer cell lines as well as mouse tumours of the breast. 
In addition it was shown that expression of casein kinase 2 (CK2), a member 
of the Wnt signalling pathway, in numerous cell lines induced expression of 
IKK whilst inhibition of CK2 reduced IKK in mammary carcinoma cell lines 
(Eddy et al., 2005). Following these observations, Adli and Baldwin reported 
that IKK is expressed in several breast and prostate cancer cell lines. 
Moreover, IKK was found to be involved in basal and constitutive 
phosphorylation of p65 at serine 536. This posttranslational modification is 
necessary for increasing p65 transactivation potential (binding to other 
transcription factors in the nucleus) and continued activity. Importantly, it was 
shown that phosphorylation of IKK was constitutive and independent of 
cytokines (Adli and Baldwin, 2006) 
 
Compounding on previous work Boehm et al. described IKK as a breast 
cancer oncogene, a gene whose product drives cellular transformation, through 
multiple functional genomic approaches (Boehm et al., 2007). The first 
approach analysed kinases that (A) replaced either activated MEK or AKT and 
(B) drove cellular transformation of human epithelial cells as indicated by 
tumour formation in nude mice and in vitro by an anchorage independent 
growth assay. IKK was one of four such kinases with transforming potential 
upon overexpression. Secondly, Boehm and colleagues used RNAi screens to 
knockdown expression of select kinases and found that IKK was necessary for 
the growth and survival of several breast cancer cell lines such as ZR-75-1 cells. 
However, both IKK and TBK-1 were required for MCF-7 viability, perhaps 
suggesting a level of redundancy between the two kinases. Lastly, they looked 
at expression of IKK in 49 breast cancer cell lines and 30 primary breast 
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tumours and showed IKBKE was amplified in 16% and 30% respectively but 
found no correlation with ER or HER2 status. Immunohistochemistry of 
primary tumours also revealed nuclear localisation of c-Rel in 100% of tumours 
with IKBKE amplification. These results were the first to show the oncogenic 
potential of IKK, whose overexpression lead to increase expression of NFB 
target genes such as MMP9 and BCL3. Importantly, these studies also 
demonstrated that knockdown of IRF3 and IRF7 did not suppress IKK 
transforming capabilities thus further implicating the NFB signalling pathway 
in breast cancer oncogenesis.  
More recently, additional; mechanisms for IKK oncogenic abilities have been 
elucidated (Figure 8). It was found that IKK phosphorylates the 
cylindramatosis tumour suppressor (CYLD) (Hutti et al., 2009). CYLD 
possesses a deubiquitinating function that removes lysine-63 linked ubiquitin 
chains important for the activation of various adaptor proteins in the NFB 
signalling pathway. Phosphorylation of CYLD precludes its ability to 
deubiquinate and inactivate its targets, leading to continued NFB activation 
and increased basal activation (Hutti et al., 2009). Moreover, it was 
demonstrated that IKK directly phosphorylates various other proteins involved 
in the activation of NFB activation including Akt (independent of PI3K) and 
TRAF2 (Guo et al., 2011, Shen et al., 2012). TRAF2 is an E3-ubiquitin ligase 
that adds lysine-63 linked ubiquitin chains to other proteins thereby leading to 
NFB activation (Shen et al., 2012). Zhou et al showed that IKK is itself 
ubiquitinated by the TRAF2 containing complex, cIAP1/cIAP2/TRAF2. This 
complex adds lysine-68 linked ubiquitin chains to IKK, which was shown to 
be vital for its NFB dependent transforming capabilities (Zhou et al., 2013). 
Furthermore, stimulation of breast cancer cells with TNF or IL-1 increased 
IKK expression above basal levels, therefore further implying a role for 
inflammation and proinflammatory cytokines produced by cells of the stroma 
in cancer progression (Zhou et al., 2013).  Guo and colleagues identified an 
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additional mechanism through which IKK executes its oncogenic effect that 
involves the inhibition of transcription factor forkhead box O3 (FOXO3). 
FOXO3 functions to up-regulate genes involved in apoptosis and down-
regulation of anti-apoptotic genes.  Phosphorylation of FOXO3 by IKK on 
serine-644 leads to abrogation of FOXO3 gene transcription thus reducing 
apoptosis of transformed cells (Guo et al., 2013). Most recently, Mukawere and 
colleagues investigated the role of oxidative stress on IKK. It was shown that 
treatment of breast cancer cell lines with redox modulating dyes or silencing of 
NOX2, a superoxide-generating enzyme, inhibited IKK expression and 
reduced the viability of breast cancer cells (Figure 8). 
Constitutive STAT-1 activation has also been documented in both primary 
breast cancer samples and cell lines (Watson, 2001). On the one hand, STAT-
1 has previously been deemed to act as a tumour suppressor within cancer cells 
due to increased death receptor and caspase transcription. However, recent 
studies have indicated that TNF-α can stimulate macrophages to release low 
levels of IFN-β, which activates STAT-1 to enhance pro-inflammatory cytokine 
production, thus amplifying tumour associated inflammation (Yarilina et al., 
2008). Furthermore, as IKK directly phosphorylates STAT-1 (Figure 8), IKK 
overexpression may increase and prolong STAT-1 activity enhancing tumour-
associated inflammation and early cancer progression (Clément et al., 2008). 
Finally, IKK has been implicated in increased resistance to chemotherapies 
and genotoxic stress in both breast and ovarian cancer. IKK was shown to be 
up-regulated in metastatic ovarian cancer and facilitated resistance to cis-platin, 
the mainstay drug treatment for ovarian cancer (Hsu et al., 2012, Guo et al., 
2009). Comparatively in breast cancer, IKK expression was shown to 
contribute to resistance to the  estrogen antagonist, tamoxifen (Figure 8). In 
breast cancer cells overexpression of IKK resulted in increased resistance to 
tamoxifen whereas IKK knockdown cells displayed sensitisation. 
Furthermore, IKK was shown to phosphorylate estrogen receptor- (ER) on 
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serine-167 resulting in its transactivation and up-regulation of cyclin-D1, one 
such major target gene of ER that drives cell cycle progression (Guo et al., 
2010, Arnold and Papanikolaou, 2005). It has also become clear that IKK 
serves to protect against DNA damage-induced cell death by a mechanism 
dependant on IKKε nuclear translocation and association with promyelotic 
leukaemia tumour suppressor (PML)(Renner et al., 2010). IKK-dependent 
phosphorylation of PML is essential for IKK nuclear retention. Once in the 
nucleus, IKK undergoes SUMOylation, by topoisomerase I-binding arginine 
serine-rich protein (TOPORS). This post-translational modification 
necessitates IKK ability to phosphorylate nuclear p65 at serine-468 and induce 
anti-apoptotic gene expression thus potentiating cell survival. Collectively, 
these findings signify additional NFB-dependent and NFB-independent 
mechanisms through which IKK maintains its oncogenic effects in 
transformed cells and identify IKK as a potential target in prevention of 
chemoresistant tumours (Figure 8). 
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Figure 8. Existing mechanisms of IKK  oncogenic activity. 
Overexpression of IKK, linked to gene amplification and superoxide production leads to a variety 
of oncogenic activity. See text in section 1.4 for detailed description.  
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1.5 The role of IKK in Bone Metastasis 
Breast cancers preferentially colonise the skeleton (Coleman and Rubens, 1987) 
Previous work in our lab has demonstrated that IKKβ expression in breast cancer 
cells increases bone metastasis and osteolysis, however IKKε is the only member 
of the NFκB family to have been shown to be a breast cancer oncogene  Several 
studies have demonstrated the role of NFB activation in tumour growth and 
metastases. In breast cancer, NFB (p65—50) activation leads to production of 
CXCR4, which enhances motility and subsequent homing to bone. (Helbig et al., 
2003). Moreover, NFB has been implicated in bone metastasis and the formation 
of osteolytic lesions (Park et al., 2006, Idris et al., 2009, Marino et al., 2018a, 
Peramuhendige et al., 2018).  Recent work by our laboratory has evidenced that 
knockdown and pharmacological inhibition of IKKβ reduces breast cancer bone 
metastasis and osteolysis (Marino et al., 2018a, Marino et al., 2018b) . In addition, 
our  recent work indicated that pharmacological inhibition of p65 with the inhibitor 
Parthenolide reduced breast cancer skeletal tumour growth and resulting osteolysis 
in vivo (Marino et al., 2017).   As IKK and its partner TBK-1 have been shown 
to directly and indirectly activate NFB, it is plausible that IKK may contribute 
to NFB-mediated breast cancer motility and associated osteoclast formation. 
Similarly, IKK activity has been shown to lead to the production of MMPs – 
critical mediators of ECM degradation and cancer invasion (Sweeney et al., 2005).  
Furthermore, pharmacological inhibition of IKK/TBK-1 has been shown to 
reduce osteoclast formation in vitro and prevent ovariectomy induced bone loss in 
vivo, thus inhibition of IKK within the bone microenvironment may prevent 
osteoclast formation and cancer-induced bone loss in models of breast cancer bone 
metastases. Thereby breaking the vicious cycle and the release of growth factors 
from the bone matrix may contribute to an inhibition of skeletal tumour growth of 
metastatic breast cancer.  
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1.6 The Aim of this Study 
The NFκB pathway has been implicated in inflammation, bone remodelling and 
tumourigenesis. The aim of this study is to elucidate how modulation of IKKε 
through loss/gain of function and pharmacological inhibition affects breast cancer 
progression, skeletal tumour growth and osteolysis through the interaction of bone 
and cancer cells in vivo and in vitro. 
We hypothesise that inhibition of IKKε, both in breast cancer cells and the 
microenvironment reduces breast cancer growth, metastasis, skeletal tumour 
burden and osteolysis.  
The specific aims of the work reported in this thesis are: 
 To examine the expression of IKKε in breast cancer patient data sets and 
a panel of breast cancer cell lines  
 To examine whether cancer-specific knockdown or overexpression of 
IKKε affects human  breast cancer cell: 
o growth, migration and invasion in vitro  
o skeletal tumour growth in vivo 
o ability to induced-osteoclast formation and osteolysis in vitro and 
in vivo 
o ability to affect-osteoblast, growth, differentiation and activity in 
vitro 
 To establish whether  pharmacological inhibition of IKKε using the 
verified IKKε/TBK-1 inhibitor, Amlexanox: 
o Reduces breast cancer cell growth, migration and invasion in vitro 
and in vivo 
o Enhances the efficacy of clinically relevant chemotherapeutic 
agents in vitro and in vivo 
o Inhibits osteoclast signalling, formation and proliferation in 
vitro  
o Influences osteoblast growth, differentiation and activity in vitro 
o Reduces breast cancer bone metastasis, skeletal tumour growth 
and osteolysis in vivo. 
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2 Materials and Methods 
Reagents and suppliers used in this thesis can be found in Appendix 1. 
2.1 Preparation of test compounds 
 
The IKKε and TBK-1 inhibitor, Amlexanox was purchased from Tocris 
Bioscience (Bristol, UK), the IKKε inhibitors CAY10575 and CAY10576 were 
purchased from Cambridge Bioscience (Cambridge, UK; Table 2). For in vitro 
experiments, all compounds were prepared according to manufacturer’s 
instructions. Amlexanox was prepared at 100mM in dimethyl sulfoxide (DMSO). 
Serial dilutions of the tested compounds were prepared and kept at -20°C.  
Concentrations used were determined by viability experiments, such that the 
concentration that had no effect on viability at a given time point were used.  
Table 2. Inhibitors used and  their targets 
2.2 Tissue Culture 
2.2.1 Tissue culture media 
Human CD14+ monocytes/macrophages, bone marrow cells, murine calvarial 
osteoblasts, MC3T3-E1 clone 4 were cultured in α-MEM supplemented with 10% 
foetal calf serum (FCS), 5% L-Glutamine, 100 U/ml penicillin and 100 g/ml 
streptomycin (standard αMEM). Human triple negative and claudin low parental 
MDA-MB-231 cancer cells were cultured in DMEM + Glutamax with 10% FCS, 
100 U/ml penicillin and 100 µg/ml streptomycin (standard DMEM). All other 
human breast cancer cell lines, ZR-75-1 (ER positive – Luminal B), SK-BR-3 
Compound Targets (Concentration) 
Amlexanox IKKε/TBK-1 (1-2μM) 
CAY10575 IKKε (15.μM) 
CAY10576 IKKε (40nM), PDK1 (80nM) 
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(HER2 enriched) and triple negative MDA-MB-468 (basal-like) were cultured in 
RPMI 1640 + Glutamax supplemented with 10% FCS, 5% L-Glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin (standard RPMI). Tissue culture medium 
(DMEM, αMEM and RPMI) FCS, penicillin and streptomycin were obtained from 
Gibco, Thermofisher (Leicestershire, UK). 
2.2.2 Cell culture conditions 
Cell culture was performed in laminar flow hood sprayed with 70% (v/v) industrial 
methylated spirit prior to use. All solutions were warmed to 37°C before use. 
Plasticware supplied by various manufactures (Corning and Thermofisher) was 
bought pre-sterilised or autoclaved prior to use. All cultures were maintained 
under standard conditions of 5% CO2: 95% air at 37°C in a humidified 
atmosphere. Phase-contrast microscopy was used routinely during the culture 
period in order to assess confluence or contamination of cultures. 
2.2.3 Cancer cell lines 
Human MDA-MB-231, MCF-7, ZR-75-1, SK-BR-3 and MDA-MB-468 breast 
cancer cell lines, Saos-2 osteoblast-like cells were purchased from ATCC 
(Manassas, VA, USA).  The luciferase-expressing 4T1-Luc2 murine breast cancer 
cells and macrophage-like RAW264.7 cells were  kindly donated by Dr. Munitta 
Muthana and Professor Dominique Heymann (University of Sheffield) 
respectively. Cancer cells were cultured in 25cm2 or 75cm2 flasks and passaged 
every 48-72 hours at a ratio of 1:5 MDA-MB- 231,  1:3 ZR-75-1, 1:3 SK-BR-3 
1:5 MDA-MB-468, 1:10 4T1-Luc2, 1:5 Saos-2, 1:10 RAW264.7. The bone-
seeking MDA-MB-231 sub-clone, MDA-BT1  (Marino et al., 2018a) were 
previously generated through in vivo passaging and donated by Dr. Nadia Rucci 
(University of L’Aquila) and sub-cultured at a ratio of 1:10.  To subculture cells, 
the monolayer was washed in pre-warmed PBS and detached by treatment with 
trypsin. Standard medium was added at 2:1 ratio to trypsin in order to inactivate 
its proteolytic activity.  The cell suspension was transferred to a fresh sterile 15 ml 
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tube that was then centrifuged at 300G for 5 minutes. The supernatant was 
removed and cells resuspended in 1 ml standard medium.  A percentage of the 
suspension was placed into a new 25 or 75 cm2 flask containing up to 15 ml 
standard medium. The remaining cells were counted and used for experiments. 
2.2.4 Preparation of Conditioned Medium 
Cancer cell conditioned mediuam was generated by the culturing of cancer cells 
in standard DMEM in 6 well plates. Once the cancer cells reached approximately 
70% confluence, the cells were washed in PBS and 2ml of serum-free medium was 
added. Cells were then cultured for a further 16 hours under standard conditions 
and the conditioned medium obtained was then removed and filtered through a 
0.2µm filter. Control conditioned medium was created from serum free medium 
cultured in the same way as cancer conditioned medium, but in a 6 well plate with 
no cancer cells present. 
2.2.5 Cell Viability  
The Alamar blue assay can be used to assess the viability of cells (O'Brien et al., 
2000). Alamar Blue reagent (ThermoFisher) contains resazurin, a blue and weakly 
fluorescent dye. Alamar Blue is non-toxic to cells and is able to pass the cell 
membrane. The environment of respiring cells reduces resazurin to highly 
fluorescent resofurin. The degree of altered fluorescence is proportional to the 
number of living cells. MDA-BT1 cells were plated at a density of 3000 cells/well 
of a 96 well plate in 100μl of standard DMEM. Cells were allowed to adhere 
overnight and the following day medium was removed and replaced with 
compounds in DMEM containing 1% FCS. Cell Viability is measured by adding 
10% (v/v) Alamar Blue reagent to each well. The plates are incubated for up to 3 
hours. Fluorescence (excitation - 530 nm, emission - 590 nm) was detected using 
a SpectraMax® M5 microplate reader. AlamarBlue was also added to wells 
containing only standard media in order to correct for background fluorescence. 
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2.2.6 Cancer cell motility 
2.2.6.1 2D directional migration 
The wound healing assay was used to measure 2D directional migration of human 
MDA-BT1 (400 x 103 cells/well) breast cancer cells plated in 24-well plate in 
standard DMEM (Logan et al., 2013, Idris et al., 2009). After 24 hours, the 
confluent monolayer was treated with 5μg/ml of mitomycin-C for 2 hours to 
inhibit proliferation. The monolayer was scratched vertically using a 10μl pipette 
tip and the cells were washed eight times with serum free medium to remove any 
loose cells and debris. The drugs, solubilised in DMEM containing 1% FCS  were 
added to the cells and the plate was placed in humidified microscope maintained 
at 37°C and 5% CO2. Migration was monitored for 16 hours with an Olympus 
scanR time-lapse imaging system. Sequential images were captured at 30-minute 
intervals. Cell viability was measured using Alamar Blue assay at the end of the 
migration assays. Percentage of wound closure was calculated using T scratch 
software (Geback et al., 2009).  
2.2.6.2 Cancer cell invasion  
Cancer cell invasion was investigated using the Boyden chamber transwell 
invasion assay (Marino et al., 2018a). Pippette tips were left in -20°C freezer 
overnight.  Growth factor reduced matrigel (Corning) was thawed on ice for 2 
hours prior to usage. After defrosting,  matrigel was diluted to a final concentration 
of 1.5mg/ml in ice-cold serum free medium. Corning™ 0.8 μm transwell inserts 
were inserted to a 24 well tissue culture plate.  Diluted matrigel (20μl) was 
carefully pipetted into the insert using ice-cold tips and allowed to solidify for 3 
hours at 37°C. Breast cancer cells were trypsinised and suspensions were prepared 
in serum free medium (3.2 x 104cells/ml). Once the matrigel was hardened, 200µl 
of cell suspension was added on to the transwell insert. Foetal calf serum (10% 
v/v) was used as a chemoattractant, thus 500µl of standard medium was placed in 
bottom of the 24-well plate and the transwell insert was added. The insert 
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containing plates were incubated at 37°C with 5% CO2 for 72 hours. Following 
this, matrigel and non-invasive cells were removed from the interior part of the 
insert using a damp cotton bud. Cells were on the insert were fixed for 5 minutes 
in 100% ethanol followed by staining in haematoxylin and eosin (H&E). Inserts 
were placed in eosin (1% w/v) for 1 minute, rinsed in tap water, stained with 
haematoxylin for 5 minutes and rinsed again. Inserts were excised and mounted 
on superfrost plus glass slides using faramount mounting solution (Dako). Inserts 
were imaged using a bright field microscope 5x magnification. The area covered 
by invasive cells was analysed using ImageJ.  
2.2.7 Bone cell cultures 
2.2.7.1 Isolation of murine bone marrow cells 
Bone marrow cells were isolated from the long bones (tibia and femur) of 
C57BL/6 female mice aged 8 weeks sacrificed by cervical dislocation as 
previously described (Takahashi et al., 2003, Sophocleous et al., 2015, Marino et 
al., 2014a). Sterilised equipment was used to perform the isolation. Briefly, the 
hind limbs were isolated and were placed in a Petri dish, the soft tissue and 
connective tissue that surrounds the bone was removed using a scalpel and the 
ends of each bone were cut off to reveal the bone marrow (Figure 9). To extract 
bone marrow cells (BM), the tibia were transferred to Eppendorf tubes with 500μl 
of standard αMEM and centrifuged at 400G for 5 minutes. This process was 
repeated twice. Bone marrow cells were passed through needles of decreasing 
gauge to generate a  single cell suspension. The cell suspension was placed into a 
15 ml tube and centrifuged at 400G for 3 minutes. The pellet was resuspended in 
an appropriate volume of standard αMEM and were plated in 96 well plates used 
for the generation of RANKL and M-CSF generated murine osteoclast cultures.  
2.2.7.2 RANKL and M-CSF generated murine osteoclast cultures 
Mouse BM cells isolated as described above were plated in 96-well at 150 x 103 
cells/well in 100µl of standard αMEM with 25ng/ml murine M-CSF to facilitate 
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adherence (Marino et al., 2014, Sophocleous et al., 2015, Takahashi et al., 2003). 
After 48 hours, medium was replaced with standard αMEM supplemented with 
100ng/ml RANKL and 25ng/ml M-CSF, Amlexanox and/or conditioned medium 
to a final volume of 150μl every 48 hours, while changing 50% of the medium 
supplemented with M-CSF and RANKL (Figure 9). Osteoclasts were identified 
using Tartrate-resistant Acid Phosphatase (TRAcP) staining as described below in 
section 2.2.8.  
 
Figure 9. Generation of murine osteoclasts from tibia.  
Schematic diagram of the isolation of murine total bone marrow from the long bones subsequent 
osteoclast formation in the presence of breast cancer cells/conditioned medium. See text in section 
2.2.7.1 and 2.2.7.2 for details.  
 
2.2.7.3 RANKL and M-CSF generated human osteoclast cultures 
2.2.7.3.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
A source of osteoclast precursor cells can also be isolated from peripheral human 
blood.  A volume equal to 100g of blood was drawn from healthy human 
volunteers in accordance with ethics given by the Ethics Committee of the 
University of Sheffield).  
CD14+ cells were isolated as previously described (Marino et al., 2014a). Blood 
was diluted with twice the volume of EDTA buffer (2mM EDTA in PBS, 2-8°C). 
A volume of 25ml of diluted blood was transferred in to 50ml falcon tubes, where 
14ml of Ficoll-Pacque (Sigma) was layered over the blood. Falcon tubes were 
centrifuged for 30 minutes at 20°C at 400G without brakes in order to separate out 
the blood. The white interphase containing peripheral blood mononuclear cells 
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(PBMCs) was aspirated and collected in a new 50ml falcon tube. PBMCs were 
resuspended and washed in 50ml of EDTA buffer. The cell suspension was 
centrifuged for 10 minutes at 20°C at 300G. The pellet was resuspended in 50ml 
EDTA buffer and centrifuged again for 10 minutes at 20°C at 200G.  The pellet 
was resuspended in an appropriate amount of buffer and cell number was 
determined.  
2.2.7.3.2 Isolation of CD14+ monocytes from PBMCs 
The osteoclast precursor cells, CD14+ monocytes, can be isolated from PBMCs 
using antibodies specific for CD14 (Sorensen et al., 2007). PBMCs were isolated 
as described in section 2.2.7.3.1. Once the number of PBMCs was determined, 
cells were pelleted and then resuspended in 80µl of 2mM EDTA buffer with 0.5% 
(w/v) BSA per 107 total cells. To this suspension, 20µl of CD14 microbeads 
(Miltenyi Biotec) were added per 107 total cells. The cell and bead suspension was 
incubated for 15 minutes at 2-8°C.  Cells were washed in 2mls EDTA buffer per 
107 cells and centrifuged at 300g for 10 minutes.  Following this, the CD14+ cells 
can be isolated using magnetic separation. The cells were resuspended in 500μl of 
buffer per 108 cells and loaded in to a MS magnetic column attached to a magnetic 
field. Three lots of washing using 500μl of buffer were performed to remove 
unbound cells. To elute bound CD14+ cells, 1ml of buffer was added and a plunger 
was used remove cells. Cells were centrifuged as previously described and cell 
number was determined. 
Figure 10. Isolation and generation of human osteoclasts from peripheral blood. 
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Schematic diagram of the isolation of human peripheral blood, isolation of CD14+ monocytes and 
subsequent osteoclast formation in the presence of breast cancer cells/conditioned medium. See 
text in section 2.2.7.3 for details.  
 
2.2.7.4 Generation of osteoclast-like cells from RAW264.7 cells 
RAW264.7 macrophage-like cells are plated in a 96-well plate at a density of 2000 
cells/100μl of standard DMEM (Collin-Osdoby and Osdoby, 2012). The following 
day, RAW264.7 cells are given 100ng/ml of RANKL plus 10% v/v conditioned 
medium. Medium is refreshed after 48 hours with RANKL and conditioned 
medium. Cultures were stopped on day 5. Osteoclast-like cells are fixed and 
stained as seen in section 2.2.8.  
2.2.8 Characterization and identification of osteoclasts 
2.2.8.1.1 Culture fixation 
To terminate the osteoclast cultures, the medium was removed and the adherent 
cells were rinsed twice with sterile PBS. Cells were then incubated in an 
appropriate volume (150µl for 96-well) of 4% (v/v) paraformaldehyde in PBS for 
10 minutes at room temperature. Following fixation, the cells were rinsed twice 
with PBS and stored at 4°C in 70% ethanol (v/v). 
2.2.8.1.2 Tartrate-resistant Acid Phosphatase (TRAcP) staining 
Multinucleated osteoclasts were identified using TRAcP staining as previously 
described in (Marino et al., 2014a). Briefly, 100 µl of TRAcP staining solution 
(Appendix 2) was added to each well and plates were incubated at 37˚C for 30-60 
minutes. The TRAcP staining solution was then removed and cells rinsed twice 
with sterile PBS and stored at 4°C in 70% (v/v) ethanol. TRAcP positive cells 
(TRAcP+) with 3 or more nuclei were considered to be osteoclasts and manually 
counted on a Zeiss Axiovert light microscope using a 10x and 20x objective lens. 
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2.2.9 Osteoblast cultures 
2.2.9.1 Isolation of calvarial primary osteoblasts 
Primary calvarial osteoblasts were  isolated as previously described (Bakker and 
Klein-Nulend, 2012). Osteoblasts were obtained by sequential collagenase 
digestion from the calvarial bones of 2 days-old mice sacrificed by decapitation. 
The calvariae were removed, washed thoroughly in PBS and transferred to 15ml 
falcon tubes containing collagenase type 1 (1mg/ml) in PBS and incubated for 10 
minutes at 37°C in a shaking water bath (Figure 11). Following the first digestion, 
the supernatant was discarded and the calvaria were incubated in fresh 5ml of 
collagenase type 1 for  30 minutes. The cell suspension obtained was mixed with 
6 ml of standard αMEM (fraction 1). The remaining tissues were washed in PBS 
and treated for 10 minutes with 4 ml of  4 mM ethylenediaminetetraacetic acid 
(EDTA) in PBS at 37°C in a water bath with regular agitation. This cell suspension 
was then removed and mixed with 6 ml of standard αMEM (fraction 2). The 
remaining tissues were incubated in 4 ml of collagenase type 1 (1mg/ml) in PBS 
for 20 minutes in order to obtain the fraction 3. The three fractions were collected 
and centrifuged at 400G for 3 minutes. The cell pellet was resuspended in standard 
αMEM and cultured under standard conditions in 75cm2 tissue culture flasks at a 
density of 3 calvariae per flask. The medium was changed 24 hours after seeding 
to remove non-adherent cells, and then every 48 hours until cells reached 
confluence. 
2.2.9.2 Osteoblast viability 
For studies of viability, osteoblasts were plated in 96-well plates (7 x 103 cells/well 
in 100µl of standard αMEM). After 24 hours, the desired treatments were added 
and left for 24 or 48 hours. Cell viability was analysed by the Alamar Blue assay 
(section 2.2.5). 
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2.2.9.3 Alkaline phosphatase assay 
Alkaline phosphatase (ALP) is  highly expressed by osteoblasts and thus is a 
marker of osteoblast differentiation (Taylor et al., 2014). This assay is a 
colorimetric assay based on the conversion of the colourless substrate p-
nitrophenol phosphate (Sigma Aldrich) into a bright yellow p-nitrophenol by the  
enzyme, alkaline phosphatase. Osteoblasts  were plated in 96-well plates at a 
density of 8 x 103 cells/well in 100µl of standard αMEM. After 24 hours, the cells 
were treated with the Amlexanox for 24 or 48 hours plus/minus conditioned 
medium from MDA-BT1 (20% v/v). Following treatment, the cell monolayer was 
rinsed with PBS and then incubated with 150µl of ALP lysis buffer (Appendix 3) 
for 20 minutes. 
A serial dilution of p-nitrophenol (0 – 30 nM) was used to generate a standard 
curve. In a new 96-well plate,  50μl of the standard solutions and tested samples 
were plated in triplicates  and 50µl of substrate solution was added on top. 
Absorbance was measured using a Molecular Devices SpectraMax M5 plate 
reader. The readings were taken at 414 nm at 37°C, at 5 minute intervals for 20 
minutes. The activity of ALP was calculated from the linear part of the kinetic 
curve and was expressed as percentage of vehicle control. Alkaline Phosphatase 
activity was further normalised to cell number as determined by the Alamar Blue 
assay. 
2.2.9.4 Bone nodule assay 
For studies addressing osteoblast activity and bone nodule formation, Saos-2 
osteoblasts were plated in 12-well plates (150 x 103 cells/well in 1 ml of standard 
DMEM). The following days, cultures were treated with the Amlexanox at the 
indicated concentration resuspended in αMEM supplemented with 50 µg/ml L-
ascorbic acid and 10 mM beta-glycerophosphate (βGP) (osteogenic medium). The 
cells were cultured for up to 11 days and the medium was refreshed three times 
per week. At the end of the cultured period the cells were fixed in 70% (v/v) 
ethanol before staining. 
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2.2.9.4.1 Alizarin Red staining. 
To quantify the formation of bone nodules by Saos-2 osteoblast-like cells, Alizarin 
Red S staining was used. Alizarin Red S bind binds to calcium deposited in 
mineralised tissues and cultures. This forms a complex that causes calcium uons 
to precipitate and form dark red deposits (Chang et al., 2000; Coelho et al., 2000). 
Alizarin Red S powder (Sigma Aldrich) was first dissolved in deionised water to 
a final concentration of 40mM, the pH was adjusted with ~100μL of 37.5% HCl 
to a pH of 4.2. Ethanol was removed from fixed Saos-2  which were then rinsed 
thrice with PBS and then incubated with 1 ml per well of a 12-well plate  with 
Alizarin Red S staining solution for 20 minutes on gentle rocking at room 
temperature. The staining solution was then removed and the culture was rinse 
thrice with de-ionized water and left to air-dry for 48 hours. Images of wells were 
taken on a standard scanner prior to destaining.  
2.2.9.5 Destaining of osteoblast cultures. 
In order to quantify  mineralisation in stained osteoblast culture, a destaining 
solution consisting of  10% (w/v) cetylpyridinium chloride in 10mM sodium 
phosphate (pH 7.0) was used for 15 minutes at room temperature on a rocker. 
Alizarin Red S concentration was determined by absorbance measured at 562 nm 
on a Bio-Tek Synergy HT plate reader. Level of mineralisation was expressed as 
percentage of control.  
 
  
Figure 11. Isolation and characterisation of primary calvarial osteoblasts. 
Calvaria from 2-day old mouse pups are digested with collagenase I. Osteoblasts are expanaded in 
standard αMEM and differentiated with OsteoMEM. Osteoblast maturation and activity are assessed by 
alkaline phosphatase activity  and alizarin staining. See text in section 2.2.9 for more details.  
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2.2.9.6 Bone cells - conditioned medium co-cultures 
For osteoclast – conditioned medium co-culture, mouse or human M-CSF 
dependent osteoclast precursors were plated in 96-well plates at 12 x 103 cells/well 
and 45 x103 cells/well in αMEM supplemented with 25ng/ml of M-CSF to allow 
attachment. After 48 hours, conditioned medium from different cancer cells (10% 
v/v), drug treatments, 100ng/ml RANKL and 25ng/ml of M-CSF were added to 
the bone marrow osteoclast precursors. The plates were cultured under standard 
conditions and treated with the desired compounds for 72-96 hours, while 
changing half of the medium supplemented with fresh conditioned medium, drug 
treatment, M-CSF and RANKL. 
For osteoblast - conditioned medium co-culture, osteoblasts were plated in 96-well 
or 12-well plates at 8 x 103 cells/well in 100µl of standard αMEM, or 150 x 103 
cells/well in 1 ml standard αMEM, respectively. In order to study the effect of 
breast cancer derived factors on osteoblast differentiation, osteoblast precursors 
were plated in 96-well plates and then treated with the desired compounds in 
presence and absence of conditioned medium (20% v/v) for 24 or 48 hours. In 
order to study the effect of breast cancer derived factors on osteoblasts activity, 
Osteoblasts were plated in 12-well plates and allowed to grow to confluency. Once 
confluent, osteoblasts were treated with the conditioned medium (20% v/v) or 
desired compounds resuspended in osteogenic medium in presence or absence of 
conditioned medium. The cells were cultured for up to 21 days and the medium 
was refreshed three times per week. At the end of the culture period, the cells were 
fixed in 70% (v/v) ethanol. 
  
Chapter 2                                                   Materials and Methods 
 
52 
 
2.3 Molecular Biology techniques 
2.3.1 Preparation of Luria-Bertani broth  
Luria-Bertani (LB) broth (2% w/v) was dissolved in distilled water, autoclaved 
and the antibiotic for selection of transduced E.coli was added to LB broth once 
cooled at a final concentration of 100μg/ml. The antibiotic used was carbenicillin.  
2.3.2 Preparation of LB/carbenicillin agar plates  
Agar powder (4% w/v) was dissolved in distilled water. The solution was 
autoclaved and cooled at room temperature to around 50°C. Carbenicillin was 
added ad a concentration of  (100μg/ml). LB agar media (20ml)  was poured into 
150mm petri dishes and left to set, then stored at 4°C.  
2.3.3 Preparation of broth culture  
 A stab from the bacterial glycerol stock was added to  100 ml of LB broth in a 
500ml conical flask to inoculate. The flasks were covered and left overnight at 
37°C in a shaking incubator at 20G to allow for bacterial expansion. The next day, 
a High Speed QIAGEN Midi prep kit was used to isolate bacterial DNA from 
according to the manufacturer’s instructions. Extracted DNA was quantified and 
assessed for purity using NanoDrop™ and stored at -20°C until further use.  
Glycerol stocks of LB culture were reserved by adding 15% glycerol to 85% 
bacterial suspension in a 2ml cryogenic vial and stored at -80°C.   
2.3.4 Lentiviral gene delivery - Short Hairpin RNA (shRNA) 
To generate knockdowns of IKK expression in human osteotropic MDA-BT1 
breast cancer cells a vector-based short hairpin RNA (shRNA) method was used 
according to manufacturer’s instructions. Use of lentiviral vectors was approved 
by the University of Sheffield Biosafety Committee under project license 
GMO2014_11. Two TRC human individual clones (IKKεKD1 - TRCN0000010035 
IKKεKD2 -TRCN0000010036; Table 3) and one empty vector control plKO.1 were 
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supplied in glycerol stocks (Thermo Scientific, Germany) ready for expansion in 
LB broth culture before use in transfection of MDA-BT1 breast cancer cells. 
Table 3.  Human IKKε targeting shRNA constructs and their target sequences  
Name Construct Targeting Sequence 
IKKεKD1 TRCN0000010035 -TGCCCACAACACGATAGCCAT- 
IKKεKD2 TRCN0000010036 -TGGGCAGGAGCTAATGTTTCG- 
 
Nucleotide Basic Local Alignment Tool (BLASTn; NIH) confirmed that these 
constructs were specific for IKBKE mRNA and did not target the other IKK and 
IKK-related proteins including IKKα, IKKβ, IKKγ or TBK-1. 
2.3.5 Lentiviral transfection  
HEK29ET cells (1 x 105 cells/cm2) were seeded in T25 flasks in 5 ml of standard 
DMEM. A transfection solution was generated by adding 5µg of indicated vector 
DNA (MOCK, IKKεKD1, IKKεKD2) to 5µg of PPAX vector DNA, 5µg of pMD2.G 
vector DNA (previously isolated by Dr. Silvia Marino) 40µl of Polyethylenimine 
(PEI) transfection reagent and 450 µl of serum free DMEM medium in 4.5ml of 
standard DMEM. Standard DMEM was removed from HEK-293ET cells and the 
monolayer was washed with PBS. The transfection medium (5ml) was added to 
HEK-293ET cells which were left under standard conditions for 24 hours. The 
transfection medium was then removed and fresh standard DMEM was added. The 
recipient MDA-BT1 (1x 104 cells/cm2) were seeded into T25 flasks.  On the fourth 
day, the virus containing medium was collected and briefly centrifuged. The viral 
supernatant (1ml) was added to 9ml of standard DMEM with polybrene (Sigma-
Aldrich)at a final concentration of 5 µg/ ml. Back-up aliquots of viral medium 
were stored at -80°C. The viral solution was filtered through a 0.45 µm (low 
protein binding) filter. Filtered medium was added to the recipient MDA-BT1 
cells. On the fifth day of the protocol,  the medium from the recipient MDA-BT1 
cells was removed and replaced with selection medium containing standard 
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DMEM and a concentration of puromycin, which would kill all non-transfected 
cells after 48 hours (1µg/ml). The chosen selection concentration was determined 
by dose-response curves on non-transfected MDA-BT1 (data not shown). The 
transfected MDA-MB-231 cells were maintained in selection for at least two 
passages until knockdown was confirmed. The efficacy of the IKK knockdown 
was determined by Western blot analysis (see section 0). 
2.3.6 Lentiviral delivery of CRISPR activation particles 
To generate IKK overexpressing MDA-BT1 cells, a lentiviral delivered CRISPR 
activation (CRISPRa) system was used. Control (only antibiotic resistance genes) 
and IKK overexpressing lentiviral particles were purchased from Santa Cruz 
Biotechnology and transfections were carried out as per the manufacturer’s 
instructions. The CRISPRa system is a repurposed version of the Streptococcus 
pyogenes  bacterial CRISPR-Cas9 system. In S. pyogenes CRISPR-Cas9 functions 
to cleaves foreign DNA, however the CRISPRa system is used to enhances 
expression from an endogenous promoter (Perez-Pinera et al., 2013). The Cas9 
nuclease has been mutated such that it loses its ability to cleave and is instead fused 
to three transcriptional activators (VP64, P65 and Rta) to form the dCas9-VPR 
protein. In addition to the mutated Cas9 protein a single guide RNA is also 
introduced. Guide RNAs are able to target upstream of the transcriptional start site 
(TSS) of a desired gene, bind the dCas9-VPR, guide the complex to the DNA 
target site, then the transcriptional activators are proximal to the TSS for up-
regulation of the target gene (Chavez et al., 2015). 
Recipient MDA-BT1  cells were seeded at a density of 1x 104 cells/cm2 into 6 well 
plates. The following day (Day 1) 20μl of control viral particles containing only 
the antibiotic selection gene or CRISPR IKK activating lentiviral particles were 
added to either well containing 2ml of standard DMEM plus 5µg/ ml polybrene 
(Sigma). On day 2, the viral containing medium was removed and replaced with 
standard DMEM. On day 3, the medium for the recipient MDA-BT1 cells was 
replaced with selection medium containing standard DMEM and concentrations 
of puromycin, hygromycin and blasticidin (Gibco), which would kill all non-
transfected cells after 48 hours (1µg/ml, 500 µg/ml and 5 µg/ml respectively). 
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Concentrations were calculated by dose response curves on non-transfected MDA-
BT1 (data not shown). The transfected MDA-BT1 cells were maintained in 
selection for at least two passages until overexpression was confirmed. The 
efficacy of the IKK overexpression was determined by Western blot analysis 
(section 0) 
2.3.7 Small interfering RNA (siRNA) knockdown 
Generation of transient protein knockdown in breast cancer cells was carried out 
using siRNAs according to manufacturer’s instructions. A pool of four annealed 
double – stranded RNA oligonucleotides (Table 4) against TBK-1 (M-003788-02-
0005), IKKβ (M-003503-03-0005), p65 (M-003533-02-0005), IRF3 (M-006875-
02-0005) or non-targeting pool no. 1 (D-001206-13-05) siRNAs were purchased 
from Dharmacon and reconstituted to a 20µM stock using 1x siRNA buffer 
(Dharmacon). Recipient cancer cells (10x103 cells/cm2) were plated in standard 
DMEM and allowed to adhere overnight. The following day the indicated siRNA 
were added at a final concentration of 25nM with Dharmafect 1 transfection 
reagent (2.5 µg/ml; Dharmacon) in 80% antibiotic free standard DMEM and 20% 
serum free DMEM and left in standard conditions until indicated time points. 
Validation of knockdown was carried out using western blotting (section 0). 
Cancer cell viability, migration and ability to induce osteoclast formation were 
assayed by Alamar blue (section 2.2.5) wound healing (section 2.2.6.1) and 
osteoclast formation assays (see section 2.2.7.4).  
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Table 4. A list of siRNA target sequences for human NFκB and IRF pathway members 
Human SMARTpool siRNA Target Sequence 
Non-Targeting 
-UAGCGACUAAACACAAUCAA- 
-UAAGGCUAUGAAGAGAUAC- 
-AUGUAUUGGCCUGUAUUAG- 
-AUGAACGUGAAUUGCUCAA- 
TBK-1 
-GAACGUAGAUUAGCUUAUA- 
-UGACAGAGAUUUACUAUCA- 
-UAAAGUACAUCCACGUUA- 
-GGAUAUCGACAGCAGAUUA- 
IKKβ 
-GAAGUACCUGAACCUAGUU- 
-CCAAUAAUCUUAACAGUGU- 
-GGAUUCAGCUUCUCCUAA- 
-GUGGUGAGCUUAAUAAUG- 
p65 
-GGAUUGAGGAGAAACGUAA- 
-CUCAAGAAUCUGCCGAGUGA- 
-GAUUGAGGAGAAACGUAAA- 
-GGCUAUAACUCGCCUAGU- 
IRF3 
-GCAAAGAAGGGUUGCGUUU 
-AUGCACAGCAGGAGGAUU- 
-GGGAAGAGUGGGAGUUCGA- 
-CCAAGAGGCUCGUGAAUGGU- 
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Western Blot 
Western blot was used to study protein expression and activity in bone and cancer 
cells as previously described in (Idris, 2012). Antibodies and their suppliers can 
be found in Appendix 7. 
2.3.8 Preparation of cell lysates 
Cells were plated in 12-well plates or 6-well plates at 150 x 103 cells/well and 
500x103 cells/well respectively in standard medium until 70% confluence was 
reached.  Medium was suctioned off  and the cell monolayer was washed with ice-
cold PBS. Cells were scraped in  60 µl (12-well) or 120μl (6-well) of RIPA lysis 
buffer (Appendix 4) supplemented with 2% (v/v) protease inhibitor cocktail 
(Sigma Aldrich, UK) and 0.4% (v/v) phosphatase inhibitor cocktail 
(Thermofisher, UK) and remained on ice 10 minutes or until cells were lysed. The 
cell lysate was transferred to a 500μl centrifuge tube and centrifuged at 14000G 
for 10 minutes at 4oC. The supernatant fraction of proteins was collected, being 
careful not to disturb the pellet and stored at -20 oC until further use or used 
immediately. 
2.3.9 Measuring protein concentration 
Protein concentration of cell lysates was determined by the bicinchoninic acid 
(BCA) Pierce protein assay according to manufacturer’s instructions (Pierce, 
USA) as previously described in (Idris, 2012). Serial dilutions of bovine serum 
albumin (BSA) (0-2000 µg/µl) were used to generate a standard curve. BCA 
standard dilutions (10 µl and protein samples (1:5 diluted in distilled H2O) were 
plated in duplicates  in a 96-well plate and 200µl of copper (II)-sulphate (diluted 
1:50 with BCA) were added in each well and the plate incubated for 20-30 minutes 
at 37 oC. Absorbance was then measured at 562 nm on a Biotek Synergy HT plate 
reader and the protein concentration in each sample was calculated from the BSA 
standard curve. 
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2.3.10 Gel electrophoresis 
In order to separate proteins by molecular weight, gel electrophoresis was 
performed using CriterionTM XT BioRad (12% Bis-Tris) pre-cast gels,. Gels were  
placed into a vertical electrophoresis tank filled with electrophoresis running 
buffer (BioRad) diluted 1:10 in distilled water . Cell lysates (30-100μg, maximum 
40µl) were mixed with 5x sample loading buffer (Appendix 4. Buffers for 
Western blotting) and heated to 95°C for 5 minutes and loaded into the well 
following a period of cooling at room temperature. Kaleidoscope pre-stained 
standard and Magic Marker XP (BioRad) western standards were used to identify 
molecular weights. Gels were run at constant voltage of 180V for 45-60 minutes 
dependant on the level of separation required.  
2.3.11 Electrophoretic transfer 
Separated proteins were transferred from polyacrylamide the gel to polyvinylidene 
difluoride (PVDF) pre-cut membranes (BioRad). PVDF membranes were 
activated in 100% methanol and then allowed to equilibrate in transfer buffer 
(BioRad) for 15 minutes. The blotting stack consisting of pre-soaked blot papers 
in transfer buffer, membrane, polyacrylamide gel, pre-soaked blot paper, was 
prepared and placed in the transfer apparatus (BioRad) at a constant voltage of 
25V and a current of up to 1A for 7 minutes.  
2.3.12 Immunostaining and antibody detection 
Following transfer, the PVDF membrane was incubated at room temperature on a 
rocker for 60 minutes in 5% (w/v) non-fat dried milk in Tris buffer saline solution 
(TBS) supplemented with 0.1% (v/v) Tween 20 (TBST). This stage is to ensure 
that sufficient blocking of non-specific binding sites. The membrane was then 
washed in TBST for 15 minutes and this was repeated thrice. The membrane was 
placed in the specified primary antibody (Cell Signalling Technologies - 1:1000 
or Santa Cruz 1:50  in 5% BSA in TBST) overnight at 4 oC with continuous 
rocking. The following day the membrane was washed three times in TBST for 15 
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minutes and incubated with the HRP-conjugated secondary antibody (1:5000 in 
5% w/v dried non-fat milk in TBST; Jackson Laboratories) for 1 hour at room 
temperature  gentle rocking. Following this stage, the antibody was removed and 
retained and the membrane was washed three times with TBST for 15 minutes 
each. Proteins on the membrane were visualised using, for the detection of the 
immunoreactivity complex, the Pierce SuperSignal® West Dura Extended 
Duration chemiluminescent detection system on a BioRad Imaging System. Signal 
intensity was quantified using ImageLab software from BioRad (Exeter, UK). 
Amount of protein of interest was normalised by housekeeping proteins (β-Actin). 
In some experiments, the membrane was incubated in stripping buffer (Appendix 
4) for 3-6 minutes at 55oC in a water both to remove all bound antibodies, then 
blocked again in blocking solution for 1 hour and re-probed with a different 
primary antibody and processed as described above. 
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2.3.13 Measurement of tumour derived cytokines 
The Proteome Profiler Human XL Cytokine Array Kit (R&D Systems) was used 
to detect the expression of cytokines produced by human MDA-BT1 cells and the 
effect Amlexanox (30µM) has on these cytokines. The cytokine array kit was 
carried out according to manufacturer’s instructions. Briefly, conditioned medium 
was generated as previously described (Preparation of Conditioned Medium) in 
the presence of 30µM Amlexanox (0.1% v/v) or DMSO however only a total of 
500µl was prepared in in order to concentrate cytokines produced. Conditioned 
medium was collected and used immediately. The cytokine array membranes were 
incubated in blocking solution for one hour prior. Meanwhile, the samples were 
diluted with blocking solution to 1.5ml. The membranes were washed and then 
placed in the prepared samples at 4°C on a rocking platform overnight. The next 
day membranes were washed in the given wash buffer three times for 10 minutes 
each. The membranes were placed in the given secondary antibody cocktail for 
one hour on a rocker at room temperature before washing as previously mentioned. 
The membranes were covered with 1x streptavidin conjugated horseradish 
peroxidase (HRP) for 30 minutes. The washing steps were repeated. The 
membranes were then exposed to the chemiluminescent detection system and 
visualised using the BioRad system as section  
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2.4 Animal Studies 
A variety of in vivo models were used to investigate how knockdown and 
pharmacological inhibition (alone and in combination with clinically relevant 
Docetaxel) affect primary tumour growth, development of metastasis, colonisation 
of the bone, skeletal tumour growth and osteolysis (Figure 12). All mice were 
placed on a 12-hour light-dark cycle with access to food and water ad libitum. 
2.4.1 Ethics  
All experimental protocols were approved by and performed in accordance with  
UK Home Office regulations under project licence 70/8964  and Italian Legislative 
Decree 116/9 and, Gazzetta Ufficiale della Repubblica Italiana no. 40, February 
18, 1992.  
2.4.2 Intratibial Injection of breast cancer cells 
The effects of cancer-specific inhibition on skeletal tumour growth and osteolysis 
were investigated through intra-tibial injection of human MDA-MB-231-BT1 
cells and was performed at the University of L’Aquila, Italy. Briefly, seven 4 
week‐old female BALB/c‐nu/nu athymic mice (Charles River, Milan, Italy) per 
group were anesthetized with i.p injections of pentobarbital (60 mg/kg). Mice  
received intra-tibial injection of 5×103 human MDA-MB-231-BT IKKε-KD2
  or IKKε-mock cells (Rucci et al., 2013). A 10μl suspension of the cells in 
PBS was injected using a 27½ gauge needle into the intramedullary space of the 
proximal tibiae. Animals were monitored weekly for the development of osteolytic 
lesions (Figure 13). Mice were anesthetized as before and subjected to X‐ray 
analysis (36 KPV for 10 seconds) using a Cabinet X‐ray system (Faxitron model 
n.43855A Buffalo Grove, IL, USA). Of note, two mock injected mice were killed 
by the anesthetic injection and thus bringing the mock group down to five. The 
experiment was terminated when significant osteolysis was observed. Animals 
were sacrificed after 21 days by carbon dioxide inhalation and cervical dislocation. 
Dissection was performed in L’Aquila by myself, lungs were observed for signs 
of macrometasases, although none were observed. Visceral organs and hind limbs 
were fixed in 10% buffered formalin and kept at 4°C.  
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2.4.3 Intracardiac Injection of breast cancer cells 
The effects of pharmacological inhibition of IKKε, on the ability of breast cancer 
cells to colonise bone, tumour growth and osteolysis were assessed through 
intracardiac injection of murine 4T1-Luc2 cells (Wright et al., 2016). Intracardiac 
injection was performed at the University of Sheffield by Dr Ning Wang (Wang 
et al., 2015)(Figure 12).  Sixteen 6-weeks old female BALB/c mice (Harlan, UK) 
were placed in the induction chamber of an anaesthetic machine filled with 2% 
isoflurane until sedated. Mice were placed supine on a sterile surgical platform 
with the forelimbs and hind limbs taped away from the torso. The chest was 
cleaned thoroughly with iodine (Sigma Aldrich). A 100μl suspension with 
100x103 4T1-Luc2 cells in PBS was drawn up in to a 29G insulin needle. The 
needle was injected the left of the sternum, to reach the left ventricle. The cells 
were injected slowly and the needle removed, with pressure being held to the 
injection site for a moment. Mice were placed in an incubator heated to 22°C for 
30-60 minutes to recover. 
After 24 hours, mice were divided in to two groups of 8 mice and treated with the 
indicated compounds (Table 5). Intraperitoneal injections were performed by Mr. 
Richard J Allen using 25G needles. Animals were monitored thrice weekly for the 
development of metastasis using the IVIS system following injection of 100µl of 
D-luciferin (1.5mg/kg; Perkin Elmer). IVIS imaging was performed by Mr 
Richard Allen and myself. Ten days post treatment, animals  developed hind-limb 
paralysis and the experiment was terminated. Animals were sacrificed by Mr Allen 
via cervical dislocation. Following sacrifice, the lungs, liver, spleen, kidneys, 
brain and hind limbs were harvested by myself. IVIS imaging was performed on 
organs ex vivo with organs and limbs being fixed in 4% paraformaldehyde for later 
processing by myself.  
Table 5. Treatment regimens of mice following intracardiac injection. 
Group Treatment 
Vehicle 200µl vehicle control i.p daily 
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Amlexanox 200µl Amlexanox (35mg/kg) i.p daily 
2.4.4 Orthotopic injection of breast cancer cells  
We studied the effects of treatment with Amlexanox, Docetaxel or a combination 
treatment on primary tumour growth and development of distant metastasis using 
the 4T1-Luc2 orthotopic injection model (Figure 12) performed by Dr. Penelope 
Ottewell. Prior to injection, a cell suspension containing 4T1-Luc2 (10x107/ml) of 
ice-cold 60% PBS, 39% growth factor reduced matrigel (Corning) and 1% trypan 
blue (Sigma Aldrich) and left on ice. Forty 6 week-old female BALB/c mice 
(Harlan, UK) were anesthetized as above and placed flat in a supine position on a 
surgical platform. Hair was removed from the mice inguinal surface and 
thoroughly cleaned with iodine as previously mentioned.  A sterile scalpel was 
used to make a 1cm incision in the midline of the mouse abdomen. A  25G needle 
with a volume of 40µl of the cell suspension was injected into the fat pad of both 
the left and right inguinal breast. Incisions were closed with 2-3 5mm wound clips 
and placed in a heated incubator as before.  
The following day mice were checked for tumour engraftment using IVIS 
Spectrum In vivo Imaging System (PerkinElmer, Buckinghamshire, UK). 
Following successful engraftment  mice were divided in to four groups 10 mice 
per group and treated with i.p injections of  vehicle, Amlexanox, Docetaxel or a 
combination (Table 6) carried out by Mrs. Diane Lefley. Animals monitored daily 
for cachexia (evaluated by body weight waste) and behavior. Drug treatments 
began the day following the injection and thus does not represent the treatment of 
a palpable tumour but rather a cell suspension of the cells in the fat pad. The size 
of each tumour was measured externally three times a week by measuring their 
two axes using a caliper and applying the formula of the volume of a sphere [4/3πr3 
where r is half the mean of the two axes]. 
Once the tumour volume had reached the maximum volume of 1cm3, the tumours 
were resected by Dr. Penelope Ottewell. Briefly, mice were anaesthetised  and an 
incision was made as before. Forceps were used to grip the skin and reveal the 
tumour. Blood vessels feeding the tumour and associated lymph nodes were 
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cortorised and the tumour resected using sterile scissors/scalpel.. In some cases, 
the tumour had invaded through the periosteum and in to the gut, deemed 
peritoneal metastasis, thus these mice were sacrificed. Incisions were closed with 
wound clips as before. Tumours were weighed and fixed in 10% buffered formalin 
by myself.  
 The development of metastases was monitored biweekly using the IVIS system. 
At the end of the experiment (when overt metastases were observed), mice were 
euthanized by cervical dislocation/cardiac exsanguination. The primary tumours 
and the lungs, brain, spleen and hind limbs of the animals were dissected formalin 
fixed (Appendix 5) for later processing. Data from this experiment is shown in 
both Figure 31 and Figure 57.  
Table 6. Treatment regimens of mice following orthotopic injections of 4T1-Luc2 cells 
Group Treatment 
Vehicle 200µl vehicle control i.p daily 
Amlexanox 
100µl Amlexanox (35mg/kg) i.p daily 
100µl of vehicle control i.p weekly 
Docetaxel 
100µl Docetaxel (15mg/kg) i.p weekly 
100µl of vehicle control i.p daily 
Combination 
100µl Docetaxel (15mg/kg) i.p weekly 100µl 
Amlexanox (35mg/kg) i.p daily. 
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Figure 12. In vivo models used to study the role of IKKε in breast cancer primary tumour growth, bone metastasis, skeletal tumour growth and osteolysis 
 A) Athymic BALB/c nu/nu mice were injected intratibially with either mock transfected human breast cancer MDA-231 cells or MDA-231 IKKε knockdown 
cells (IKKεKD2. B)  BALB/c mice were injected intracardiacally with luciferase expressing 4T1 cells (4T1-Luc2) and given daily i.p injections of Amlexanox 
(35mg/kg) or weekly i.p injections of docetaxel (15mg/kg) or a combination of the two. C) BALB/c mice were injected in to the mammary fat pad with 4T1-
Luc2 cells and given daily i.p injections of Amlexanox (35mg/kg) or weekly i.p injections of docetaxel (15mg/kg) or a combination of the two. Primary tumours 
were resected when they reached 1cm3, mice were monitored for development of metastases. Mice were sacrificed following detection of metastases using 
IVIS.  
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Figure 13. Development of osteolytic lesions following intratibial injection of MDA-BT1 cells. 
A Schematic diagram of the intratibial injection of MDA-BT1 cells. B X-ray images of one mouse over three weeks following intratibial injection into the left tibia legs (top) and 
non-tumour bearing legs (bottom). Red arrow indicates the presence of osteolysis.  
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2.5 Histological processing of samples 
2.5.1 Fixing of tissues 
Hind limbs were trimmed of excess muscle and soft tissue to reveal bone. Limbs 
and internal organs were placed in 10% buffered formalin  (Appendix 5) for 48 
hours. Following this, samples were washed in PBS and then placed in 70% (v/v) 
ethanol and stored at 4°C for later processing.  
2.5.2 Microcomputed tomography (µCT) 
Microcomputed tomography (µCT) was employed to assess the bone structure and 
architecture following colonization and subsequent destruction of the bone by 
breast cancer cells (Campbell and Sophocleous, 2014). Hind limbs were scanned 
using an ex vivo scanning system (SkyScan). Hind limbs were wrapped in 
cellophane to prevent desiccation and placed upright in the scanner. Legs were 
scanned using an x-ray radiation source to 60kV and 150μA . The pixel size was 
set to 6µM for the intratibial injections 4.3µm for the intracardiac injections. 
NRecon software (Skyscan) was used to generate 3D image stacks by 
reconstructing the data from the rotation image projections. The beginning of the 
tibia on each leg was chosen as a reference point and 1000 frames below that were 
chosen for reconstruction (Table 5). 
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Table 7.  Processes used for µCT analysis   
  
2.5.3 Decalcification of hind limbs 
Hind limbs of mice were decalcified to remove mineral from the bone in order to 
provide quality sections such that the internal cellular structure remains intact. A 
chelating neutral EDTA buffer was chosen as it acts slowly, leaving the tissue 
intact and has little effect on conventional stains such as TRAcP. Hind limbs were 
placed in labelled histological cassettes (Fisher Scientific) submerged in neutral 
EDTA buffer. Cassettes were placed on a rocker at 20 RPM at 4°C. Neutral EDTA 
buffer was decanted and refreshed every 48 hours for 21 days.  
2.5.4 Embedding and sectioning of tissues 
Embedding of tissues in to paraffin blocks was performed as a service by the 
Skelet.AL lab (Sheffield, UK). Briefly, sections were dehydrated through various 
percentages of alcohols before placing in paraffin wax. Sectioning of tissues was 
performed on a Leica microtome (Leica microsystems, Germany) and sections of 
4µm were placed on microscope slides before staining (Thermo Fisher, UK) by 
Danielle de Ridder.  
2.5.5 TRAcP staining of histological sections 
The TRAcP staining of osteoclasts in sections is carried out with similar 
methodology as the staining of osteoclasts in culture. Briefly, sections were 
rehydrated through xylene and alcohols (Table 8). Solutions are incubated in 
Parameter Description Setting 
Smoothing Noise removed and image smoothed 
Pixel 
width 
Beam 
Hardening 
Factor 
Correction 
Corrects for the absorbance of low energy x-ray on the 
outside of the specimen 
9% 
Ring 
correction 
level 
Corrects for the non-linear behaviour of pixels causing 
ring artefacts 
3 
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Solution A (Appendix 2) for 30 minutes at 37°C. Solution A is removed and 
replaced with Solution B (Appendix 2) for 18 minutes. Sections are rinsed twice 
in running tap water to remove remaining solutions. Sections are then 
counterstained in Gill’s Haemotoxylin for 20 sections. Washing in water will blue 
the sections. Sections are dehydrated by quickly reversing the steps in Table 8 so 
that the sections are in each solution for no more than 20 seconds.  Sections can 
be mounted with DPX mounting medium and a coverslip. 
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Table 8. Process of dewaxing and rehydrating histological sections 
Solution Time (Minutes) Process 
100% Xylene 5 Dewax sections 
100% Xylene 5 Dewax sections 
100% Ethanol 5 Clear Xylene 
100% Ethanol 5 Clear Xylene 
95% Ethanol 5 Dehydrate sections 
70% Ethanol 5 Dehydrate sections 
dH2O 1 Rinse sections 
 
2.6 Gene expression analyses 
Copy number variation (CNVs) and gene expression data were analysed using 
cBioPortal (Gao et al., 2013, Cerami et al., 2012). The Molecular Taxonomy of  
Breast Cancer International Consortium ((METABRIC (Curtis et al., 2012) and 
The Cancer Genome Atlas (TCGA (The Cancer Genome Atlas, 2012) studies were 
combined to analyze CNVs in a total of 2951 breast cancer patients. Only the 
METABRIC study had clinical data of the PAM50+Claudin Low molecular 
stratification thus was used to assess mRNA levels in each classification. For 
survival analysis, claudin-Low and Basal classifications were combined to form 
triple negative group. For analysis of association IKBKE copy number variations 
and metastasis, data from the Metastatic Breast Cancer Project was used (ongoing 
–published to cBioPortal (Cerami et al., 2012). Patients were separated in to those 
who were diploid for IKBKE or those who had increased expression (IKBKE 
duplication and amplification). 
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2.7 Statistical Analyses 
Where appropriate comparison between groups was done by analysis of variance 
(ANOVA) followed by Bonferroni post-hoc test using GraphPad Prism 7. A 
student’s T-test was used to determine the significance between two groups using 
GraphPad Prism 7.  Kaplan-Meier curves were calculated in GraphPad Prism 7.0. 
To analyse significant differences between presence of metastasis i.e. yes 
metastasis or no metastasis contingency tables and Fisher’s exact value were 
calculated. A p-value value of 0.05 or below was considered statistically 
significant, and a p-value of 0.01 or below highly statistically significant. 
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3 Chapter 3 
3.1  Summary  
Metastasis to the skeleton occurs in up to 70% of breast cancer patients and is often 
deemed incurable (Coleman, 2001). IKKε is a breast cancer oncogene and has 
been shown to promote the formation of mammary tumours through activation of 
the NFκB pathway (Boehm et al., 2007). However, the role of IKKε in bone 
metastasis and skeletal tumour growth has yet to be assessed. In this study, we 
show that IKKε is amplified in around a fifth of breast cancer patients and is 
associated with triple negative breast cancers. In addition, this was associated with 
poorer overall survival in triple negative patients. Moreover, for the first time, we 
have shown an association between IKKε amplification and the development of 
bone metastasis.  
Knockdown and pharmacological inhibition of IKKε reduced human triple 
negative and osteotropic MDA-MB-231 (MDA-BT1) growth, migration and 
invasion whilst overexpression was stimulatory. Mechanistic studies revealed that 
IKKε driven growth and migration are dependent on NFκB pathway expression. 
Furthermore, cancer specific inhibition of IKKε reduced skeletal tumour growth 
of MDA-BT1 cells following intratibial injection. In addition, for the first time, I 
have shown that pharmacological inhibition of IKKε reduced skeletal and primary 
tumour growth of syngeneic 4T1 mouse breast cancer cells. Overall, this chapter 
demonstrates that selective inhibition of IKKε in cancer cells and/or the 
environment can reduce both primary and skeletal tumour growth and thus may be 
of value in the treatment of breast cancer.  
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3.2 Introduction 
Breast cancers are a highly heterogeneous group of diseases, thus efforts have been 
made to identify distinct intrinsic molecular subtypes such as the PAM50 
stratification, which divides breast cancers in to luminal-A, luminal B, HER2, 
enriched, normal like and basal (Prat and Perou, 2010). Following these, the 
claudin-low group of highly metastatic triple negative breast cancers was added to 
these subtypes. Molecular stratification of cancer can be important in 
understanding clinical phenotypes, prognosis and response to therapies. It is 
important to identify genomic alterations and copy number variations (CNVs), 
namely chromosomal amplifications, deletions and rearrangements within these 
sub-types in order to develop novel targeted therapies that can be used as 
monotherapies or in combination with existing clinically relevant treatments to 
enhance patient survival and quality of life. 
IKKε was first described as a breast cancer oncogene in 2007 by Boehm and 
colleagues (Boehm et al., 2007), who showed the overexpression of constitutively 
active and wild-type IKKε could cooperate with activated MAP kinase pathway 
signalling to induce the transformation of mammary epithelial cells leading to the 
formation of mammary tumours in mice. Furthermore, the authors showed that a 
third of breast cancer patient samples (n=30) express IKBKE CNVs, however they 
found no association of IKBKE gain/amplification with hormone receptor or HER2 
status. They showed that IKBKE locus (1q32) amplification was present in 16.3% 
of breast cancer cell lines (n=49) and that its shRNA mediated inhibition in luminal 
A MCF7 and luminal B ZR-75-1 breast cancer cells caused a reduction in cell 
viability. Thereby, implicating IKKε as a breast cancer oncogene, which promotes 
the initiation of de novo tumours. In a follow-on study, Barbie and colleagues 
(2014) showed that IKBKE mRNA expression was upregulated in a subset of 
triple-negative breast cancers in patients (Barbie et al., 2014). Furthermore, they 
showed that IKKε expression lead to an IL-1β driven inflammatory phenotype and 
its pharmacological and shRNA-mediated inhibition reduced the growth of several 
Chapter 3     IKKε inhibition reduces triple negative breast cancer cell metastatic behaviour 
75 
 
triple negative cell lines. They showed that inhibition of IKKε/TBK-1/JAK 
signalling slowed tumour growth however, when combined with a MEK inhibitor, 
this completely prevented tumour growth of primary triple negative patient-
derived xenografts.  These studies indicate that both inhibition of IKKε alone or 
in combination with other targets could be of value in the prevention and treatment 
of primary breast cancer; however, the validity of IKKε as a driver of metastatic 
breast cancer has yet to be examined.  
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3.3 Aim 
The aims of this chapter were to assess the expression of IKKε in breast cancer 
and investigate the role of IKKε in breast cancer cell metastatic behaviour in vitro 
and in vivo.  
These aims were achieved by examining: 
 the presence of IKBKE CNVs in large clinical datasets 
 the protein expression of IKKε in breast cancer cell lines 
 the effects of stable shRNA mediated knockdown and pharmacological 
inhibition of IKKε on MDA-MB-231-BT breast cancer viability and 
migration in vitro 
 the effects of stable CRISPRa mediated overexpression of IKKε on MDA-
MB-231-BT breast cancer viability and migration in vitro 
 The effect of shRNA mediated knockdown of IKKε on human MDA-BT1 
breast skeletal growth in vivo 
 The effect of Amlexanox on mouse 4T1-Luc2 breast cancer bone 
metastasis following intracardiac injection into syngeneic 
immunocompetent mice 
 The effect of Amlexanox on mouse 4T1-Luc2 breast cancer general 
metastasis following intracardiac injection into syngeneic 
immunocompetent mice 
 The effect of Amlexanox on mouse 4T1-Luc2 breast cancer primary 
tumour growth following orthotopic injection into syngeneic 
immunocompetent mice 
 
 
  
Chapter 3     IKKε inhibition reduces triple negative breast cancer cell metastatic behaviour 
77 
 
3.4 Results 
3.4.1 IKBKE copy number variation is associated with a shorter overall 
survival in triple negative breast cancers  
Studies have indicated that breast cancer is primarily driven by genomic copy 
number variations (Ciriello et al., 2013). In addition, Boehm and colleagues 
showed that IKBKE, the gene encoding IKKε was amplified in around 30% of 
breast cancer patient samples. With this in mind, I first carried out a retrospective 
analysis of amplifications of the IKK genes in a large combined cohort of breast 
cancer patients. To do this I combined the Molecular Taxonomy of  Breast 
Cancer International Consortium ((METABRIC (Curtis et al., 2012) and The 
Cancer Genome Atlas (TCGA (The Cancer Genome Atlas, 2012) cohorts which 
looked at putative CNVs in primary breast cancer patient samples, using 
cBioPortal (Cerami et al., 2012, Gao et al., 2013).  This analysis revealed for the 
first time that IKBKE was the most amplified IKK gene, where it was amplified in 
20.4% of breast cancer patients (Figure 14). Comparatively, CHUK (IKKα), 
IKBKB (IKKβ) and TBK1 had copy number amplifications in 0.3%, 10% and 1.4% 
of breast cancer patients (n=2951) respectively. Further analysis of these cohorts 
revealed that only 35.5% of breast cancer patients being diploid for IKBKE, a very 
small percentage having deletions in the IKBKE locus (0.3%) and the remaining 
patients exhibiting duplications (43.5%).  
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Figure 14. IKBKE copy number is amplified in a fifth of breast cancer patients.  
A) Combined retrospective analysis of the METABRIC (Curtis et al., 2012) and TCGA 2012 (The 
Cancer Genome Atlas, 2012) studies revealed that 20% of breast cancer patients in a cohort of 
2951 have copy number alterations in IKBKE. Comparatively, the other IKK genes, CHUK, 
IKBKB and TBK-1 only had copy number variation in 0.3%, 10% and 1.4% of breast cancer 
patients within the same cohort. B) Further analysis of these cohorts revealed that only 35.5% of 
patients were diploid for IKBKE, whereas 43.5% showed gain of IKBKE, 20.4% had 
amplifications and 0.7% had deletions of IKBKE. Del, deletion; dip, diploid; dup, duplication; 
amp, amplification 
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Next, I examined within which breast cancer molecular subgroup IKBKE 
expression is upregulated. Using the METABRIC cohort on the cBioPortal. 
IKBKE mRNA expression was found to be highest in the triple negative basal-like 
and claudin-low subgroups, significantly higher than luminal-A, luminal-B, HER2 
enriched and normal-like (Figure 15). In addition, I also examined a panel of breast 
epithelial cells and different breast cancer cell lines for IKKε protein expression 
using Western Blot. In broad agreement with the METABRIC analysis, the two 
human triple negative cell lines MDA-MB-468 (basal-like) and MDA-MB-231 
(claudin-low) breast cancer cell lines had the highest levels of IKKε when 
compared to non-transformed MCF10a breast epithelial cell line, with 7.5 ±1.33 
(p<0.001) and 7.2 ±0.3 (p<0.01) fold higher levels of IKKε protein, respectively. 
The luminal B (ZR-75-1) and the HER-enriched (SK-BR-3) cell lines had also 
significantly higher IKKε expression than non-transformed breast epithelial cell 
line, MCF10a with 6.5 ±0.6 (p<0.01) and 4.7±0.5 (p<0.05) fold higher protein 
levels, respectively.  There was no significant difference in IKKε expression 
between the luminal A MCF7 and MCF10A cells.   
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Figure 15. IKBKE expression is upregulated in basal-like and claudin low molecular breast cancer subtypes. 
 A) Analysis of the METABRIC study showed that IKBKE mRNA is most highly expressed in basal-like and claudin-low triple negative breast cancers 
compared to Luminal A, Luminal B, HER2-enriched, Normal-like molecular subtypes. *** p < 0.001 from total median. B) Western blot analysis of cell 
lysates from non-transformed breast epithelial cells (MCF10a), luminal A (MCF7), luminal B (ZR-75-1), HER2-enriched (SK-BR3), basal-like (MDA-
468) and claudin-low (MDA-231) breast cancer cells showed IKKε is most highly expressed in basal-like and claudin-low triple negative breast cancer 
cells. Values are mean ± SD from 3 independent experiments. * p < 0.05 ; ** p < 0.01; *** p < 0.001 compared to non-transformed MCF10a  
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3.4.2 IKBKE CNVs are associated with reduced overall survival in TNBC 
IKKε has previously been shown to be a breast cancer oncogene (Boehm et al., 
2007). However, its role in tumour progression has never been evaluated. 
Therefore, I wanted to examine if there was an association between IKKε 
expression and overall survival in patients. Having shown there is an association 
with triple negative breast cancers, I analysed the METABRIC study survival data. 
These data (Figure 16) revealed that triple negative patients with gain or 
amplification of IKKε had a median overall survival of 78.6 months compared to 
those who were diploid who had a median overall survival of 99.7 months (21.1 
month shorter overall survival,  p<0.05).  In a cohort of all breast cancer patients, 
IKBKE CNVs had no effect on overall survival in this study (Figure 16).  
 
 
 
 
 
 
 
  
Figure 16. TNBC patients with IKBKE CNVs  have significantly shorter overall survival  
A) Combined retrospective analysis of the METABRIC and TCGA 2012 studies indicated that 
breast cancer patients with gain or amplification of IKBKE (n=1544) have no difference in 
overall survival to those diploid for IKBKE (n=871). B) Combined retrospective analysis of the 
METABRIC and TCGA 2012 studies indicated that breast cancer patients with triple negative 
and gain or amplification of IKBKE (n=285) have significantly reduced overall survival 
compared to triple negative breast cancer patients that are diploid for IKBKE (n=192) * p<0.05. 
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3.4.3 IKBKE CNVs are associated with bone metastasis 
Breast cancer predominately metastasises to bone followed by lung, liver and 
brain. Thus I wanted to examine whether increased copy number of the IKBKE 
gene locus is associated with increased metastasis to common sites in patients. To 
do this I analysed data from the Metastatic Breast Cancer Project (provisional; 
n=155). In this study 13.79% of patient samples were diploid for IKBKE, 63.45% 
had duplications and 22.76% had amplifications of the IKBKE locus. Analysis of 
the metastatic locations, in Figure 17, shows that breast cancer patients with copy 
number variations of IKBKE had significantly more bone metastases compared 
with those who were diploid (p<0.05). Furthermore, when further stratified it was 
shown that an even higher percentage of patients who have amplifications of 
IKBKE  developed bone metastases when compared to patients who were diploid 
for IKBKE (P<0.05). Interestingly, there was no difference between the percentage 
of patients in the two groups with lung, liver or CNS/brain metastases.  
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Figure 17. IKBKE CNVs are associated with bone metastasis. 
Retrospective analysis of the association between IKBKE CNVs and site of breast cancer metastasis in the Metastatic Breast Cancer Project. The percentage of patients 
with metastasis at bone, lung, liver or CNS/brain. Diploid of IKBKE (n=31) ; Gain of IKBKE (N=91); Amplifications of IKBKE (n=33). * p<0.05 from diploid group.  
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3.4.4 IKKε is expressed in both parental and osteotropic MDA-MB-231 
breast cancer cells 
I had previously demonstrated that IKKε CNVs are associated with bone 
metastasis in breast cancer patients. Therefore, I assessed if IKKε was upregulated 
in the osteotropic human MDA-BT1 compared to parental MDA-MB-231 cells. 
As seen in Figure 18, IKKε was detected in both parental MDA-MB-231 and 
osteotropic MDA-BT1 cells, however, there was no significant difference in 
expression.  
 
Figure 18. IKKε is expressed in triple negative parental and osteotropic MDA-MB-231. 
A) Western blot quantification of cell lysates from human triple negative parental MDA-MB-231 
and osteotropic MDA-BT1. Cell lysates were subject to western blot and probed with anti-IKKε 
and anti-Actin antibodies. Results are indicative of the mean from at least three independent results. 
B) Representative western blot photomicrograph from the experiment in A. 
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3.4.5 IKKε expression was successfully knocked down in MDA-BT1 by 
shRNA 
To investigate the effects of IKKε inhibition on the metastatic behaviour of breast 
cancer cells I first stably knocked down IKKε in the human triple negative and 
osteotropic MDA-MB-231-BT cells using short-hairpin RNA (shRNA). MDA-
MB-231-BT cells were transfected with a mock pLKO vector only containing a 
puromycin resistance gene or one of two independent shRNA constructs targeting 
IKKε were used to silence its expression. Following, one passage in standard 
DMEM after selection, cells were cultured in serum free medium and lysed. 
Lysates were collected at one, two and four weeks for the remaining experiments.  
Cell lysates underwent western blotting. Figure 19 shows that the two shRNA 
constructs successfully knocked down IKKε by 72.9% ±10.5 (p<0.01) and 
86.7%±9.5 (p <0.001) for IKKεKD1 and IKKεKD2 respectively.  Interestingly, the 
two IKKε mRNA targeting constructs also knocked down TBK-1 protein 
expression by 88.6 ±1.6 % (p<0.001) and 75.0 ±3.6% (p <0.01) for IKKεKD1 and 
IKKεKD2 respectively. Neither construct had any effect on the expression of the 
other IKK family of kinases namely IKKα and IKKβ.
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Figure 19. IKKε was successfully knocked down in MDA-231-BT using shRNA 
A Western Blot quantification of the differential expression of IKKε, TBK-1, IKKα, IKKβ actin in total cell lysates obtained from mock 
control or MDA- BT1-IKKεKD1 and KD2 breast cancer cells. B Representative images of the western blots described in A. Values are mean 
± SD from at least three independent experiments; ** p < 0.01, *** p<0.001. 
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3.4.6 IKKε was successfully overexpressed in MDA-BT1 using CRISPRa 
To further validate the role of IKKε in breast cancer bone metastases, I chose to 
also overexpress IKKε in the human triple negative and osteotropic MDA-BT1 
cells using the Clustered Regularly Interspaced Short Palindromic Repeats Cas9 
activation (CRISPRa) system. Lentiviral particles for CRISPR-Cas9 induced 
activation of IKKε or those containing a non-specific guide RNA as a control 
(mock) were incubated with MDA-BT1 cells as previously described. After 
selection, MDA-BT1 were cultured in selection-free medium for 72 hours and 
lysed. Lysates were subject to western blotting. As is evident in Figure 20, IKKε 
was successfully overexpressed in MDA-BT1 cells. CRISPRa led to a 5.2-fold 
increase (p<0.05) in IKKε expression in MDA-BT1IKKεOE compared to MDA-
BT1Mock cells. Overexpression of IKKε had no effect on protein expression of 
the homologous kinases TBK-1, IKKα, IKKβ (Figure 20).  
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Figure 20. IKKε was successfully overexpressed in MDA-231-BT using CRISPRa. 
A Western Blot quantification of the differential expression of IKKε, TBK-1, IKKα, IKKβ over actin in total cell lysates obtained 
from mock control or MDA- BT1-IKKεOE breast cancer cells. B Representative images of the western blots described in A. Values 
are mean ± SD from at least three independent experiments; ** p < 0.01. 
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3.4.7 Knockdown and pharmacological inhibition of IKKε reduces 
osteotropic breast cancer cell viability  
Several studies have indicated that inhibition of IKKε primary breast cancer cells 
reduces the viability and growth of primary breast cancer cells (Boehm et al., 2007, 
Barbie et al., 2014, Qin and Cheng, 2010). Therefore, I wanted to assess if IKKε 
regulates the growth and viability of MDA-BT1 cells. Firstly I wanted to examine 
how both knockdown and overexpression of IKKε in MDA-BT1 breast cancer 
cells affects cell viability (MDA-BT1 mock, IKKεKD1, IKKεKD2 or MDA-BT1 
mock and IKKεOE cells were plated in a 96-well plate and allowed to grow in 1% 
FCS containing DMEM. Viability was assessed after 24, 48 (data not shown) and 
72 hours (Figure 21). Knockdown of IKKε reduced MDA-BT1 cell viability by 
20.3% ±1.7 (IKKεKD1, p=0.003) and 37.3% ±6.4 (IKKεKD2, p=0.001). 
Contrastingly, IKKε overexpression significantly increased MDA-BT1 cell 
viability by 31% ±1.2 (p<0.001) after 72 hours compared to MDA-BT1Mock 
(Figure 21).   
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Figure 21. Knockdown of IKKε reduces MDA-BT1 cell viability whereas overexpression of 
IKKε enhances cell viability. 
Panel (left) shows the viability of human MDA-BT1 mock (pLKO.1) and IKKε deficient MDA-
BT1 (IKKεKD1 and IKKεKD2). Cell viability was determined using the Alamar Blue assay and 
expressed as a percentage of the values of the mock cells. Representative photomicrographs from 
cultures previously described are also shown.   Right panel shows the viability of human MDA-
BT1 mock (CRISPR) and IKKε overexpressing MDA-BT1 (IKKεOE) Representative 
photomicrographs from cultures previously described are also shown.  The results shown are 
representative of three independent experiments. Values are mean ± SD from at least three 
independent experiments; ** p < 0.01 from mock control. 
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I also tested the effects of three verified IKKε inhibitors Amlexanox, CAY10575 
and CAY10576 (Reilly et al., 2013) on the viability of MDA-BT1 cells using the 
Alamar Blue assay.  As seen in Figure 22, at 30µM and 100µM all compounds 
significantly reduced MDA-BT1 viability after 48 and 72 hours of treatment. 
Although, no compound was able to give an accurate IC50, at 100µM Amlexanox 
(0.1% v/v)  reduced MDA-BT1 viability by 37.5% ±3.6 after 72h in 1% FCS 
containing DMEM compared to DMSO (0.1% v/v) control.  
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Figure 22.  Pharmacological inhibition of IKKε reduces MDA-BT1 viability. 
MDA-BT1 cells were plated in 96 well plates and treated with the indicated doses of Amlexanox, CAY10575 or CAY10576. Cell viability was determined using 
the Alamar Blue assay and expressed as a percentage of the values of the vehicle treated cells. Cell viability of the vehicle treated control was taken as 100%. 
Results shown are mean  ± SD from at  least 3 independent experiments from 48 and 72 hours of treatment.  *p<0.05 **p<0.01, from vehicle treated MDA-BT1 
human breast cancer cells. 72 hours of treatment.  *p<0.05 **p<0.01, from vehicle treated MDA-BT1 human breast cancer cells. 
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3.4.8 Amlexanox inhibited IKKε-driven growth in osteotropic breast cancer 
cells  
Once I established the effects of these compounds on the endogenous levels of 
IKKε, I tested the effects of Amlexanox on cell overexpressing IKKε. Amlexanox 
(10μM) had no effect on MDA-BT1 Mock cell viability (Figure 23). However, in 
stark contrast, Amlexanox (10μM) completely abolished IKKε driven cell viability 
(Figure 23) in MDA-BT1 IKKεOE(p<0.01). 
 
Figure 23. Amlexanox inhibits IKKε-driven MDA-BT1 viability.  
The viability of human MDA-BT1 Mock and IKKε overexpressing MDA-BT1 (IKKεOE) treated 
with either vehicle DMSO (0μM) or Amlexanox (10μM) after 72 hours. Representative 
photomicrographs from cultures previously described are also shown.  The results shown are 
representative of three independent experiments. Values are mean ± SD from at least three 
independent experiments; ** p < 0.01 from vehicle-treated mock control. ++ p < 0.01 from vehicle-
treated MDA-BT1 IKKεOE. 
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3.4.9 Knockdown and pharmacological inhibition of IKKε reduces 
osteotropic breast cancer motility 
Several studies have shown that IKKε contributes to breast cancer cell motility 
(Qing and Cheng, 2010). Here, I assessed the effects of pharmacological and 
shRNA mediated inhibition of IKKε on MDA-BT1 directional 2D migration using 
the wound healing assay (section 2.2.6.1). As shown below in Figure 24 and 
Figure 25, knockdown of IKKε reduced MDA-BT1 2D directed migration by 
18.3% ±8.1 and 20.4±5.6% respectively after 12 hours compared to mock MDA-
MB-231 (p<0.01). Similarly treatment  of Mock MDA-BT1 with 10µM 
Amlexanox reduced 2D directed migration by 15.6 ±8.6%  (p<0.05) after 12 hours 
when compared to vehicle treated mock cells. No difference in cell number was 
observed at the end of the experiment (16 hours) as assessed by the Alamar blue 
assay (Figure 24).  
I also assessed the effects of overexpression of IKKε bone tropic MDA-MB-231 
directional 2D migration using the wound healing assay. As shown in Figure 24 
and Figure 25, overexpression of IKKε enhanced MDA-MB-231-BT1 2D directed 
migration by 21.1 ± 2.9%  after 8 hours compared to mock MDA-MB-231-BT1 
(p<0.05). I also treated IKKε overexpressing MDA-BT1 with Amlexanox (3µM), 
which completely abolished the effects of IKKε overexpression on cell migration.  
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Figure 24. Inhibition of IKKε reduces MDA-BT1 2D cell migration whereas overexpression of IKKε enhances 2D cell migration 
A (Left) shows the 2D directed migration of human MDA-BT1 mock (pLKO.1) and IKKε deficient MDA-BT1 (IKKεKD1 and IKKεKD2) after 12 
hours. Migration was analysed using T-scratch software following a scratch assay. (Right) shows the cell viability at the end of the experiments (16 
hours) and was determined using the Alamar Blue assay and expressed as a percentage of the values of the mock cells. B (Left) shows the 2D directed 
migration of human MDA-BT1 mock (CRISPR) and IKKε overexpressing MDA-BT1 (IKKεOE) treated with DMSO or Amlexanox 10µM at 8 hours. 
Migration was analysed using T-scratch software following a scratch assay. (Right) shows the cell viability at the end of the experiments (16 hours) 
and  was determined using the Alamar Blue assay and expressed as a percentage of the values of the mock cells  The results shown are representative 
of three independent experiments. Values are mean ± SD from at least three independent experiments; * p < 0.01 ** p < 0.01 from mock control; + 
p < 0.05 from DMSO treated MDA-BT1 IKKεOE. 
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Figure 25. Pharmacological and shRNA mediated inhibition of IKKε reduces MDA-BT1 2D cell 
migration whereas overexpression of IKKε enhances 2D cell migration 
Representative images from the experiments described in Figure 24.  
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3.4.10 Knockdown and pharmacological inhibition of IKKε reduces 
osteotropic breast cancer invasion in vitro. 
A crucial stage in the metastatic process is the invasion of local tissues by tumour 
cells followed by extravasation into the circulatory system (Nguyen et al., 2009). 
Thus I assessed the effect of pharmacological inhibition, knockdown and 
overexpression of IKKε on the invasive capacity of MDA-BT1 cells using the 
transwell invasion assay (section 2.2.6.2). In brief, matrigel, an ECM-like 
substance, was coated over transwell inserts. MDA-BT1 deficient in or 
overexpressing IKKε or their relative controls were seeded on to the matrix in 
serum free medium containing either DMSO or Amlexanox. Standard DMEM was 
used as the chemoattractant in the bottom chamber (see section 2.2.6.2). Following 
72 hours, cells were fixed, stained with H&E and quantified. As seen in Figure 26, 
both shRNA (IKKεKD1, 32.1± 5.7%, p<0.01 and IKKεKD2 38.5± 3.5%, p<0.01) and 
pharmacological inhibition (42.2± 6.6%, p<0.01) of IKKε  using Amlexanox 
reduced the invasive capacity of MDA-BT1 cells whereas overexpression was 
stimulatory (19.3± 7.5%, p<0.01). Again,  addition of Amlexanox (3µM) to IKKε 
overexpressing MDA-BT1 cells completely prevented the IKKε driven 
invasiveness of these cells in vitro. 
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Figure 26. Pharmacological and shRNA mediated inhibition of IKKε reduces MDA-BT1 
invasion whereas overexpression of IKKε enhances invasion 
A (Left) shows the invasion of human MDA-BT1 mock (pLKO.1) and IKKε deficient MDA-BT1 
(IKKεKD1 and IKKεKD2) or MDA-BT1 treated with Amlexanox (10µM) after 72 hours. (Right) 
Representative images from the experiment described.  B (Left) shows the invasion of human 
MDA-BT1 mock (CRISPR) and IKKε overexpressing MDA-BT1 (IKKεOE) treated with DMSO 
or Amlexanox 10µM at 8 hours. (Right) Representative images from the experiment described. 
Invasive capacity was assessed by H&E staining; the area of invasive cells covered was quantified 
in Image J and assessed as a percentage of the relative MDA-BT1 mock. The results shown are 
representative of three independent experiments. Values are mean ± SD from at least three 
independent experiments; ** p < 0.01 from mock control; + p < 0.05 from DMSO treated MDA-
BT1 IKKεOE. 
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3.4.11 Knockdown and pharmacological inhibition of IKKε reduce NFκB 
activation in osteotropic breast cancer cells in vitro 
The activation of the NFκB pathway through the phosphorylation and subsequent 
degradation of IκB proteins has been shown to be constitutively active in breast 
cancer cells (Adli and Baldwin, 2006). Additionally, NFκB activation has been 
shown to contribute to metastasis in breast cancer and other cancers (Huber et al., 
2004, Park et al., 2006, Idris et al., 2009, Marino et al., 2018a). Both shRNA-
mediated and pharmacological inhibition of IKKε have been shown to reduce 
MDA-BT1 cell viability, migration and invasion thus indicating a reduced 
metastatic potential. Therefore, I assessed the effects of shRNA-mediated and 
pharmacological inhibition of IKKε on the activation of IκBα (Figure 27).  As 
shown in Figure 27, both shRNA (IKKεKD1 – 45.1± 11.6%, p<0.05; IKKεKD2 – 
46.3 ± 5.0%, p<0.05) and pharmacological inhibition of IKKε (AmX100 – 
48.4±18.2%, p<0.05) lead to a significant reduction in basal levels of 
phosphorylated IκBα when compared to vehicle treated MDA-BT1 cells.  
Consequently, IKKεKD1 (+34.8 ± 13.8%, p<0.05) and IKKεKD2 (+42.5 ± 12.6%, 
p<0.05) MDA-BT1 cells had significantly more IκBα protein overall compared to 
vehicle treated MDA-BT1 Mock cells suggestive of inhibition of IκBα 
degradation. 
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Figure 27. ShRNA- and pharmacological inhibition of IKKε reduces basal phosphorylation of IκBα and increases total IκBα in MDA-BT1 breast cancer cells 
A Representative images of the western blots of the differential expression of serine-36 phosphorylated-IκBα (p- IκBα), total IκBα, over actin in total cell lysates of MDA-
BT1. Lysates were obtained from mock control (pLKO.1)or MDA- BT1-IKKεKD1/KD2treated with vehicle or mock MDA-BT1 treated with the indicated concentrations of 
Amlexanox for 72 hours B Western blot quantification described in A. Values are mean ± SD from at least three independent experiments; * p < 0.01 from Mock vehicle 
treated MDA-BT1.  
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3.4.12 IKKε driven breast cancer growth and motility is mediated through 
the NFκB pathway. 
Since IKKε was first suggested to be an oncogene, there have been various 
mechanisms that help to elucidate its role in tumourigenesis. Many of these have 
been via activation of transcription factors involved in survival and the production 
of proinflammatory factors. Boehm and colleagues showed, IKKε mediated 
tumourigenesis was conveyed through the NFκB pathway, specifically p65 and c-
Rel. IRF3 has also been shown to be involved in antiapoptosis under genotoxic 
stress and in the production of pro-proliferative cytokines such as RANTES and 
IL-8 (Kim et al., 1999, Korherr et al., 2006).  With this in mind, I assessed whether 
IKKε-driven breast cancer cell growth and motility was mediated through the 
NFκB and/or the IRF3 pathway. To do this, I knocked down key components of 
these pathways namely, TBK-1, IKKβ, p65 and IRF3 using pooled siRNA 
targeting in MDA-BT1-IKKεOE and MDA-BT1 Mock cells.  Each cell line was 
plated in 12-well plates and incubated with transfection medium and 5nM of the 
indicated siRNA or a scrambled siRNA (Scr). After 24, 48 and 72 hours, the cells 
were lysed and expression of indicated proteins was assessed using western 
blotting. After 24 hours no proteins were knocked down (data not shown) and after 
48 hours IKKβ and p65 were not significantly knocked down (data not shown). 
However, after 72 hours all indicated proteins were successfully knocked down by 
their targeting siRNA in both MDA-BT1 mock and IKKε OE cells, whereas no 
significant difference was observed between protein expression between mock and 
IKKεOE cells treated with scrambled siRNAs (Figure 28). TBK-1 expression was 
reduced by 89±6.2% (p<0.001) and 76.6 ±6.2% (p<0.001), IKKβ expression was 
reduced by 86.7 ±16.5% (p<0.001)  and 67.4 ±25.8% (p<0.01), p65 expression 
was reduced by 43.2 ±22.5% (p<0.05)  and 39.1 ±14.7% (p<0.05) and IRF3 
expression was reduced by 87±4.0% (p<0.001) and 95.3±1.7% (p<0.001) in 
MDABT1 mock and IKKεOE cells respectively.     
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Figure 28. TBK-1, IKKβ, p65 and IRF3 were successfully knocked down by siRNA after 72 hours in MDA-BT1 Mock and IKKεOE 
(Top) Representative images of the western blots of the differential expression of TBK-1, IKKβ, p65 and IRF3 over actin in total cell lysates obtained from mock control 
or MDA- BT1-IKKεOE breast cancer cells treated with the indicated siRNA or a scrambled control (Scr). (Below) Western blot quantification of the respective siRNA 
knockdowns above. Values are mean ± SD from at least three independent experiments; Results are mean ± SD.  * p < 0.05; **p < 0.01; ***p<0.001. 
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After successful knockdown of each protein of interest I assessed the viability of 
these cells using Alamar blue assay.  A non-transfected (NT) control was used as 
dsRNA in high concentrations induces cell death. After 72 hours, both NT and Scr 
treated IKKεOE cells had significantly more cells compared to MDA-BT1 Mock 
controls. After 72 hours, only siRNA knockdown of IKKβ in MDA-BT1 Mock 
cells caused a significant reduction of viability (15.2± 1.5%; p<0.05) compared to 
Scramble siRNA treated control. SiRNA knockdown of IKKβ and p65 reduced 
MDA-BT1 IKKεOE cell viability by 24.0 ± 5.3% (p<0.05) and 29.8 ± 5.5% 
(p<0.05) respectively compared to Scramble siRNA treated MDA-BT1 IKKεOE 
cells.  
 
 
 
 
 
 
 
 
 
Figure 29. SiRNA knockdown of IKKβ and p65 inhibits IKKε-mediated increased cell 
viability.  
MDA-BT1 Mock or IKKεOE were plated in 12-well plates and treated with the indicated 
siRNAs, a scrambled siRNA or not transfected. Cell viability was measured after 72 hours using 
the Alamar Blue assay. Results are mean ± SD. * p<0.05 from Scrsi Mock; # p<0.05 from Scrsi 
IKKεOE MDA-BT1 cells. Red dotted line indicates  MDA-BT1 Mock baseline.  
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Overexpression of IKKε in MDA-BT1 lead to increased migration as assayed by 
the wound healing assay. Therefore, I aimed to explicate which pathway 
contributed to IKKε driven migration in these cells.  Cells were plated and treated 
with indicated siRNA as before. After 72 hours, when confluence was reached 
migration was assessed using the wound healing assay (see section 2.2.6.1). As 
shown in Figure 30, overexpression of IKKε increased migration by 35.7 ± 8.1 % 
(NT; p<0.05) and 27.0 ± 9.3% (Scr; p<0.05) when compared to MDA-BT1 
MockScr. Knockdown of TBK-1, IKKβ and p65 significantly reduced migration of 
MDA-BT1 Mock when compared to Scramble siRNA treated Mock cells (Figure 
30). Additionally, knockdown of TBK-1, IKKβ, p65 and IRF3 all inhibited the 
IKKε-driven migration of MDA-BT1 IKKεOE cells after 16 hours.  
 
 
 
  
Figure 30. SiRNA knockdown of TBK-1, IKKβ, p65 and IRF3 inhibit IKKε-mediated 
increased cell migration.  
MDA-BT1 Mock or IKKεOE were plated in 24-well plates and treated with the indicated 
siRNAs, a scrambled siRNA or not transfected. After 72 hours, monolayer was scratched and 
cell migration was measure over time and analysed using T-scratch.. Results are mean ± SD. 
* p<0.05 from Scrsi Mock; ** p<0.01 from Scrsi Mock; # p<0.05 from Scrsi IKKεOE; ## p<0.01 
from Scrsi IKKεOE; ### p<0.01 from Scrsi IKKεOE MDA-BT1 cells. Red dotted line indicates 
MDA-BT1 Mock baseline.  
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3.4.13 Amlexanox partially reduces primary tumour growth after 4T1-luc2 
orthotopic injection 
IKKε has previously been described as a breast cancer oncogene, however, no 
compounds that directly inhibit IKKε have been examined on their ability to 
inhibit primary breast cancer growth (Boehm et al., 2007). Therefore, I tested the 
effects of IKKε on primary breast cancer tumour growth using the 4T1-Luc2 
mouse breast cancer cells in syngeneic immunocompetent BALB/c. 4T1-Luc2 
cells were injected orthotopically with 1x106 cells being injected into each of the 
left and right mammary fat pads. The following day mice were injected with 
1.5mg/kg D-Luciferin to check for tumour engraftment, where all mice developed 
tumours.  The tumour was then measured with calipers. Mice were split in two 
groups (n=10/group) and administered vehicle (DMSO; 10% v/v in PBS), 
Amlexanox (35mg/kg/5-times-weekly (Figure 31A). The tumour volume was 
measured thrice weekly and was calculated using the volume of a sphere.  
Treatments were initiated on day 0 (the day after orthotopic injection) and no 
significant effect was observed on primary tumour growth at days 3, 5 and 7 
between vehicle- or Amlexanox -treated groups of mice. However, after day 9 the 
primary tumours of mice treated with Amlexanox showed a significant 31.73 ± 
15.8% reduction (p<0.05).   
Chapter 3     IKKε inhibition reduces triple negative breast cancer cell metastatic behaviour 
106 
 
Figure 31. Treatment with Amlexanox partially reduces primary tumour growth of 4T1-Luc2 cells in vivo 
A 4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads of syngeneic BALB/c mice. Mice were split into four groups (n=10/group) 
and given daily i.p. injections of vehicle or Amlexanox (35mg/kg). B Primary orthotopic tumours were measured using callipers at the indicated time points. C. Mice were 
injected with D-luciferin and imaged using the IVIS system. Results shown are mean values ± SEM. * p<0.05 from vehicle treated group. Related to Figure 57.  
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3.4.14 Amlexanox reduces mouse 4T1 breast cancer metastatic growth in vivo 
following intracardiac injection 
In order to examine the effect of systemic IKKε inhibition  on breast cancer cell 
skeletal growth we injected mouse 4T1-Luc2 breast cancer cells intracardiacally 
to mimic the dissemination of cancer cells throughout the circulatory system. In 
vivo bioluminescence of 4T1-Luc2 cells was detected every second day until the 
end of the experiment. Daily treatment with Amlexanox (35mg/kg) via i.p 
injection was initiated the following day. 4T1-Luc2 cells were detected in the hind 
limbs of mice 3 days after initial injection of cells in both vehicle and Amlexanox 
treated groups. Moreover, after 11 days of treatment Amlexanox reduced hind 
limbs tumour growth by 48.0 ±19.3% (Figure 32) 
 
 
   Chapter 3     IKKε inhibition reduces triple negative breast cancer cell metastatic behaviour 
 
 
108 
 
Figure 32 Amlexanox reduces skeletal tumour growth following intracardiac injection of 4T1-Luc2 mouse breast cancer cells  
4T1-Luc2 cells (1x105/100µl PBS) were injected in to the left ventricle of syngeneic BALB/c  mice. Mice were split into two groups (n=8/group) and given daily i.p. injections 
of vehicle or Amlexanox (35mg/kg) Development and relative size (photons/s) of  hind limb metastases were monitored thrice weekly using the IVIS system. Results are mean 
values± SEM.   *p<0.05 from vehicle treated mice.  
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As breast cancers, especially triple negative disease, spread to other sites in the 
body, namely lung, liver and brain in patients, I also looked at the general 
metastatic spread of the mouse 4T1-Luc2 cells. To do this I selected the body of 
the mouse quantified the metastatic growth over time using LivingImage software.   
Again, Figure 33  shows that Amlexanox reduced the general metastatic growth 
after 10 days of treatment (p<0.05). 
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Figure 33. Amlexanox reduces general metastatic tumour growth following intracardiac injection of 4T1-Luc2 mouse breast cancer cells 
4T1-Luc2 cells (1x105/100µl PBS) were injected in to the left ventricle of syngeneic BALB/c mice. Mice were split into two groups (n=8/group) and 
given daily i.p. injections of vehicle or Amlexanox (35mg/kg) Development and relative size (photons/s) of  general metastases were monitored thrice 
weekly using the IVIS system. Results are mean values ± SEM *p<0.05 from vehicle treated mice.  
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In order to determine the organotropism of 4T1-Luc2 cells and in which organs 
Amlexanox reduced the growth of metastatic breast cancer, immediately following 
sacrifice and dissection, bioluminescence of the organs and hind limbs were 
assessed. Intracardiac injection of 4T1-Luc2 lead to the development of detectable 
metastases in the hind limbs (tibia and femur), lungs, liver, spleen and kidneys of 
mice (no brain metastases were detected). Bioluminescent signals were quantified 
using Living Image software. All eight mice per group developed metastases in 
the organs shown in Figure 34.  
  
  Chapter 3     IKKε inhibition reduces triple negative breast cancer cell metastatic behaviour 
 
 
112 
 
Figure 34. Amlexanox significantly reduced the size of skeletal hind limb but not metastatic lung, liver, kidney or spleen metastases of 4T1-Luc2 cells.  
4T1-Luc2 cells (1x105/100µl PBS) were injected in to the left ventricle of syngeneic 6-week old immunocompetent BALB/c mice. Mice were split into two groups (n=8/group) 
and given daily i.p. injections of vehicle or Amlexanox (35mg/kg). After sacrifice, internal organs were collected and bioluminescence was detected. Relative size (photons/s) 
Hind Limbs (A), lungs (B), liver (C), kidney (D) and spleen (E) metastases are shown. All mice (8 per group) developed detectable metastases in these organs. . Results are 
mean values ± SEM  ** p<0.01 from vehicle treated mice.  
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3.4.15 Cancer-specific knockdown of IKKε in MDA-BT1 breast cancer cells 
reduces skeletal tumour growth in vivo. 
IKKε, a breast cancer oncogene, has been shown to contribute to the 
transformation of breast epithelial cells and the growth of cancer cells in vitro and 
in vivo (Boehm et al., 2007, Barbie et al., 2014, Qin and Cheng, 2010). However, 
the contribution of cancer-specific IKKε to breast cancer skeletal growth has not 
been investigated. In order to assess this, we injected MDA-BT1 Mock or MDA-
BT1 IKKεKD2 cells intratibially in to female athymic BALB/c- nu/nu mice. The 
development of osteolytic lesions were monitored using weekly X-ray images 
(Figure 13). Mice were sacrificed after 21 days. Tumour bearing legs were 
processed and sectioned. Tumour size following TRAcP and eosin staining was 
determined on the Osteomeasure software. All mice in both groups (n=5 mock; 
n=7 IKKεKD2) developed skeletal tumours, however, as seen in Figure 35, mice 
inoculated with MDA-BT1 IKKεKD2 cells had significantly smaller tumours 
(30.4±18.2%; p<0.05) than those inoculated with MDA-BT1-Mock cells after 21 
days.  
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Figure 35. Breast cancer specific knockdown of IKKε reduces MDA-BT1 skeletal tumour growth in vivo 
A) MDA-BT1 Mock (n=5) or IKKεKD2 cells (n=7) were injected intratibially in to athymic BALB/c  nu/nu mice. The development 
of osteolytic lesions were monitored by x-ray. Mice were sacrificed 21-days post inoculation of tumour cells. B) Tumour Area was 
measured on histological sections stained for TRAcP and with H&E at 4x magnification on Osteomeasure software. Results are the 
mean ± SD from three non-consecutive depths. C) Representative Images from the experiment described in B. * p<0.05 from Mock 
MDA-BT1 tumours.  
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3.5 Discussion 
IKKε has been implicated in breast cancer tumourigenesis and was found to be 
overexpressed in approximately 30% of breast cancer patient samples and 16% of 
breast cancer cell lines.  Furthermore, several studies have shown the siRNA 
knockdown of IKKε reduces breast cancer cell growth, migration and invasion in 
various breast cancer cell lines (Boehm et al., 2007, Qin and Cheng, 2010).Upon 
overexpression, IKKε has been shown to phosphorylate and enhance IκB 
degradation leading to p65 activation and thus causing mammary oncogenesis. 
The aim of this chapter was to assess IKKε expression in breast cancer and to 
examine how IKKε contributes to breast cancer cell metastatic behaviour.  
The development of sporadic breast tumours is thought to account for upwards of 
90% of all breast cancers (Srihari et al., 2016). Whilst many breast cancers contain 
mutations in oncogenes and tumour suppressor genes, breast cancers are thought 
to be largely characterised by copy number variations (Ciriello et al., 2013).  
CNAs can affect cancer driver or suppressor genes and function to enhance 
development and ultimately the progression of cancers. Previous studies have 
shown that many IKKε overexpressing luminal breast cancer cell lines harbour an 
amplification of the IKBKE gene locus, whereas a subset of triple negative breast 
cancer cell lines were shown to overexpress IKKε without gene amplification. In 
this study, I combined the METABRIC and TCGA studies to look at CNVs of the 
IKKs and IKK-related proteins, IKKα and β and TBK-1 and IKKε respectively. 
This analysis confirmed that in primary breast cancers, IKKε is amplified in 
around a fifth of all breast cancer patients, whereas IKKβ was overexpressed in a 
tenth. Next, I looked to see if, IKKε mRNA expression was associated with any 
of the breast cancer molecular subtypes in the METABRIC study. Consistently, 
with Barbie and colleagues, I found that increased IKKε expression correlated with 
basal-like and claudin-low sub-types, which are generally considered triple 
negative (Barbie et al., 2014). In concordance with these results, western blot 
analysis of a panel of human breast cancer cell lines showed that IKKε was 
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overexpressed at the protein level in all breast cancer cells lines examined. 
Expression was significantly higher in the luminal B cell line ZR-75-1 and in the 
triple negative and highly metastatic basal-like MDA-468 and claudin-low MDA-
MB-231 human breast cancer cell lines compared to the non-transformed breast 
epithelial cell line, MCF10a. Moreover, I assessed the effect of IKKε amplification 
and duplication on the survival of breast cancer patients in the aforementioned 
studies. When assessing all subtypes as a whole, IKKε overexpression/duplication 
had no effect on the overall survival of breast cancer patients. However, when 
looking at the survival of triple negative breast cancer patients, I found that those 
who were diploid for IKKε had a 21 months longer median survival than those 
with amplification or duplication. Unlike ER+ and HER2 amplified breast cancers, 
triple negative breast cancers have no known druggable targets, therefore these 
data indicate the a subset of triple negative breast cancers may benefit from 
inhibitors that target IKKε.  
It is the spread of breast cancer to vital organs that leads to the death of patients 
and not the primary breast cancer; therefore, we may speculate from these data 
that IKKε does contribute to diseases recurrence and/or metastasis in these triple-
negative patients.  Neither the METABRIC nor TCGA cohorts had data on the 
sites of metastasis of the patients, thus I analysed data from the on-going 
Metastatic Breast Cancer Project. Although this cohort was smaller, this analysis 
revealed that patients with copy number variations for IKBKE had increased 
tendency to develop bone metastasis, thus IKKε may be ideal target to prevent 
bone metastasis in breast cancer patients.  These results further validate the role of 
IKKε and related proteins in the regulation of triple negative and bone metastatic 
breast cancer cells.  
With this in mind, I assessed how cancer-specific IKKε contributes to bone tropic 
MDA-MB-231 (MDA-BT1) breast cancer cell growth, migration and invasion. 
Here, IKKε regulates the growth of  triple negative osteotropic breast cancer cells. 
I have demonstrated that knockdown or pharmacological inhibition of IKKε 
significantly reduced the growth of MDA-BT1 cells. Additionally, IKKε 
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overexpression enhanced the growth of these cells.  All three compounds, not 
previously tested on their ability to reduce breast cancer cell growth, significantly 
reduced MDA-BT1 cell viability at high concentrations. However these 
concentrations are unlikely to be reached in vivo. Qing and Cheng (2014) showed 
inhibition of IKKε reduced the proliferation of luminal A MCF7 and HER2-
enriched SK-BR-3 human breast cancer cells, not by inducing apoptosis as shown 
by annexin-V  and propidium iodide staining, but by arresting cells in the G0/G1 
phase of the cell cycle through downregulation of Cyclin-D (Qin and Cheng, 
2010). Future studies should aim to assess whether inhibition of cell viability 
knockdown of IKKε in triple negative breast cancer cells is carried out through a 
similar mechanism.  
The spreading of primary breast cancer to secondary sites such as bone and lung 
requires that cells become motile, detaching from the underlying basement 
membrane, invading through the ECM and entering the bloodstream. Here I 
showed that breast cancer specific IKKε regulates cell motility. Both 
pharmacological and shRNA-mediated inhibition of IKKε reduced MDA-BT1 
migration and invasion. Contrastingly, IKKε overexpression in MDA-BT1 cells 
enhanced both migration and invasion. Besides, addition of Amlexanox to these 
cells completely prevented the IKKε driven invasion. Previous studies have 
demonstrated that activation of NFκB inhibition using a non-phosphorylatable 
IκBα reduces the ability of MDA-MB-231 cells to invade in vitro. In agreement 
with this, I have showed that, both knockdown and pharmacological inhibition of 
IKKε reduces basal levels of IκBα phosphorylation, leading to increased total 
levels of IκBα suggestive of reduced NFκB pathway activation.  
Knockdown of IKKε was achieved through a lentivirally delivered plasmid that 
produces IKKε targeting shRNA. This targeting IKKε shRNA had no effect on 
the expression of canonical IKKs alpha and beta. Surprisingly, TBK-1 was also 
downregulated in these cells. To ensure that this was not due to direct targeting of 
TBK-1 mRNA, I carried out a BLAST search of the target sequence. The BLAST 
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search revealed that the sequences had 100% similarity with IKKε mRNA and no 
similarity with TBK-1, indicating that the knockdown is most likely not due to off 
target binding. The observed knockdown could be due to a feedback mechanism 
between IKKε and TBK-1. Additionally, Amlexanox the verified IKKε inhibitor 
has also been shown to inhibit TBK-1 at similar concentrations (Reilly et al., 
2013). Therefore, regardless of what the mechanism may be, I cannot discount the 
fact that some of the observed effects in these cells may be due to the combined 
inhibition of both IKKε and TBK-1.    
Breast cancer that has metastasised to the bone is considered incurable (Roodman, 
2009). The median survival for patients with secondary breast cancer in the 
skeleton is between 19 and 25 months. Furthermore, breast cancers, once in the 
skeleton, influence the cells of the bone to produce predominantly 
osteolytic/mixed lesions and this is associated with significant morbidities such as 
hypercalcaemia, bone pain and pathological fractures (Coleman, 2001). Once 
breast cancer cells have homed to the bone, they must survive and ultimately begin 
to proliferate. Encouraged by the results that targeting of IKKε could inhibit 
MDA-BT1 metastatic behaviour I assessed the effect of both IKKε knockdown 
within the cancer cells on skeletal tumour growth and systemic IKKε/TBK-1 
inhibition with Amlexanox on breast cancer metastasis and primary tumour growth 
using three models.   
Here we showed that IKKε inhibition reduced the skeletal growth of MDA-BT1 
cells in vivo following intratibial injection. Similar studies have shown that 
inhibition of NFκB pathway through knockdown of RANK or IKKβ and 
expression of inactive IκBα inhibit the ability of breast cancer cells to grow in the 
bone (Zheng et al., 2014, Marino et al., 2018a, Park et al., 2006). In the syngeneic 
model of breast cancer metastasis, in which murine breast cancer 4T1-luc2 are 
injected intracardiacally in to mice, I observed a significant reduction in the 
skeletal growth of 4T1-luc2 cells with Amlexanox treatment. This is the first study 
to show that pharmacological inhibition of IKKε/TBK-1 with Amlexanox can 
reduce the ability of breast cancer cells to grow within the bone. Considering the 
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fact that many patients present with stage II or stage III disease, we were also 
excited to assess the potential of Amlexanox as an inhibitor of primary tumour 
growth using the syngeneic 4T1-luc2 orthotopic model. However, Amlexanox 
only reduced primary tumour growth of the aggressive 4T1-luc2 cells at one time 
point. This perhaps suggests that IKKε/TBK-1 inhibition is more effective at 
reducing skeletal growth as those cells that thrive in the bone microenvironment 
upregulate members of the NFκB pathway. To that end, Sadanandam and 
colleagues demonstrated through characterising the gene expression profile of 
syngeneic breast cancer cells of differing metastatic potential, grown within the 
tumour bone microenvironment upregulated NFκB pathway members.  
Having shown that IKKε inhibition could reduce tumour growth in three models 
of breast cancer I sought out to assess the mechanisms of which IKKε inhibition 
could reduce tumour growth. In one approach, I attempted to delineate the 
molecular pathways through which IKKε may drive the breast cancer metastatic 
phenotype. To do this, I utilised siRNA to knockdown proteins in MDA-BT1 
Mock and IKKεOE cells. TBK-1 was chosen as it forms a complex with IKKε to 
activate the NFκB and IRF3 transcription factors. IKKβ was also chosen as 
previous studies have postulated that neither IKKε nor TBK-1 are true IKK 
proteins as they are unable to directly target both serines on IκBα for degradation 
but function to stimulate the canonical pathway and enhance p65 transactivation 
through direct phosphorylation. These experiments revealed that knockdown of 
IKKβ and p65 reduced IKKε-driven and basal growth of MDA-BT1 cells, 
indicating that the NFκB pathway is responsible for IKKε-mediated enhanced 
viability. Whilst investigating motility, knockdown of TBK-1, IKKβ, p65 and 
IRF3 all reduced basal and IKKε-driven growth suggesting that both the NFκB 
and IRF3 pathways and their regulated factors contribute to IKKε driven motility 
in vitro. 
In conclusion, these collective data demonstrate that IKKε is overexpressed in a 
subset of triple negative breast cancer patients and these patients have a reduced 
overall survival and an increased tendency to develop bone metastasis thus 
indicating IKKε as a viable target for the treatment of metastatic breast cancer. For 
the first time, I have shown that IKKε regulates the growth and motility of a human 
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bone tropic triple negative breast cancer cell line in vitro and that its inhibition via 
shRNA or with commercially available selective compounds can reduce in vitro 
metastatic phenotype.  Similarly, these studies are the first to show that breast 
cancer specific knockdown of IKKε reduces the ability of an osteotropic triple 
negative breast cancer cell line to grow within the skeleton. Whilst previous 
studies have pharmacologically targeted the IKKε-driven cytokine network to 
reduce primary tumour growth, we are the first to show that direct pharmacological 
inhibition of IKKε and TBK-1 with Amlexanox reduces both primary and 
metastatic tumour growth in vivo. Overall, we have shown that targeting of the 
IKKε/TBK-1 axis  may be a suitable therapy for  all stages of breast cancer.
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4 Chapter 4 
4.1 Summary 
Skeletal metastases are accompanied by the formation of osteolytic and/or 
osteoblastic lesions. Osteolytic lesions result in enhanced osteoclast formation and 
activity which results in excessive weak resorption whilst osteoblastic lesions are 
characterised by deposition of weak disorganised bone. Bone metastases are 
associated with poor quality of life, hypercalcaemia and pathological fractures.  
The IKK/NFκB pathway plays an important role in bone metastasis and osteolysis 
(Idris et al., 2009, Marino et al., 2018a, Peramuhendige et al., 2018). Here, I have 
shown that inhibition of IKKε reduces breast cancer- and RANKL-induced 
osteoclast formation in vitro, whilst overexpression of IKKε enhanced osteoclast 
formation. Mechanistic studies revealed that IKKε-driven breast cancer support 
for osteoclast formation required expression of either the NFκB or IRF3 signalling 
pathways. Moreover, inhibition of IKKε in breast cancer cells reduced the 
expression of inflammatory cytokines involved in osteoclast formation and 
activity such as M-CSF, TNFα and MMP9. Importantly, both breast cancer 
specific and pharmacological inhibition of IKKε reduced breast cancer associated 
osteoclast formation and osteolysis in vivo. Overall, this chapter demonstrates that 
IKKε is an attractive druggable target for the treatment of advanced breast cancer 
and the arising skeletal complications.   
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4.2 Introduction 
Breast cancer commonly metastasises to the bone, with upwards of 70% of patients 
with secondary exhibiting disease skeletal involvement (Coleman, 2001, Lipton et 
al., 2009). Breast cancers tend to spread to highly vascularised bones, those with 
red marrow, such as the pelvic bones, sternum, and ribs (Chen et al., 2017). Once 
there, breast cancer cells disrupt not only bone cell activity and bone remodelling 
but also the immune system and haematopoiesis.  
Following arrival in the skeleton, breast cancer cells produce factors that 
ultimately lead to increased osteoclast numbers (Guise, 2000). Osteolytic lesions 
arise because of enhanced osteoclastic bone resorption. Metastases with a net loss 
of bone are deemed osteolytic whilst those with enhanced deposition of bone are 
termed osteosclerotic/osteoblastic.  Although osteoclastic bone resorption and 
osteoblastic mineral deposition are linked and both thought to occur in early 
metastases, breast cancers, are majority osteolytic (Macedo et al., 2017). The 
symptoms and clinical manifestations of osteolytic lesions include bone loss, bone 
pain, nerve compression syndrome, hypercalcaemia, pathological fractures and a 
reduced quality of life (Waning and Guise, 2014).  
Early researchers suggested that osteolytic lesions were a result of the compression 
of the bone by an expanding tumour, coupled with resorption by the tumour cells. 
Although there is evidence to propose that tumour derived MMPs from breast 
cancers can resorb bone in vitro and in vivo (Lee et al., 2001), it is largely well 
accepted that the increase in osteoclast formation and activity influenced by the 
tumour cells that drives the formation of osteolytic lesions (Clohisy et al., 1995, 
Clohisy et al., 2000).  
The observation that breast cancers metastasise to the skeleton has led to the 
conception of the vicious cycle paradigm (Mundy, 1997). In this concept, bone-
homing breast cancer cells produce numerous growth factors and cytokines that 
stimulate osteoclast formation and enhance their activity. This increased 
osteoclastic bone resorption leads to the release of bone matrix-stored growth 
factors such as TGF-β, Insulin-like growth factors (IGFs) BMPs, FGF and VEGFs 
that can enhance tumour cell growth and cytokine release thus sustaining 
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osteoclast hyperactivity and the vicious cycle of bone metastasis (refer back to 
section 1.2.2 and Figure 5) 
Whilst osteolytic lesions may be driven by enhanced OC formation, there is 
evidence to indicate that bone loss in these scenarios is, in part, a consequence of 
osteoblasts inability to deposit  new matrix. Evidence from the literature suggests 
that bone metastatic cancer cells produce factors that inhibit osteoblast number and 
differentiation such as DKK-1, whilst enhancing osteoblast-derived 
osteoclastogenic cytokines such as IL-1, IL-6 and IL-8. In addition, within 
extensive bone metastatic lesions osteoblasts are almost absent (Phadke et al., 
2006).  
It is well established that activation of NFκB within osteoclasts and their 
precursors is essential for their formation and activity. RANKL produced by cells 
of the osteoblast lineage is essential for osteoclast formation, whilst other 
cytokines such as TNFα, CD40L and IL-1 aid in osteoclast formation and survival 
(Boyce et al., 2015).  Additionally, NFκB activity within osteoblasts inhibits their 
differentiation and ability to mineralise. Furthermore, recent studies have indicated 
that the cancer-specific activation of NFκB through various members of the 
pathway, including IκBα, TRAF2 and IKKβ, contribute to osteoclast formation 
and osteolytic lesions. This was shown to be due to the production of numerous 
osteoclastogenic cytokines, (Park et al., 2006, Peramuhendige et al., 2018, Marino 
et al., 2018a). However, no studies to date have assessed the role of IKKε on the 
ability of breast cancer cells to influence osteoclastogenesis, osteoblast 
differentiation, skeletal tumour growth or osteolysis.  
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4.3 Aims 
The aim of this chapter was to investigate the role of IKKε in human breast cancer 
and bone cell interactions in vitro and breast cancer skeletal tumour growth and 
osteolysis in vivo. The aims of this chapter will be realised by examining: 
 The effect of knockdown and pharmacological inhibition of IKKε on 
skeletal tumour growth and osteolysis in vivo. 
 The effect of on RANKL-induced and breast cancer support for 
osteoclastogenesis. 
 The effect of knockdown and pharmacological inhibition of IKKε on 
breast cancer ability to influence osteoblast viability, differentiation and 
activity.  
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4.4 Results 
4.4.1  Cancer specific IKKε regulates breast cancer support for osteoclast 
formation.  
Osteolytic lesions are characterised by an increase in osteoclast number, size and 
bone resorption that fuels the growth of the cancer cells.  With this is mind, I 
assessed how IKKε in cancers cells and osteoclast precursors regulates breast 
cancer support for osteoclastogenesis. I isolated human and mouse osteoclast 
precursor cells (see section 2.2.7) and co-cultured together with MDA-BT1 (IKKε 
KD1/KD2, IKKεOE and control) cells and RANKL (100ng/ml) and M-CSF (25ng/ml) 
for a total of 5 days. As shown in Figure 36, overexpression of IKKε in osteotropic 
MDA-BT1 enhances their ability to support human osteoclast formation by 45.2 
±15.9% (p<0.05) compared to mock transfected MDA-BT1. Addition of 
Amlexanox (1μM) to these cultures, prevented the IKKε-driven increase in  MDA-
BT1 IKKεOE cultures (p<0.05). Conversely, knockdown of IKKε in MDA-BT1 
reduced their ability to support osteoclast formation as evidenced by a reduction 
of  36.5 ±9.8% and  39.4 ±7.5%  for IKKεKD1 and IKKεKD2 co-cultures 
respectively. Again, addition of Amlexanox (1μM) to MDA-BT1 mock cultures 
also reduced their ability to support osteoclast formation by  54.7 ±10.4% .  In 
mouse bone marrow co-cultures, those cultured with IKKεKD1 and IKKεKD2 had a 
reduction of  36.8±8.9% (p<0.05) and 32.9±5.9%    (p<0.05) when compared to 
MDA-BT1 mock co-cultures. 
Chapter 4                       IKKε inhibition inhibits osteoclast formation in vitro & osteolysis in vivo 
 
127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. IKKε regulates breast cancer cell support for osteoclastogenesis 
A)  Schematic diagram of the experiment in B and C to generate osteoclasts. B) Number of human TRAcP+ multinucleated osteoclasts per well as a percentage of the Mock 
MDA-BT1 Cell treated well. AmX (1µM) or DMSO were added to the osteoclast precursors one hour before addition of Cells or cytokines (left) Number of human TRAcP+ 
multinucleated osteoclasts per well as a percentage of the Mock MDA-BT1 CM treated well. AmX (1µM) or DMSO were added to the osteoclast precursors one hour before 
addition of CM or cytokines (right). C) Number of mouse TRAcP+ multinucleated osteoclasts per well as a percentage of the Mock MDA-BT1 CM treated well. AmX (1µM) 
or DMSO were added to the osteoclast precursors one hour before addition of CM or cytokines. D) Representative images from the experiment in B 
Chapter 4                       IKKε inhibition inhibits osteoclast formation in vitro & osteolysis in vivo 
 
128 
 
Breast cancers produce a number of factors that support osteoclast formation, 
therefore I wanted to see if IKKε supports osteoclast formation through the 
production of tumour derived factors. To do this I generated condition medium 
from MDA-BT1 IKKε deficient, IKKε overexpressing and their respective mock 
cells as previously described (section 2.2.4) and cultured it with mouse and human 
osteoclast precursor cells in the presence or absence of Amlexanox (Figure 37). 
Addition of MDA-BT1 IKKεOE cell CM (10% v/v) to human macrophages 
increased osteoclast formation by 69.3± 6.3% (p<0.01) compared to MDA-BT1 
Mock CM. Additionally, Amlexanox (0.3µM) completely prevented the increase 
in human osteoclast formation in cultures exposed to MDA-BT1 IKKεOE condition 
medium. In accordance with these results, a reduction of 28.2± 5.1% and 34.7± 
14.1% was observed in cultures exposed to MDA-BT1 IKKεKD1 and IKKεKD2 CM 
respectively, when compared to MDA-BT1 Mock CM. Moreover, Amlexanox 
(1µM) also significantly reduced MDA-BT1 Mock CM support for human 
osteoclast formation by 67.1± 9.9%. In mouse bone marrow cultures exposed to 
MDA-BT1 IKKεKD1 and KD2 CM, a reduction of 54.6± 4.5% and 60.9± 2.1% 
respectively. Similarly, to human cultures, addition of Amlexanox to MDA-BT1 
Mock CM treated murine osteoclast precursors reduced osteoclast formation by 
81.7± 1.5% (p<0.01). 
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Figure 37. IKKε regulates breast cancer cell support for osteoclastogenesis through production of tumour derived factors. 
A)  Schematic diagram of the experiment in B and C to generate osteoclasts. B) Number of human TRAcP+ multinucleated osteoclasts per well as a 
percentage of the Mock MDA-BT1 CM treated well. AmX (0.3µM) or DMSO were added to the osteoclast precursors one hour before addition of CM or 
cytokines (left) Number of human TRAcP+ multinucleated osteoclasts per well as a percentage of the Mock MDA-BT1 CM treated well. AmX (1µM) or 
DMSO were added to the osteoclast precursors one hour before addition of CM or cytokines (right). C) Number of mouse TRAcP+ multinucleated 
osteoclasts per well as a percentage of the Mock MDA-BT1 CM treated well. AmX (1µM) or DMSO were added to the osteoclast precursors one hour 
before addition of CM or cytokines. D) Representative images from the experiment in B. *** p<0.001 
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4.4.2 Knockdown of NFκB and IRF3 pathway inhibits IKKε-driven MDA-
BT1 support for osteoclast formation 
In chapter 3, I showed that successful knockdown of the NFκB and IRF pathway 
members, namely TBK-1, IKKβ, p65 and IRF3 reduces IKKε-driven growth and 
migration in MDA-BT1 cells in vitro. I also wanted to assess which pathways were 
involved in IKKε-driven MDA-BT1 support for osteoclast formation, as both the 
NFκB and IRF3 pathways are known for regulating the production of 
proinflammatory factors and those involved in osteoclast formation. To do this, I 
used siRNA to knockdown TBK-1, IKKβ, p65 or IRF3 in both MDA-BT1 mock 
and IKKεOE and generated conditioned medium as described previously. The 
various conditioned medium (10% v/v) were added to RAW264.7 cells with 
100ng/ml RANKL. Cultures were terminated after 120 hours. TRAcP staining was 
used to identify multinucleated (>3 nuclei) osteoclasts (see section 2.2.7). As seen 
in Figure 38,  IKKε-over expression increases MDA-BT1 ability to support 
osteoclast formation in vitro. However, knockdown of TBK-1, IKKβ, p65 and 
IRF3 reduced osteoclast formation by 72.79±17.6% (p<0.01), 75.5±27.8% 
(p<0.01), 89.1±32.3% (p<0.01) and 103±24.5% (p<0.01) respectively compared 
to scramble treated MDA-BT1 IKKεOE conditioned medium. Similarly, 
knockdown of TBK-1, IKKβ, p65 and IRF3 reduced support for osteoclast 
formation in Mock MDA-BT1 cells by 79.1 ± 21.5%, 55±9.8%, 32.5±8.1, 
46.5±8.1% respectively compared to  MDA-BT1 mock scramble conditioned 
medium.  
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Figure 38. SiRNA knockdown of TBK-1, IKKβ p65 and IRF3 inhibits IKKε-mediated increased 
osteoclast formation.  
MDA-BT1 Mock or IKKεOE were plated in 12-well plates and treated with the indicated siRNAs, a 
scrambled siRNA or not transfected. Conditioned medium was collected and added (10% v/v) to 
RAW264.7 cells cultures with RANKL 100ng/ml every 48 hours for 120 hours. Cultures were fixed 
and TRAcP stained. Osteoclast were counted and expressed as a percentage of NT-Mock-BT1. 
Results are mean ± SD from at least three independent experiments. *p < 0.05 from MockScrsi; 
**p<0.01 from Mock Scrsi ## p<0.01 from IKKεOE Scrsi MDA-BT1 cells. Red dotted line indicates 
NT MDA-BT1 Mock baseline. 
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Figure 39 Knockdown of the NFκB and IRF3 pathways in MDA-BT1  Mock and IKKε OE cells reduced breast cancer support for osteoclast formation. 
RAW264.7 cells were plated in a 96-well plate and exposed to conditioned medium (10%v/v) from MDA-BT1 mock and IKKεOE cells treated with scramble siRNA or TBK-
1, IKKβ, p65 or IRF3 targeting siRNA. Osteoclast-like cells were fixed, TRAcP stained and the number of TRAcP+ multinucleated OCs were counted. Above shows 
representative images. 
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4.4.3 IKKε regulates tumour-derived proinflammatory cytokine production 
by osteotropic breast cancer cells 
The production of secreted factors by breast cancer cells has been shown to 
enhance cancer cell proliferation, migration, EMT-induction and priming of the 
metastatic niche for colonisation. Moreover, the NFκB pathway and IKKε are 
known to regulate a variety of cytokines and proinflammatory factors such as 
TNFα, MMP-9, IL-6, and IL-8 (Boehm et al., 2007, Adli and Baldwin, 2006, Peant 
et al., 2009, Barbie et al., 2014). Therefore, I examined the changes in cytokine 
production in MDA-BT1 cells in response to pharmacological inhibition of IKKε 
using Amlexanox.  MDA-BT1 cells were treated with vehicle (0.01% v/v DMSO) 
or Amlexanox (30μM) for 24 hours. Conditioned medium was generated as 
previously described (See section 2.2.4).  MDA-BT1-derived cytokines were 
measured using the Proteome Profiler Human XL Cytokine Array Kit (see section 
2.3.13). 
Of the 102 cytokines assayed. Six cytokines were upregulated by more than two-
fold and fourteen were down regulated by more than two fold in MDA-BT1 cells 
treated with Amlexanox compared to vehicle treated cells (Figure 40). Amongst 
the cytokines that were upregulated in Amlexanox treated MDA-BT1 Mock cells 
compared to vehicle treated MDA-BT1 Mock cells were relaxin-2 (296.2%), 
angiogenin (281.4%), osteopontin (246.2%), Intercellular Adhesion Molecule 1 
(ICAM; 243.0%), granulocyte-colony stimulating  factor (G-CSF; 225.0%), 
extracellular matrix metalloproteinase inducer (EMMPRIN; 219.6%). Cytokines 
produced at 50% or less in MDA-BT1 cells exposed to Amlexanox include 
macrophage-colony stimulating factor (M-CSF; 47.5%), interleukin-24 (IL-24; 
46.4%); tumour necrosis factor-alpha (TNFα; 44.8%), fms related tyrosine kinase 
3 ligand (Flt-3 ligand; 43.3%) trefoil factor 3 (TFF3;  42.0%);  chemokine C-X-C 
motif ligand 1 (CXCL1; 41.2%);  Dickkopf-related protein 1 (DKK-1; 37.4%);  
matrix metalloproteinase-9 (MMP9; 37.3%);     stromal –cell derived factor 1a 
(SDF1a; 33.7%); interleukin 23 (IL-23; 29.7%);     adiponectin (22.1%);  brain-
derived neurotrophic factor (BDNF;7.9%);  Cystatin C (7.9%); cluster of 
differentiation 30 (CD30; 3.8%)
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Figure 40. Differential expression of cytokines in the conditioned medium of MDA-BT1 cells treated with Amlexanox . 
(Left) Quantification of cytokines in the conditioned medium of MDA-BT1 exposed to AmX for 24 hours compared to vehicle treated MDA-BT1.  Yellow highlight 
shows  upregulated and downregulated cytokines in conditioned medium of MDA-BT1 cells following treatment with AmX compared to vehicle treated MDA-BT1. 
Red dotted upper line indicates a 2.0 fold production of cytokines. Lower red dotted line indicates a 0.5-fold production in cytokine. These results are representative of 
an individual biological repeat. (Right) Venn diagram of differentially regulated breast cancer, bone metastatic, osteoclastic and osteoblastic mediators in MDA-BT1 
CM in response to Amlexanox (30μM). See Table 9 for more details. 
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4.4.4 Knockdown and pharmacological inhibition of IKKε have no effect on 
osteoblast viability, differentiation and activity 
Breast cancers once in the skeleton influence osteoblasts to produce disorganised 
woven bone resulting in osteoblastic metastases. With this is mind, I assessed the 
effects of cancer specific knockdown of IKKε in MDA-BT1 cells and 
pharmacological inhibition of IKKε/TBK-1 cells on viability, differentiation and 
activity. To do this calvarial osteoblasts were isolated as described (2.2.9.1). 
Osteoblasts were cultured in the presence of the indicated MDA-BT1 conditioned 
medium (20% v/v) with or without Amlexanox. After 3 days the osteoblast 
viability was measured (2.2.5) and the cells were lysed and assayed for alkaline 
phosphatase levels (2.2.9.3) as seen in, cancer-specific knockdown of IKKε had 
no effect on osteoblast viability or alkaline phosphatase activity. Similarly, 
pharmacological inhibition of IKKε with Amlexanox had no effect on osteoblast 
viability or alkaline phosphatase activity (Figure 41). Osteoblast-like Saos-2 cells 
were used to study the effect of inhibition of IKKε using Amlexanox on osteoblast 
activity. As shown in Figure 41D-E, pharmacological inhibition of IKKε in 
osteoblast-like cells had no effect on osteoblast activity in the presence of MDA-
BT1 cell conditioned medium (20% v/v). 
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Figure 41. IKKε inhibition has no effect on osteotropic breast cancer cell support for osteoblast differentiation or activity.  
A)  Schematic diagram of the experiment in B and C to isolate calvarial osteoblasts. B) Calvarial osteoblasts were co-cultured with 20% v/v MDA-BT1 Mock or IKKεKD1/2 CM  
with DMSO or MDA-BT1 Mock CM plus AMX at the indicated concentrations for 72 hours. C) Cells were lysed and Alkaline phosphatase activity was measured. D Saos-2 
osteoblast-like cells were co-cultured with 20% v/v MDA-BT1 Mock or IKKεKD1/2 CM  with DMSO or MDA-BT1 Mock CM plus AMX at the indicated concentrations for 
ten days, then fixed and stained with Alizarin red to show bone nodules.  E. Representative images of the experiment in D. Results are mean ± SD from at least three independent 
experiments.
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4.4.5 Amlexanox inhibits RANKL-induced osteoclast formation without 
affecting osteoclast precursor viability 
A recent study by Zhang and colleagues showed that the verified IKKε/TBK-1 
inhibitor reduced ovariectomy-induced bone loss in mice by osteoclast inhibition 
(Zhang et al., 2015). Thus, I aimed to examine whether IKKε/TBK-1 inhibition 
affects RANKL-induced human and mouse osteoclast formation in the absence of 
osteotropic breast cancer cells and their derived factors.  Addition of RANKL 
(100ng/ml) to human CD14+ macrophages induced the formation of TRAcP 
positive multinucleated osteoclasts, and exposure to Amlexanox (1-3µM) 
significantly reduced the formation of osteoclasts by 29.6± 9.4% (p<0.05) and 
48.4± 2.2% (p<0.01) (Figure 42) . Similarly, Amlexanox (1-3µM) reduced the 
formation of osteoclasts in RANKL stimulated mouse bone marrow cultures by 
57.5± 3.3% (p<0.01) and 77.2 ± 3.4% (p<0.01) respectively (Figure 42). 
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Figure 42. Amlexanox inhibits RANKL-induced human and mouse osteoclast formation. 
A Schematic diagram of the experiment in B and C to generate osteoclasts. Bone marrow was isolated by flushing of mouse tibia. PBMCs were isolated from whole blood and 
CD14+ cells were selected for using antibody bound beads. MCSF was added for 48 hours to induce the differentiation to macrophages. RANKL and MCSF were added to 
induce osteoclast formation.  Amlexanox was added at indicated concentrations and 50% of medium was refreshed every 48 hours until fixation and TRAcP staining. B Number 
of human TRAcP+ multinucleated osteoclasts per well as a percentage of the vehicle treated wells. C Number of human TRAcP+ multinucleated osteoclasts per well as a 
percentage of the vehicle treated wells. D Representative Images from the experiment described in B. Values are mean ± SD from at least three independent experiments; * p < 
0.05, ** p < 0.01 from vehicle treated control. 
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As Amlexanox reduced the formation of osteoclasts following exposure to 
RANKL, I examined if this reduced osteoclast formation was due to a reduction 
in the viability of precursor cells. Human CD14+ monocytes were cultured in 
MCSF for 48 hours to generate M-CSF dependant macrophages, which were 
exposed to various concentrations of Amlexanox. Amlexanox had no effect on the 
viability of human M-CSF dependant macrophage cells at concentrations that 
inhibited osteoclast formation for up to 5 days (Figure 43).  
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Figure 43. Amlexanox has no effect on human CD14+ MCSF generated macrophages 
A. Schematic diagram of the experiment. PBMCs were isolated from whole blood and CD14+ cells were 
selected for using antibody bound beads. MCSF was added for 48 hours to induce the differentiation to 
macrophages. Amlexanox was added at indicated concentrations and 50% of medium was refreshed every 
48 hours until fixation. B Relative cell viability at the end of the experiment as determined by Alamar 
Blue C Representative images of macrophage/osteoclast precursors following fixation and TRAcP 
staining. Values are mean ± SD from at least three independent experiments.  
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4.4.6 Amlexanox inhibits RANKL- but not MDA-BT1 CM-induced 
phosphorylation of IκBα in osteoclast precursors  
RANKL and MCSF are essential cytokines for the formation, survival and activity 
of osteoclasts (Nakagawa et al., 1998, Fuller et al., 1993). However, only RANKL 
regulates the formation of osteoclasts through the phosphorylation of IκB and 
subsequent activation of NFκB (Boyce, 2013). In view of this, I went on to test 
the effects of Amlexanox on RANKL-induced phosphorylation of IκB by RANKL 
and osteotropic tumour cell derived factors (Figure 44). To do this, I exposed 
macrophage-like RAW264.7cells to RANKL  following pre-treatment with 
vehicle or Amlexanox. Macrophage-like cells were lysed and subject to western 
blotting.  RANKL (100ng/ml) increased the phosphorylation of IκBα by 3.26 fold 
(p<0.05), however, prior treatment with Amlexanox (10µM) prevented this 
increase (Figure 44). Moreover, 30µM of Amlexanox reduced phosphorylation of 
IκBα by 0.58 fold (p<0.05) of the basal levels of phosphorylation.  
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Figure 44. Amlexanox inhibits RANKL-induced phosphorylation of IκBα. 
A) Western blot of mouse macrophage-like RAW264.7treated with vehicle (0.1% DMSO), Amlexanox (10 and 30 μM), for 1 hour prior to stimulation with vehicle 
(0.3% bovine serum albumin), RANKL (100 ng/ml) for 10 minutes. Total cellular protein was subjected to western blot analysis (70 µg/lane) using primary rabbit 
anti-phospho IκBα, rabbit anti-IκBα and rabbit anti-β-actin. The results shown are representative of three independent experiments. B) Quantification of the amount 
of phosphorylated IκBα over total IκBα (left) and total IκBα over actin as a percentage of vehicle control. Values are mean ± SD from at least three independent 
experiments;   * p<0.05; ** p < 0.01. 
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Osteotropic breast cancer cells are able to support osteoclast formation through 
production of a variety of other factors including TNFα, IL-1, IL-6, IL-8, IL-23 
IL-17, TGFβ, VEGF-A. In view of the above, I assessed whether Amlexanox was 
able to inhibit the phosphorylation of IκBα in macrophage-like osteoclast 
precursors. RAW264.7 were treated with DMSO (0.1%), Amlexanox (10 or 
30µM) prior to stimulation with MDA-BT1 CM (20%) for ten minutes. 
RAW264.7were lysed and subject to western blotting. Western blot revealed that 
MDA-BT1 CM increased the phosphorylation of IκBα (5.72 fold increase, 
p<0.001) in RAW264.7 cells, leading to the degradation of IκBα (0.26 fold 
difference, p<0.001). Treatment with Amlexanox was not sufficient to 
significantly reduce the phosphorylation nor the degradation of IκBα (Figure 45). 
Interestingly, a trend towards more total IκBα was observed.  
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Figure 45. Amlexanox has no effect on MDA-BT1 CM induced phosphorylation and degradation of IκBα. 
A) Western blot of mouse macrophage-like RAW.267 treated with vehicle (0.1% DMSO), Amlexanox (10 and 30 μM), for 1 hour prior to stimulation with control 
CM (20 % v/v) or MDA-BT1 CM (20 % v/v) for 10 minutes. Total cellular protein was subjected to western blot analysis (70 µg/lane) using primary rabbit anti-
phospho-IκBα, rabbit anti-IκBα and rabbit anti-β-actin. The results shown are representative of three independent experiments. B) Quantification of the amount of 
phosphorylated IκBα over total IκBα (left) and total IκBα over actin as a percentage of vehicle control. Values are mean ± SD from at least three independent 
experiments;  **p<0.01 , *** p < 0.001 from vehicle/Control CM treated control;  
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4.4.7 Cancer-specific knockdown of IKKε in osteotropic breast cancer cells 
reduces osteolysis in mice 
The growth of breast cancer cells within the bone microenvironment often leads 
to the formation of osteolytic lesions. To examine the role of cancer specific IKKε 
on the ability to MDA-BT1 cells to induce osteolysis, IKKε knockdown (IKKεKD2) 
mock transfected MDA-BT1 cells were injected in to the left tibia of nude mice 
(see section 2.4.2) and monitored for the development of osteolytic lesions. 
Osteolysis was assessed using detailed μCT analysis of several features of the bone 
in the proximal tibial metaphysis.  As shown in Figure 46, there was no significant 
difference in the total bone volume between mice intratibially injected with mock 
MDA-BT1 and MDA-BT1 IKKεKD2 cells. 
 
Figure 46. Knockdown of IKKε in MDA-BT1 had no effect on total bone volume. 
4-week old athymic BALB/c nu/nu mice received injections of 4x103 MDA-BT1 Mock or 
IKKεKD2 human breast cancer cells into the left tibiae and a sham injection of PBS into the right 
tibia. Animals were sacrificed 21 days after intratibial injection. Microcomputed tomography 
(µCT) was used to analyse changes in bone.   
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Detailed analysis of the trabecular and cortical compartments individually showed 
that mice injected with MDA-BT1 IKKεKD2 had significantly more trabecular bone 
(72.8± 36.2 %) at the end of the experiment as indicated by BV/TV (p<0.05 Figure 
47A and F).  Interestingly, breast cancer specific knockdown of IKKε had no 
significant effect in trabecular number (Figure 47B), trabecular thickness (Figure 
47C) nor separation (Figure 47D), however, trabecular were significantly less 
porous   (Figure 47E, 3.1 ± 1.4% reduction in porosity, p<0.05).  
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Figure 47. Breast cancer specific knockdown of IKKε reduces MDA-BT1 induced osteolysis in vivo  
4-week old athymic BALB/c nu/nu mice received injections of 4x103 MDA-BT1 Mock or IKKεKD2 human breast cancer cells into the left tibiae and a sham injection of 
PBS into the right tibia. Animals were sacrificed 21 days after intratibial injection. Microcomputed tomography (µCT) was used to analyse changes in bone. Trabecular 
parameters analysed were bone volume/tissue volume (BV/TV%; A), trabecular number (Tb.N; B) trabecular thickness (Tb.Th; C), separation (Tb.Sp; D) and 
porosity(Po(op)%; E) Representative 3D reconstructions are shown in panel F. Values are means ± standard deviation. Five mice in the mock injected group and seven 
mice in the IKKεKD2 group. *p<0.05 from mock MDA-BT1 injected legs. 
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Additionally I sought to evaluate the effect of knockdown of IKKε in MDA-BT1 
on the osteolysis of cortical bone in mice. However, as shown in Figure 48, breast 
cancer specific knockdown of IKKε had no significant effect on cortical BV nor 
porosity.  
 
  
Figure 48. Breast cancer specific knockdown of IKKε has no effect on MDA-BT1 induced 
cortical osteolysis in vivo 
4-week old athymic BALB/c nu/nu mice received injections of 4x103 MDA-BT1 Mock or 
IKKεKD2 human breast cancer cells into the left tibiae and a sham injection of PBS into the right 
tibia. Animals were sacrificed 21 days after intratibial injection. Microcomputed tomography 
(µCT) was used to analyse changes in bone.   
 
Chapter 4                        IKKε inhibition inhibits osteoclast formation in vitro & osteolysis in vivo 
 
149 
 
4.4.8 Cancer-specific knockdown of IKKε in MDA-BT1 breast cancer cells 
reduces osteoclast formation but has no effect on osteoblasts  
To uncover the cellular changes associated with a reduction in bone loss in mice 
inoculated with MDA-BT1 IKKεKD2 cells, I carried out histomorphometric 
analysis of the mouse tibiae from the aforementioned experiment (Figure 49 and 
Figure 50). This analysis revealed there was a significant reduction in osteoclast 
number (40.7± 19.2% reduction; Figure 49A) but no difference in the size of 
osteoclasts formed (Figure 49B). Complementary to in vitro results, cancer cell-
specific knockdown of IKKε had no effect on osteoblast number or activity as 
indicated by osteoblast number per bone surface (Ob.N/BS;Figure 49C) and 
osteoblast size (Ob.S/BS;Figure 49D) 
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Figure 49. Breast cancer specific knockdown of IKKε reduces osteoclast formation associated 
with MDA-BT1, whilst having no effect on osteoclast size, osteoblast number or size. 
4-week old athymic BALB/c nu/nu mice received injections of 4x103 MDA-BT1 Mock or IKKεKD2 
human breast cancer cells into the left tibiae and a sham injection of PBS into the right tibia. 
Animals were sacrificed 21 days after intratibial injection. A The number of osteoclasts per bone 
surface area and B the size of osteoclast per bone surface area. C The number of osteoblasts per 
bone surface area and D the size of osteoblast per bone surface area. Values are means ± standard 
deviation *p<0.05 from mock MDA-BT1 injected legs. 
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Figure 50.  Breast cancer specific knockdown of IKKε reduces osteoclast number in vivo. 
4-week old athymic BALB/c nu/nu mice received injections of 4x103 MDA-BT1 Mock or IKKεKD2 
human breast cancer cells into the left tibiae and a sham injection of PBS into the right tibia. Animals 
were sacrificed 21 days after intratibial injection. Representative images of the experiment described in 
Figure 49. Green arrows indicate TRAcP positive osteoclasts on the bone surface (top row). Yellow 
areas indicate cuboidal osteoblasts along bone surface (bottom row). 
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4.4.9 Amlexanox reduced breast cancer induced osteolysis  
As cancer-specific IKKε inhibition reduced trabecular bone loss but not cortical, 
we hypothesised that host cells of the tumour microenvironment might be more 
involved. To examine this, we tested Amlexanox in immunocompetent mice using 
the 4T1-Luc2 model. I performed detailed μCT analysis of trabecular bone in the 
proximal right tibial metaphysis of mice injected intracardiacally with 4T1-Luc2 
cells. This experiment revealed that mice treated with Amlexanox (35mg/kg/day) 
had significantly more bone (20.2±9.1% more; p<0.05) than vehicle treated mice.  
 
 
 
 
 
 
 
Figure 51. Amlexanox reduced 4T1-Luc2 induced osteolysis. 
4T1-Luc2 cells (1x105/100µl PBS) were injected in to the left ventricle of syngeneic 6-week old 
immunocompetent BALB/c mice. Mice were split into two groups (n=8/group) and given daily i.p. 
injections of vehicle or Amlexanox (35mg/kg). After sacrifice, microcomputed tomography (µCT) was 
used to analyse changes in bone volume of the right tibia of mice. 
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Again I aimed to assess in which compartment there was a protection against bone 
loss by analysing the cortical and trabecular compartments individually. As seen 
in Figure 52A and F shows that mice treated with Amlexanox (35mg/kg) following 
intracardiac injection of 4T1-Luc2 cells had  more trabecular bone at the end of 
the experiment as indicated by BV, however this did not reach significance. 
Further µCT analysis showed that there was no significant difference in trabecular 
number, spacing, or porosity (Figure 52B-C) between mice treated daily with 
Amlexanox or vehicle control.  
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Figure 52. Amlexanox has no effect on trabecular bone parameters in mice following intracardiac injection of 4T1-Luc2 cells 
4T1-Luc2 cells (1x105/100µl PBS) were injected in to the left ventricle of syngeneic 6-week old immunocompetent BALB/c mice. Mice were split 
into two groups (n=8/group) and given daily i.p. injections of vehicle or Amlexanox (35mg/kg). After sacrifice, microcomputed tomography (µCT) 
was used to analyse changes in bone of the right tibia of mice. Trabecular parameters analysed were bone volume (BV; A), trabecular number (Tb.N; 
B) trabecular thickness (Tb.Th; C), separation (Tb.Sp; D) and porosity (Po(op)%; E) Representative 3D reconstructions are shown in panel F. Values 
are means ± standard deviation. (8 mice per group) 
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The intracardiac injection of 4T1-Luc2 cells lead to a dramatic loss of trabecular 
bone after 11 days. During µCT scanning and analysis, it was evident that 4T1-
Luc2 cells had caused significant osteolysis even in the cortex of the tibia; 
therefore, I also examined the cortical bone parameters (Figure 53A-C). These 
data indicate that daily treatment with Amlexanox lead to a significant protection 
of cortical bone loss (40.8 ± 16.4% more bone; p<0.01) and the cortical bone was 
significantly less porous (5.1 ± 1.2% less; p<0.05). 
 
 
 
 
 
 
 
 
 
Figure 53. Amlexanox treated mice had more cortical bone than vehicle treated mice following 
intracardiac injection of 4T1-Luc2 cells  
4T1-Luc2 cells (1x105/100µl PBS) were injected in to the left ventricle of syngeneic 6-week old 
immunocompetent BALB/c mice. Mice were split into two groups (n=8/group) and given daily i.p. 
injections of vehicle or Amlexanox (35mg/kg). After sacrifice, microcomputed tomography (µCT) 
was used to analyse changes in bone of the right tibia of mice. Cortical parameters analysed were 
bone volume (BV; A) and porosity (%; B). Representative 3D images of the cortical bone are shown 
in C. Values are means ± standard deviation. (8 mice per group) *p<0.05;**p<0.01 from vehicle 
treated control group. 
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4.5 Discussion  
The IKK/NFκB pathway plays a key role in the formation and activation of 
osteoclast formation. (Chang et al., 2009a). Previous studies in our laboratories 
and in the literature have indicated that NFκB pathway in breast cancer cells 
contributes to their ability to grow, migrate, stimulate osteoclast formation and 
induce osteolysis (Idris et al., 2009, Marino et al., 2014, Peramuhendige et al., 
2014, Park et al., 2006). However, the role of IKKε in breast cancer – bone cell 
interaction has yet to be investigated. The aim of this chapter was to assess both 
the cancer specific and bone cell contribution of IKKε to breast cancer support for 
osteoclast formation and osteoblast activity in vitro and in vivo.  
In Chapter 3, I have shown that cancer-specific knockdown of IKKε reduced the 
skeletal tumour growth of MDA-BT1 cells in vivo following intratibial injection. 
Furthermore, pharmacological inhibition of IKKε also reduced the skeletal tumour 
growth of 4T1-luc2 cells in vivo following intracardiac injection. Following 
detailed microcomputed tomographic analysis, in this chapter I have shown that 
these observed reductions in tumour growth were accompanied by a reduction in 
osteolytic bone damage. In the intratibial model, I observed a reduction in bone 
loss in the trabecular of mice following injection of IKKε deficient breast cancer 
cells. Histomorphometry of these tibia revealed that these bones had no difference 
in osteoblast numbers but less osteoclasts. In the intracardiac model, there was no 
difference in the trabecular bone compartment. As there was very little trabeculae 
left at all, this may explain why we did not see a significant protection of bone in 
this aggressive model. However, we did observed a reduction in osteolysis of the 
cortical compartment. Mice treated with Amlexanox had more cortical bone 
compared to vehicle treated. As both knockdown and pharmacological inhibition 
of IKKε in cancer cells reduced cell viability in vitro (Chapter 3), we cannot yet 
conclude that the observed effect is not due to a cancer-specific effect on growth 
leading to less osteoclasts or rather the breast cancer cells are unable to stimulate 
osteoclast formation and subsequent osteolysis in vivo due to inhibition of the 
NFκB pathway in the environment. Although the overall reduction in tumour 
burden is likely due to both reduction of cancer-cell viability and osteoclast 
formation, future studies should address the effect of inhibiting IKKε in both the 
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cancer and the microenvironment on osteolysis in a model that removes growth 
inhibition as a factor such as the supracalvarial model of osteolysis. Here, 
conditioned medium from breast cancer cells is injected over the calvaria of young 
mice to induce osteolysis, thus one can examine how cancer-cell specific inhibition 
of IKKε may reduce osteolysis.  
Here I have shown that in mouse bone marrow cultures, co-culture of MDA-BT1 
cells deficient in IKKε or their conditioned medium greatly decreases their ability 
to support osteoclast formation Similarly, in human pre-osteoclast cultures, 
knockdown of IKKε in MDA-BT1 cells reduced their ability to support osteoclast 
formation; conversely, overexpression of IKKε in MDA-BT1 enhanced their 
support for osteoclast formation in vitro. In order to attempt to demarcate the 
pathways by which IKKε supports osteoclast formation, in a similar manner to 
chapter 3, I knocked down TBK-1, IKKβ, p65 and IRF3 using siRNA in both 
MDA-BT1 mock and IKKεOE  then added these conditioned media to osteoclast 
precursor cultures. Knockdown of all proteins examined significantly reduced 
breast cancer support for osteoclast formation and all reduced IKKε driven support 
for osteoclast formation suggesting that IKKε enhances osteoclast formation 
through activation of both the NFκB and IRF3 pathways. These data suggest that 
the activation of the IKKε/NFκB/IRF3 axis within breast cancer cells leads to the 
production of inflammatory factors that contribute to their ability to enhance 
osteoclast formation in vitro. Firstly, I assessed the proinflammatory factors that 
were regulated by Amlexanox. Amlexanox reduced the expression of several 
proinflammatory factors involved in breast cancer growth, metastasis and 
osteolysis such as TNFα, M-CSF, DKK-1, MMP-9, BDNF, IL-23 (Table 9). 
However, interestingly, Amlexanox also upregulated the production of several 
factors such as osteopontin, ICAM-1 and Emmprin, three factors which have been 
identified as molecules that promote breast cancer metastasis. In an elegant study 
carried out by the Massagué group, in which MDA-MB-231 cells were 
sequentially passaged through mice via intracardiac injection in order to isolate 
bone or lung metastatic variants, it was shown that osteopontin expression by 
breast cancer cells was significantly associated with increased bone metastasis and 
this correlated with reduced overall survival in patients (Kang et al., 2003). This 
could perhaps explain the reason why there was not an observed reduction in bone 
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metastasis in our 4T1-Luc2 model when treated with Amlexanox. Thus, significant 
work to understand the molecular mechanisms of how IKKε inhibition promotes 
the upregulation of these factors should be carried out. Nevertheless, treatment of 
mice with Amlexanox did partially reduce metastatic breast cancer growth in this 
model.   Moreover, conditioned medium from cells deficient in IKKε failed to 
support osteoclastogenesis to the same level as IKKε replete cells suggesting that 
the factors downregulated or upregulated in response to IKKε inhibition play a 
role in breast cancer support for osteoclast formation. 
Understanding the mechanisms that drive the bone metastatic vicious cycle are 
pertinent to designing new and effective therapeutics. Current therapies are 
designed to break the perpetual cycle of bone loss and tumour growth by targeting 
of osteoclasts. Bisphosphonates, a family of hydroxyapatite binding compounds, 
are endocytosed by osteoclasts leading to inhibition of the mevalonate pathway 
and the induction of apoptosis (Kavanagh et al., 2006).  Bisphosphonates, the most 
potent being Zoledronic acid, and  have been the gold standard of care for decades 
now. However, Denosumab, a monoclonal antibody against RANKL, has been 
shown to be superior in preventing skeletal-related events compared to Zoledronic 
acid in breast, prostate and myeloma patients (Stopeck, 2010).  In this chapter, I 
tested the ability of Amlexanox to inhibit both breast cancer support for osteoclast 
formation and RANKL-induced osteoclast formation. Zhang and colleagues have 
previously shown that Amlexanox is able to reduce osteoclast formation in vitro 
and in vivo, though for the first time I have shown through addition of Amlexanox 
to cultures exposed to both RANKL and breast cancer conditioned medium that 
Amlexanox is also effective at inhibiting breast cancer support for 
osteoclastogenesis. Mechanistically, I showed that Amlexanox reduced the 
phosphorylation of IκBα in response to RANKL suggestive of NFκB inhibition, 
the essential transcription factor for osteoclast formation. Interestingly, 
Amlexanox was unable to reduce the phosphorylation of IκBα in response to 
MDA-BT1 CM. This could be due to the fact that the conditioned medium contains 
numerous cytokines that activate NFκB (TNFα, IL17A, CD40L) through the 
canonical pathway and thus inhibition of IKKε/TBK-1 is not sufficient to inhibit 
NFκB.  In the other bone cell compartment, breast cancer cells also influence 
osteoblasts by inhibiting their differentiation and ability to mineralise, however, 
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no effect on osteoclast differentiation or mineralisation was observed in primary 
osteoblasts or Saos2 osteoblast-like cultures, exposed to MDA-BT1 conditioned 
medium. Of note, Amlexanox had no significant effects on osteoblasts either at 
concentration inhibitory to osteoclast-formation or higher. This study showed that 
Amlexanox reduced breast cancer skeletal tumour growth and the resultant 
osteolysis, however, pre-clinical data suggests that Zoledronic acid and OPG-Fc 
(Denosumab) inhibit osteolysis in vivo without affecting skeletal tumour growth 
(Buijs et al., 2009) , therefore it would be beneficial to test Amlexanox, Zoledronic 
acid and Denosumab comparatively on their ability to reduce breast cancer skeletal 
tumour burden of established bone metastases.  
The NFκB pathway and its role in bone has long since been established. Expanding 
evidence is demonstrating that NFκB activation within cancer cells enables them 
to establish osteolytic tumours through the production of  various inflammatory 
factors (Park et al., 2006, Idris et al., 2009, Peramuhendige et al., 2018, Marino et 
al., 2018a). This work has helped establish this role. Future studies, using cancer-
specific CRISPR knockouts of the IKKs and the NFκB transcription factors should 
be carried out head-to-head to help establish which protein and at which level 
would be best to target to reduce skeletal tumour burden. Following this work, we 
may establish new treatments to compare or even combine with current bone 
targeted agents for the treatment of breast cancer associated osteolysis. 
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Table 9. Differentially regulated cytokines in MDA-BT1 following treatment with Amlexanox 
and their known effect on breast cancer,  bone metastasis, osteoclasts and osteoblasts. 
 
Protein 
Breast 
cancer 
Bone 
metastasis 
Osteoclasts Osteoblasts Ref 
Relaxin-2 ↑↓ - ↑ ↑ 
(Radestock et al., 
2008, Binder et 
al., 2002, Duarte 
et al., 2014) 
Angiogenin 
(ANG) 
↑↓ - ↑↓ - 
(Montero et al., 
1998, Morita et 
al., 2008) 
Osteopontin 
(OPN) 
↑ ↑ ↑ ↓ 
(Chellaiah et al., 
2003, Holm et 
al., 2014, 
Chakraborty et 
al., 2008, Kruger 
et al., 2014) 
ICAM-1 ↑ ↓ ↑ ↓ 
(Guo et al., 2014, 
Yang et al., 2015, 
Fernandes et al., 
2008) 
Emmprin ↑ - ↑ - 
(Nishioku et al., 
2016, Zhou et al., 
2005) 
M-CSF ↑ ↑ ↑ - 
(Mancino et al., 
2001, Ide et al., 
2008, Richardsen 
et al., 2015) 
TNFα ↑ ↑ ↑ ↓ 
(Lam et al., 2000, 
Abbas et al., 
2003) 
FLT3 
ligand 
↓ - ↑ - 
(Lean et al., 
2001, Braun et 
al., 1999) 
TFF3 ↑ ↑ - - 
(Pandey et al., 
2014, Kannan et 
al., 2010) 
CXCL1 ↑ ↑ ↑ ↑ 
(Hardaway et al., 
2015, Acharyya 
et al., 2012) 
DKK1 ↑ ↑ ↑ ↓ 
(Qiang et al., 
2008, Mariz et 
al., 2015, Fujita 
and Janz, 2007) 
MMP9 ↑ ↑ ↑ ↔ 
(Mehner et al., 
2014) 
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An upwards arrow (↑) represents an increase in breast cancer or bone (any cancer) metastasis, 
osteoclasts formation and osteoblast activity whereas a downwards arrow (↓) represents an 
inhibition. Both upwards and downwards arrows (↑↓) indicates both an increase and decrease 
reported.  Horizontal arrows (↔) denotes no change in breast cancer or bone (any cancer) 
metastasis, osteoclasts formation and osteoblast activity. A hyphen (-) designates no reported 
effect. Cytokines above the red line are upregulated and those below are downregulated.  
 
 
 
SDF1a ↑↓ ↑ ↑ ↓ 
(Sun et al., 2014, 
Roccaro et al., 
2014, Yu et al., 
2003, Shahnazari 
et al., 2013) 
G-CSF ↑ ↑ ↑ ↓ 
(Hirbe et al., 
2007, 
Christopher and 
Link, 2008) 
IL-23 ↑ ↑ ↓ ↔ 
(Teng et al., 
2010, Kamiya et 
al., 2007) 
Adiponectin ↑↓ ↓ ↓ ↑ 
(Landskroner-
Eiger et al., 2009, 
Liu et al., 2013, 
Oshima et al., 
2005) 
BDNF ↑ ↑ ↑ ↑ 
(Yang et al., 
2012, Choi et al., 
2016, Sun et al., 
2012, Ida-
Yonemochi et 
al., 2017) 
Cystatin C ↑ - ↓ ↑ 
(Završnik et al., 
2017, Lerner et 
al., 1997, Danjo 
et al., 2007) 
CD30 - - - -  
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5 Chapter 5 
5.1 Summary  
The treatment of triple negative breast cancers often relies on a surgery, 
radiotherapy or chemotherapy. NFκB activity has been demonstrated to a be a 
potential mechanism of resistance to mainstay chemotherapies in triple negative 
breast cancer (Chuang et al., 2002). In this chapter, I demonstrate that 
pharmacological inhibition of IKKε enhances the cytotoxic effects of a panel of  
chemotherapeutic agents at inhibiting triple negative breast cancer cell viability in 
vitro and has synergy with a number including FDA-approved standard of care 
Docetaxel. In addition, treatment of breast cancer cells with Docetaxel increased 
IKKε expression in vitro.  
Next I demonstrated, for the first time, that combined administration of 
Amlexanox and Docetaxel significantly and consistently inhibits mammary 
tumour growth in mice. In addition, combined administration of Amlexanox and 
Docetaxel significantly reduced the development of metastasis and lead to a 
significantly longer overall survival when compared to vehicle or either treatment 
as a monotherapy. Overall, this chapter demonstrates that inhibition of IKKε in 
combination with clinically relevant chemotherapies may be of use for the 
treatment of local and advanced triple negative breast cancer.  
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5.2 Introduction 
Triple negative breast cancer is a highly heterogeneous group of breast cancers 
that affects up to 20% of all breast cancer patients (Ferlay et al., 2015).  Therapies 
that target hormones and their receptors such as aromatase inhibitors or tamoxifen 
and HER2-targeting drugs such as trastuzumab lack efficacy in triple negative 
diseases owing to their lack of receptor status.  Thus chemotherapy remains the 
standard of care for triple negative disease. A tumour that remains localised can 
be treated with various surgical options. Moreover, systemic delivery of 
chemotherapy can be administered in an attempt to eliminate disseminated cancer 
cells. In the case of overt metastatic disease chemotherapy is used to improve 
quality of life and extend progression-free and overall-survival. Many 
chemotherapies such as Docetaxel, paclitaxel, doxorubicin, cyclophosphamide  
and 5-flurouracil function to cause DNA or cytoskeletal damage or target vital 
cellular pathways such as rapamycin and thus, whilst being efficacious, have 
systemic and often serious adverse side effects(Malhotra and Perry, 2003).  
Single agent treatment has shown promising results in preclinical and clinical 
studies, however, often do not eradicate later stage aggressive disease owing to 
various mechanisms of resistance that arise in these heterogeneous tumours. 
Recent scientific efforts have been focusing on combination therapies in an 
attempt to improve overall survival in multiple cancers, including breast cancer. 
Combination therapy, is the administration of two or more drugs with usually 
differing modes of action to enhance the efficacy of both drugs. In fact, around 
80% of all clinical trials in triple negative breast cancers are exploring the efficacy 
of combination treatments (Chalakur-Ramireddy and Pakala, 2018).  
A body of increasing evidence has shown that activation of the NFκB pathway has 
been shown to be a key contributing factor to chemoresistance. Moreover, a variety 
of chemotherapies such as taxanes and anthracyclines have been shown to activate 
the NFκB pathway and its contribution to chemoresistance mediated through the 
activation of a variety of anti-apoptosis and survival genes such as Bcl-2, Bcl-xl, 
XIAP and Survivin (Chuang et al., 2002, Li and Sethi, 2010). Furthermore, a 
number of studies in the past decade have implicated IKKε in both NFκB-
dependent and independent resistance to chemotherapies. Following genotoxic 
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stress via DNA damaging agents, IKKε has been found to translocate to the 
nucleus where it phosphorylates p65 at serine-468 to induce gene expression that 
prevent apoptosis (Renner et al., 2010). Furthermore, IKKε has been shown to 
promote resistance to tamoxifen in ER+ breast cancers and carboplatin resistance 
in ovarian cancers (Guo et al., 2010, Guo et al., 2009) . In previous chapters, I have 
shown that inhibition of IKKε using shRNA or pharmacologically with 
Amlexanox reduces both skeletal and primary tumour growth of breast cancer 
cells, therefore I hypothesised that combined administration of IKKε with a 
clinically relevant compound would reduce the growth  and metastasis of triple 
negative breast cancer cells in vitro and in vivo.   
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5.3 Aims 
The aim of this chapter was to assess whether pharmacological inhibition of IKKε 
using Amlexanox enhances the efficacy of clinically relevant chemotherapeutic 
agents on breast cancer cells in vitro. In addition, I aimed to test the if combined 
administration of  Amlexanox  with a chemotherapeutic agent in the neoadjuvant 
setting reduces primary tumour growth, the occurrence of metastasis and improves 
survival in a 4T1-Luc2 model in vivo. The aims of this chapter will be realised by 
examining: 
 The effect of chemotherapies alone and in combination with Amlexanox 
on breast cancer cell viability in vitro. 
 The effect of chemotherapeutic agents on IKKε expression in vitro.  
 The effect of Amlexanox, Docetaxel and their combined administration on 
mouse 4T1-Luc2 breast cancer primary tumour growth in vivo. 
 The effect of Amlexanox, Docetaxel and their combined administration on 
mouse 4T1-Luc2 breast cancer and the development of metastases 
following primary orthotopic tumour removal in vivo. 
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5.4 Results 
5.4.1 Amlexanox enhances the efficacy of a panel of several 
chemotherapeutic agents 
Triple-negative breast cancers currently have no targeted therapies like ER/PR and 
HER2 expressing breast cancers. Thus in their absence, patients are often 
administered chemotherapeutics, as single or combination therapies. Activation of 
the NFκB pathway has been shown to be a mechanism of chemoresistance in 
several cancers including breast and pharmacological inhibition of the pathway 
enhances efficacy (Baldwin, 2001, Sweeney et al., 2005, Zhang et al., 2009). For 
these reasons, I decided to test the effects of combined administration of 
Amlexanox with various clinically relevant compounds with different modes of 
action on the viability of parental MDA-MB-231 cells. All compounds alone 
achieved IC50 values in the micromolar range except Docetaxel, paclitaxel and 
doxorubicin, which had IC50 values in the nanomolar after 72 hours (Figure 54 and 
Table 10). Interestingly, cyclophosphamide was only effective in the milimolar 
range. Amlexanox (30μM) significantly reduced the IC50 values of all compounds 
tested apart from doxorubicin (Table 10).  
 
 
 
 
 
Table 10. Half maximal inhibitory concentration (IC50) values of chemotherapeutic agents 
alone or combined with Amlexanox (30µM) on MDA-231 cell viability after 72 hours 
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Figure 54. Amlexanox enhances the efficacy of a panel of chemotherapeutic agents  
MDA-BT1 cells were plated in 96 well plates and treated with the indicated of Amlexanox (A) or the indicated doses of Docetaxel (B), Doxorubicin (C), Rapamycin (D), 
Tamoxifen (E), Cyclophosphamide (F), Paclitaxel (G), 5-Fluorouracil (H), alone (white circles) or with Amlexanox (30µM; black circles). Cell viability was determined using 
the Alamar Blue assay and expressed as a percentage of the values of the vehicle treated cells. Values are means ± standard deviation from at least three independent 
experiments. 
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5.4.2 Docetaxel increases the expression of IKKε in MDA-MB-231 cells 
Many cancers develop resistance mechanisms to aid in survival leading to the 
development of resistant tumours. Therefore, it is important to find drug 
combinations that are synergistic such that results that are more effective are 
achieved, at lower doses and thus avoiding side effects.  For this reason, I used the 
Chou-Talalay Method using CompuSyn Software to calculate the Combination 
Index values of the indicated drug combinations. Briefly, a drug combination that 
has a CI value of   <1 would be deemed synergistic, equal to 1 is additive and 1 to 
∞ is antagonistic.  CI values of each concentration of the combinations were then 
plotted against the fraction-affected value (Fa). CompuSyn analysis revealed that 
Docetaxel, Rapamycin,   Doxorubicin acted synergistically with Amlexanox at all 
doses tested (Figure 55).  Tamoxifen, Paclitaxel, and Cyclophosphamide were 
mostly synergistic at more effective concentrations of chemotherapy, however 
were partially antagonistic at lower Fa values. Interestingly, the combination of 5-
Fluorouracil and Amlexanox (30μM) were shown to be antagonistic with the 
majority of CI values greater than 1 (Figure 55). 
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Figure 55. Amlexanox and Docetaxel, Rapamycin and Doxorubicin act synergistically at all doses whereas Tamoxifen, Cyclophosphamide, Paclitaxel and 5-
Fluorouracil are antagonistic at lower doses 
MDA-231 cells were plated in 96-well plates and treated with Docetaxel (A), Rapamycin (B),  Doxorubicin (C), Tamoxifen (D), Cyclophosphamide (E), Paclitaxel (F), 5-
Fluorouracil (G), alone) or with Amlexanox (30µM). Cell viability was determined using the Alamar Blue assay. The Chou-Talalay Method was used to calculate CI values 
plotted against Fa values to assess potential drug combination synergy. Synergistic CI <1 (yellow), Additive = 1 (dotted line), Antagonistic CI>1 (grey) Values are calculated 
using the means from at least three independent experiments 
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Owing to the fact that one of the potential benefits of finding new synergistic 
combinations of therapeutic agents is the potential to use them at lower 
concentrations to reduce side effects in the patient whilst maintaining efficacy, I 
decided to eliminate the chemotherapeutics (Tamoxifen, Cyclophosphamide, 
Paclitaxel, and 5-Fluorouracil) which I have shown to be antagonistic at lower 
doses. Following this, I examined the effect of chemotherapy treatment on the 
expression of IKKε in parental MDA-MB-231 breast cancer cells. 
Treatment with Docetaxel (1nM) significantly increased the expression of IKKε 
by 48.3 ± 11.3% (p<0.05) compared to DMSO-treated control after 72 hours 
(Figure 56). Exposure to Rapamycin (10µM) had no effect on IKKε expression 
after 72 hours compared to DMSO-treated control (Figure 56). Interestingly, 
treatment with Doxorubicin (10nM) significantly reduced IKKε expression by 
37.4± 16.8% (p<0.05; Figure 56).  
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Figure 56. Docetaxel increases expression of IKKε in MDA-231 cells 
Parental MDA-231 cells were exposed to Docetaxel (1nM), Rapamycin (10µM), 
Doxorubicin (10nM) or vehicle (DMSO) for 72 hours. Cells were lysed and total cellular 
protein was subjected to western blot analysis (70 µg/lane) using primary rabbit anti-
IKKε and rabbit anti-β-actin. A) Quantification of the amount IKKε as a percentage of 
vehicle treated control. B) Representative Western blot image from the experiment 
described. Values are mean ± SD from at least three independent experiments;  *p<0.05 
from vehicle treated control  
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5.4.3 Combined administration of Amlexanox significantly inhibits  
mammary tumour growth in mice.  
In Chapter 3, I have shown that Amlexanox (35mg/kg/5-day) reduced the growth 
of skeletal breast cancer metastases following intracardiac injection of 4T1-Luc2 
cells in immunocompetent BALB/c mice. However, the majority of breast cancer 
patients do not present with advance disease, rather where the tumour remains 
localized. With this in mind, we wanted to test the effects of Amlexanox, 
Docetaxel and the combined administration of either agent in the neoadjuvant 
setting.  To do this, we again utilised 4T1-Luc2 mouse breast cancer cells in 
syngeneic immunocompetent BALB/c, however, this time 4T1-Luc2 cells were 
injected orthotopically with 1x106 cells being injected into each of the left and 
right mammary fat pads. The following day mice were injected with 1.5mg/kg D-
Luciferin to check for tumour engraftment, where all mice developed tumours. 
The tumour was then measured with callipers. Mice were randomized to four 
groups (n=10/group) and administered vehicle (DMSO; 10% v/v in PBS), 
Amlexanox (35mg/kg/5-times-weekly), Docetaxel (15mg/kg/week) or the 
combination of either treatment (Figure 57A). The tumour volume was measured 
thrice weekly and was calculated using the volume of a sphere. When at least one 
of the tumours per mouse reached the maximum volume of 1000mm3, they were 
then surgically resected 
Treatments were initiated on day 0 (the day after orthotopic injection) and no 
significant effect was observed on primary tumour growth at days 3, 5 and 7 
between vehicle-, Amlexanox-, Docetaxel- or Combination-treated groups of 
mice. However, after Day 9 the primary tumours of combination treated mice had 
the largest reduction in tumour growth, with a 56.5± 23.1% reduction compared 
to vehicle treated controls (Figure 57B), whereas mice treated with Amlexanox 
showed a significant 31.73 ± 15.8% reduction, Docetaxel treated mice had a 29.1± 
17.2% reduction and. Furthermore, the observed reduction in combination treated 
mice was significant when compared to Docetaxel as a single agent. Additionally, 
this significant reduction in tumour growth was maintained to the following time 
point, Day 11. There was a reduction of 37.9 ± 27.3% and 59.5 ± 17.7 % in primary 
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tumour growth of Docetaxel and Combination treated mice, respectively 
compared to vehicle treated control mice.  Detailed statistical analyses can be seen 
in Table 11. Correspondingly, the combination treatment of Amlexanox and 
Docetaxel delayed the last tumours reaching maximum volume until day 18, 
compared to all mice in the vehicle control and Amlexanox treated groups reaching 
the maximum tumour volume of 1000mm3 by day 11 of treatment, the Docetaxel 
group reached maximum volume at day 16 and the combination group reached 
maximum volume at Day 17.   
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Figure 57. Combined administration of Amlexanox and Docetaxel significantly reduces primary tumour growth of 4T1-Luc2 cells after orthotopic injection. 
A 4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left  and right mammary fat pads of syngeneic BALB/c mice. Mice were split into four groups (n=10/group) 
and given daily i.p. injections of vehicle or Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination of Amlexanox and Docetaxel. Primary orthotopic 
tumours were measured using callipers at the indicated time points. Results shown are mean values ± SEM. Related to figure Figure 31.  
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Table 11. Detailed Statistical Comparisons of the 4T1-Luc2 primary tumour volume from mice treated with vehicle, Amlexanox, Docetaxel or Combination (Amlexanox 
and Docetaxel) 
Comparison 
Day 0 Day 3 Day 5 Day 7 Day 9 Day 11 Day 14 Day 16 Day 18 
Summary p-value Summary p-value Summary p-value Summary p-value Summary p-value Summary p-value Summary p-value Summary p-value Summary p-value 
Veh vs. AmX ns 0.9888 ns 0.2953 ns 0.7824 ns 0.799 * 0.036 ns 0.2292 NA - NA - NA - 
Veh vs. 
Doc 
ns 0.9527 ns 0.1941 ns 0.7941 ns 0.9377 * 0.0318 *** 0.0005 NA - NA - NA - 
Veh vs. Com ns 0.9998 ns 0.0898 ns 0.145 ns 0.3925 **** <0.0001 **** <0.0001 NA - NA - NA - 
AmX vs. Doc ns 0.9977 ns 0.9959 ns >0.9999 ns 0.9797 ns 0.9956 ns 0.6597 NA - NA - NA - 
AmX vs. 
Comb 
ns 0.9797 ns 0.9382 ns 0.6479 ns 0.9086 ns 0.1489 * 0.0197 NA - NA - NA - 
Doc vs. Comb ns 0.9317 ns 0.9849 ns 0.5995 ns 0.6835 * 0.049 ns 0.0879 ns 0.1322 ns 0.1322 NA - 
Multiple comparisons were calculated using Two-way ANOVA followed by Tukeys Test on GraphPad Prism 7.0. Comparison of two groups at Day 16 and Day 18 were calculated 
using student’s T-test. NS denotes ‘not significant’; NA denotes ‘not applicable’ where statistical comparisons were not possible. Related to Figure 57 
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Figure 58. Representative images of tumour growth with Amlexanox, Docetaxel and combination treatment in mice. 
4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads of syngeneic BALB/c mice. Mice were split into four groups (n=10/group) 
and given daily i.p. injections of vehicle or Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination of Amlexanox and Docetaxel. IVIS system was used 
to detect in vivo primary tumours at day 9 following 1.5mg/kg injection of D-luciferin. 
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5.4.4 Combined administration of Amlexanox and Docetaxel had no 
significant effect on primary tumour weight following removal.  
In order to assess for the development of distant overt metastases using the IVIS 
system, it was important to allow the primary tumours to reach the same end point 
of 1000mm3. Upon removal, the tumours were weighed and no significant 
difference in primary tumour weight was observed between vehicle, Amlexanox, 
Docetaxel or Combination treated mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59. No significant difference in tumour weight between groups following tumour removal 
4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads of 
syngeneic BALB/c mice. Mice were split into four groups (n=10/group) and given daily i.p. injections 
of vehicle or Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination of Amlexanox 
and Docetaxel. Upon surgical resection, primary tumours were weighed. Results shown are mean ± 
SD. 
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5.4.5 Combined administration of Amlexanox and Docetaxel reduced body 
weights of mice 
Amlexanox has been shown to reduce body weight of obese mice (Reilly et al., 
2013). Furthermore, Docetaxel can cause significant unwanted side effects as a 
single agent in patients such as anaemia, loss of appetite, nausea, diarrhoea and 
weight loss thus it was important to regularly monitor the behaviour and body 
weight of the mice. As seen in Figure 60, neither Amlexanox nor Docetaxel had 
any significant effect on the body weight of mice compared to the vehicle treated 
group. However, from 7 to 21 days of combination treatment, this group had 
significantly lower body weight than compared to vehicle treated mice (day 7 
p<0.05; day 14 p <0.001; day 21 p <0.05). Of note, mice given combined 
administration of Amlexanox and Docetaxel did appear distressed in the hours 
after treatments. Although, it is important to note that the none of the mice lost 
more than 20% of their body weight, the allowed threshold.  
    
Figure 60. Combined administration of Amlexanox and Docetaxel reduced body weights of mice. 
4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads of syngeneic 
BALB/c mice. Mice were split into four groups (n=10/group) and given daily i.p. injections of vehicle or 
Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination of Amlexanox and Docetaxel. Mice 
were weighed at the indicated time points. Results shown are mean ± SD. Dotted line indicates 80% of 
starting mean body weight. Detailed statistical analysis shown in Table 12. 
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 Table 12. Detailed Statistical Comparisons of the mouse body weights from groups treated with vehicle, Amlexanox, Docetaxel or Combination (Amlexanox and     
Docetaxel) 
Multiple comparisons were calculated using Two-way ANOVA followed by Tukeys Test on GraphPad Prism 7.0. NS denotes ‘not significant’; Related to Figure 60 
 
Comparison 
Initial Day 0 Day 7 Day 14 Day 21 
Summary P-value Summary P-value Summary P-value Summary P-value Summary P-value 
Veh vs. AmX ns 0.480 ns 0.491 ns 0.317 ns 0.43 ns 0.88 
Veh vs. Doc ns 0.985 ns 0.968 ns 0.460 ns 0.67 ns 0.35 
Veh vs. AmX/Doc ns 0.318 ns 0.856 * 0.029 *** 0.001 * 0.02 
AmX vs. Doc ns 0.283 ns 0.283 ns 0.243 ns 0.94 ns 0.97 
AmX vs. AmX/Doc ns 0.992 ns 0.992 ns 0.926 ns 0.27 ns 0.54 
Doc vs. AmX/Doc ns 0.167 ns 0.167 ns 0.591 * 0.02 ns 0.35 
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5.4.6 Combined administration of Amlexanox and Docetaxel prolonged 
metastasis-free survival in mice 
Following the removal of the primary tumour, I observed the development of 
secondary metastases. The development of metastases was monitored bi-weekly 
after the removal of the primary tumours using the IVIS system. Upon detection 
of a secondary metastasis, the primary end goal was reached and mice were 
sacrificed.  As shown in  Figure 61, vehicle treated mice had a median metastasis 
free survival of 17 days however, combined administration of daily Amlexanox to 
weekly Docetaxel significantly increased the median metastasis free survival by 
1.82-fold to 31 days (p<0.001). Moreover, Amlexanox treated mice also had a 
median metastasis free survival of 17 days. Docetaxel treated mice had a median 
survival of 21 days; however this was not significantly longer than vehicle treated 
mice (Figure 61).   
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Figure 61. Combined administration of Amlexanox and Docetaxel prolonged metastasis-free survival in mice. 
4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads of syngeneic BALB/c mice. Mice were split into four groups 
(n=10/group) and given daily i.p. injections of vehicle or Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination of Amlexanox and Docetaxel. 
Following primary tumour removal, mice were monitored for the development of metastasis using IVIS system. Mice were sacrificed following detection of 
tumour. A Metastasis free survival curves for the 4 treatment groups. B Representative IVIS images at two time points. *** p<0.001 from vehicle treatment; 
p<0.001 from Amlexanox treatment; # p<0.05 from Docetaxel treatment. 
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5.4.7 Combined administration of Amlexanox and Docetaxel reduces breast 
cancer metastases in mice. 
Breast cancers preferentially spread to bone, lung, liver and brain (Wu et al., 
2016). Following sacrifice, the internal organs were collected and imaged in the 
IVIS system. Ex vivo bioluminescence analysis revealed that vehicle-treated mice 
developed an average of 3 metastases however, combined administration of 
Amlexanox and Docetaxel markedly reduce the number of metastases observed to 
an average of 1.1 per mouse (p<0.01). There was no significant change in the 
average number of metastases observed in mice treated with Amlexanox or 
Docetaxel as single agents, with each group developing an average of 3.6 and 2.9 
respectively  
  
Figure 62.  Combined administration of Amlexanox and Docetaxel  reduced metastases in mice.  
4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads of 
syngeneic BALB/c mice. Mice were split into four groups (n=10/group) and given daily i.p. 
injections of vehicle or Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination 
of Amlexanox and Docetaxel. Following primary tumour removal, mice were monitored for the 
development of metastasis using IVIS system. Mice were sacrificed following detection of 
metastases. Organs were collected and ex vivo bioluminescence was performed using the IVIS 
system. Results shown are mean ± SD. ** p< 0.01 from vehicle treated controls.  
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Further ex vivo examination of the individual organs and the femur and tibiae bones of 
the mice using bioluminescence revealed that control mice developed lung, bone, brain 
and spleen metastases (no liver or kidney metastases were observed in this model). 
Mice also developed peritoneal metastases, in which the metastases had invaded from 
the primary tumour and through the peritoneum in to the gut. Combined administration 
of Amlexanox and Docetaxel significantly reduced lung and spleen metastases 
(compared to vehicle-, Amlexanox-, and Docetaxel-treated mice). Additionally 
combined administration of Amlexanox and Docetaxel reduced the number of invasive 
peritoneal metastases compared to vehicle and single agent Amlexanox (Table 13). In 
concordance with the previous results, mice given either Amlexanox or Docetaxel 
developed metastases in these organs also and no significant difference in the incidence 
of organ specific metastases was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fisher’s exact test was used to calculate statistical differences between metastatic incidences. *p<0.05 
from vehicle; + p<0.05 from Amlexanox treated; # p<0.05 from Docetaxel treatment.  
 Frequency of Metastasis 
Organ 
- 
- 
AmX 
- 
- 
Doc 
AmX 
Doc 
Lung 10/10 9/10 10/10 6/9*+# 
Bone 3/40 7/40 5/40 0/36 
Brain 1/10 3/10 2/10 0/9 
Spleen 7/10 6/10 5/10 0/9*+# 
Peritoneal 9/10 9/10 6/10 4/9*+ 
Table 13. The incidence of secondary metastases in BALB/c mice treated with vehicle, Amlexanox, 
docetaxel or a combination treatment in the neoadjuvant setting. 
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5.4.8  Amlexanox, Docetaxel and their combination had no significant effect on 
the individual size of metastases in mice. 
Having shown that the combination of both Amlexanox and Docetaxel significantly 
reduce metastatic development following orthotopic injection of 4T1-Luc2 cells yet 
neither Amlexanox (35-mg/kg/5-times weekly) nor Docetaxel (15mg/kg/weekly) alone 
reduced the incidence of overt metastases thus  I decided to see if either treatment alone 
and in combination was sufficient to reduce the size of metastatic tumours in the organs 
collected. As seen in Figure 63, a trend to smaller lung metastases was observed in the 
single and combination treated groups, however, this trend was not significant. 
Similarly, no significant difference was observed in the size of brain or spleen 
metastases in mice treated with Amlexanox, Docetaxel or Combination treatments 
compared to vehicle treated control mice. No differences in volume of bone metastases 
were observed between mice treated with control or single drug, alone, however, no 
bone metastases were detected following combination treatment. 
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Figure 63. Amlexanox, Docetaxel and their combination had no significant effect on the size 
of metastases in mice ex vivo. 
4T1-Luc2 cells (1x106/100µl PBS/TB) were injected in to the left and right mammary fat pads 
of syngeneic BALB/c mice. Mice were split into four groups (n=10/group) and given daily i.p. 
injections of vehicle or Amlexanox (35mg/kg) or weekly Docetaxel (15mg/kg) or a combination 
of Amlexanox and Docetaxel. Mice were sacrificed following detection of metastases. Organs 
were collected and ex vivo bioluminescence was used to calculate the size of tumours in organs. 
Results shown are mean ± SD.  
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5.5  Discussion  
Aberrant expression and regulation of the NFκB signalling cascade is implicated in the 
oncogenesis and progression of various haematological and solid malignancies 
including breast cancer through mediation of cell death, cell cycle progression and 
inflammatory processes (Baldwin, 2001). Recent studies have showed that a multitude 
of chemotherapeutics activate the NFκB signalling pathway, which in this context 
functions to prevent apoptosis via induction of anti-apoptotic genes. In the preceding 
chapters,  I have shown that Amlexanox alone reduces in vitro breast cancer cell growth 
and skeletal tumour growth of triple negative breast cancer cells in vivo. Here, I wanted 
to assess whether pharmacological inhibition of IKKε could enhance the effects of 
chemotherapies.  
Firstly,  I tested a panel of clinically available FDA-approved chemotherapies alone or 
in combination with Amlexanox on triple negative breast cancer cell viability in vitro. 
Amlexanox reduced the IC50 value of all of the chemotherapies tested and higher doses 
were synergistic in their action, however, at lower doses the combination of paclitaxel, 
tamoxifen, cyclophosphamide or 5-flurouracil with Amlexanox was found to be 
antagonistic. Chemotherapies, although efficacious in prolonging disease-free and 
overall survival following the removal of the primary tumour, often have unwanted 
side effects that halt their continued use in clinics such as cardiotoxicity, anaemia, 
diarrhoea, and hair loss. One of the potential benefits of combination therapies may be 
using chemotherapies at lower doses to avoid or reduce adverse side-effects. Thus those 
that had demonstrated antagonistic potential were eliminated from further studies. 
Further studies showed that Docetaxel treatment increased IKKε expression, whilst 
rapamycin and doxorubicin had no effect and reduced expression respectively. 
Encouraged by these results, I went on to test the effects of combined treatment of 
Amlexanox and Docetaxel in the neoadjuvant setting in vivo. 
Localised breast cancer has a favourable outlook, with around a 95% 5-year survival 
rate. Management of breast cancer varies greatly depending on the size; grade and 
receptor status however usually includes surgery, radiation and/or systemic delivery of 
therapy. Breast cancers, in humans can have a long latency period and relapses in 
secondary organs develop many years after the removal of the primary tumour. 
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Therefore, I used a model that recapitulates the human condition but in a shorter time 
space.  In this model, combined treatment of Amlexanox and Docetaxel reduced 
primary tumour growth and the number of overt metastases and enhanced metastasis-
free survival following surgical removal of the primary tumour, significantly more so 
than vehicle or either agent alone. Interestingly, combination treated mice also lost 
significantly more weight than vehicle treated mice or either agent alone. Of note, a 
study by Reilly and colleagues showed that Amlexanox prevented diet-induced obesity 
in mice by inducing thermogenesis, potentially explaining the reduction in weight loss 
(Reilly et al., 2013). 
A number of studies have previously shown that IKKε contributes to chemoresistance 
in various cancer models (Guo et al., 2009, Guo et al., 2010). However, no studies to 
date have combined Amlexanox with clinically relevant chemotherapies to reduce 
breast cancer cell growth in vitro or in vivo. Future studies, using platforms such as 
Nanostring, should aim to elucidate the mechanisms through which combined 
treatment of Amlexanox and Docetaxel reduce tumour growth and metastasis. In 
addition, further preclinical studies should also aim to assess different dosing and 
scheduling strategies in order to minimise potential side effects whilst maximising the 
observed anti-cancer effects of these two FDA-approved drugs, such that first in man 
trials could be carried out. Together, these data implicate IKKε in Docetaxel resistance 
and identify it as potential target for the treatment of breast cancer in combination with 
taxanes and other chemotherapies.  
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6 Chapter 6 
6.1 General Discussion 
The IKK/NFκB signalling pathway plays a role in the development of breast cancer 
(Lee et al., 2007, Hu et al., 2004), and inflammation-induced bone loss (Ruocco et al., 
2005, Idris et al., 2010, Otero et al., 2010, Park et al., 2007, Idris et al., 2009). Past 
studies have implicated both the canonical and non-canonical NFκB pathways in the 
regulation of breast cancer bone metastasis (Park et al., 2007), and recent work by our 
laboratories has found that pharmacological and cancer specific inhibition of these 
pathways reduces the progression of breast cancer osteolytic metastastasis (Idris et al., 
2009). Furthermore, a recent study by Zhang and colleagues showed that 
pharmacological inhibition of the IKK-related kinases, IKKε and TBK-1 significantly 
reduced ovariectomy-induced bone loss in vivo (Zhang et al., 2015).  
Interestingly, IKKε is the only IKK family member that has been deemed a breast 
cancer oncogene through its activation of the NFκB pathway (Boehm et al., 2007). 
However, its contribution to breast cancer bone metastasis has not been previously 
investigated. Here I provide evidence for a previously unknown role of IKKε in the 
regulation of skeletal tumour growth and breast cancer induced osteolysis. Previous 
studies have shown that overexpression of IKKε in normal mammary epithelial cells 
results in tumourigenesis and primary tumour growth (Boehm et al., 2007) . Originally, 
these  studies found no association with hormone receptor positive, HER2 
overexpressing or triple negative breast cancer using a small cohort of patients, 
however, after retrospectively assessing two independent large cohorts of breast cancer 
patients, this study has found that IKKε is amplified in around 20% of breast cancer 
patients and that its expression is associated with triple negative disease. This is in 
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agreement with previous studies that found IKKε to be linked to a subset of 
inflammation-driven triple negative breast cancers (Barbie et al., 2014). Furthermore, 
using larger patient cohorts, I have shown that high expression of IKKε is associated 
with a significantly shorter overall survival.  With this in mind I expanded on these 
aforementioned studies where I have shown that IKKε regulates breast cancer cell 
metastatic and osteotropic potential in  two independent triple negative breast cancer 
models.   
I demonstrated that overexpression of IKKε in an aggressive osteotropic variant of 
MDA-MB-231 (MDA-BT1) enhances cell growth, migration and invasion in vitro. 
Additionally, IKKε overexpression in MDA-BT cells also enhanced their ability to 
support osteoclastogenesis, a characteristic of bone metastatic breast cancers. The 
increased osteotropic capacities of these cells could be abrogated through siRNA-
mediated inhibition of the IRF3 or NFκB signalling pathways.   Preceding studies have 
shown that IKKε-induced transformation is dependent on p65 and not IRF3 and 
similarly, I have shown that IKKε driven growth is dependent on NFκB rather than 
IRF3. However, IKKε-driven osteoclast formation was driven by both NFκB and IRF3 
pathways, both pathways having been previously implicated in cancer cell secretion of 
inflammatory factors. Conversely, inhibition of IKKε in MDA-BT using either shRNA 
or pharmacologically using the IKKε/TBK-1 inhibitor, Amlexanox significantly 
reduced the growth, migration, invasion and ability to support osteoclast formation of 
osteotropic MDA-MB-231 breast cancer cells. Inhibition of IKKε was associated with 
a reduction in a variety of  proinflammatory cytokines, osteoclastic cytokines and 
matrix remodeling proteins. Furthermore, knockdown of IKKε in the aggressive 
osteotropic sub-clone of MDA-MB-231 cells significantly reduced skeletal tumour 
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burden and their ability to cause osteolysis in immuno-deficient mice thus implicating 
a prior unidentified role of IKKε in breast cancer skeletal tumour growth.  
Osteotropic breast cancer cells acquire the capability to promote osteolysis by 
influencing the differentiation of osteoclasts and osteoblasts (Yoneda and Hiraga, 
2005, Siclari et al., 2006, Zhang et al., 2013). We, and others, have previously reported 
that pharmacological inhibition of NFκB activity reduced bone loss through inhibition 
of osteoclastic bone resorption and stimulation of osteoblast differentiation (Otero et 
al., 2010, Chang et al., 2009b, Alles et al., 2010, Ruocco et al., 2005, Idris et al., 2010). 
The findings of the present study expand on these observations and demonstrate that 
pharmacological inhibition of IKKε/TBK-1 in the tumour bone microenvironment 
using the inhibitor, Amlexanox significantly reduced skeletal tumour growth and the 
resultant osteolysis caused by murine 4T1 breast cancer cells in immunocompetent 
mice. Mechanistic studies revealed that Amlexanox prevented the RANKL-induced 
phosphorylation of IκB in macrophages cells and RANKL induced osteoclast 
formation in vitro. These data further suggest that suppression of IKKε/NFκB in the 
bone microenvironment suppresses osteoclast formation and skeletal tumour burden in 
mice.  
IKKε and NFκB signalling have been implicated in the growth of primary breast cancer 
and its resultant metastasis to distant sites (Boehm et al., 2007, Barbie et al., 2014, Qin 
and Cheng, 2010, Park et al., 2007, Peramuhendige et al., 2018). With this in mind, we 
aimed to examine the efficacy of IKKε/TBK-1 inhibition using Amlexanox on primary 
tumour growth. As a single agent, Amlexanox reduced the tumour growth of syngeneic 
mouse breast cancer cells following orthotopic injection yet had no effect on the 
number of metastases or metastasis-free survival of mice following removal of the 
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primary tumour. Considering that targeting of a single pathway, is unlikely to provide 
long-term benefits in terms of metastatic spread, secondary tumour growth and overall 
patient survival in a disease as complex as breast cancer, we also evaluated the effects 
of Amlexanox in combination with FDA-approved Docetaxel (Zeichner et al., 2016).  
Amlexanox exerted a synergistic effect with Docetaxel resulting in a significant 
reduction of primary tumour growth, a reduction in the number of overt metastases and 
almost a 2-fold improvement in metastasis-free survival when compared to vehicle or 
either treatment as a single-agent. However, I did observe that mice given the 
combination treatment lost significantly more body weight than those treated with 
individual agents. From a clinical point-of-view weight loss and cachexia are serious 
complications of cancer and its treatments for breast cancer patients. In a similar vein, 
NFκB and cytokine production is a vital part of the innate immune system (Bonizzi and 
Karin, 2004). In addition breast cancer patients who take Docetaxel often suffer with 
neutropenia (Montero et al., 2005). Although not addressed in this study, subsequent 
studies should assess levels of white blood cells in mice treated with the combination 
of Amlexanox and Docetaxel.  Impairment of the immune system is a serious adverse 
complication for advanced breast cancer patients (Montero et al., 2005).   
Irrespective of the potential downsides, the observed synergism between Amlexanox 
and Docetaxel in inhibiting tumour growth and recurrent metastases in vivo suggests 
the combination of Docetaxel and therapeutic targeting of IKKε/TBK-1 may be of 
value of the treatment of metastatic breast cancers. In addition, these findings lend 
credence to the notion that blocking more than one aspect of metastatic breast cancer 
may have added benefits to chemotherapy in terms of clinical outcomes. 
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Collectively, the results of the present study demonstrate that IKKε plays a significant 
role in the regulation of bone metastasis, skeletal tumour growth, osteolysis and 
enhanced bone cell activity associated with advanced breast cancer. These results offer 
new insight into the crosstalk between breast cancer cells and bone cells of the tumour 
microenvironment, and provide evidence to show that disruption of IKKε/TBK-1, 
alone or in combination with clinically relevant chemotherapies such as taxanes, may 
have potential therapeutic efficacy in all stages of breast cancer.  
6.2 On-going and Future studies 
6.2.1 IKKε, bone metastasis and osteolysis  
In this study, I have demonstrated that pharmacological inhibition and knockdown of 
IKKε reduces breast cancer skeletal tumour growth and subsequent osteolysis. 
However, as the tumour growth and osteolysis were both reduced, we cannot yet deem 
if IKKε is necessary for breast cancer induced osteolysis or only a reduction in  skeletal 
tumour growth. In a similar manner, Amlexanox reduced breast cancer skeletal tumour 
growth and osteolysis. In order to address this issue, conditioned medium from MDA-
BT1 Mock and MDA-BT1 IKKεKD should be injected supracalvarially in to mice to 
induce osteolysis thus removing the effect of tumour growth inhibition (Marino et al., 
2014a, Marino et al., 2018a, Peramuhendige et al., 2018). In addition, it would be 
beneficial to address the effect of Amlexanox alone and in combination with Docetaxel 
on bone metastasis and skeletal colonisation. To do this, mice should be pre-treated 
with Amlexanox and/or Docetaxel before injection of bone-seeking breast cancer cells 
such as MDA-MB-231-I.V/B02 (Nutter et al., 2014, Peyruchaud et al., 2001). Similar 
studies have sought to establish the effects of combined administration of anti-cancer 
and anti-resorptive agents (zoledronic acid) on skeletal tumour burden (Ottewell et al., 
2008). However, owing to the fact that Amlexanox functions as both an anti-resorptive 
and an anti-cancer agent, the combination of Amlexanox and Docetaxel may be 
superior at inhibiting skeletal tumour growth in the osseous microenvironment.  
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6.2.2 Combined administration of chemotherapies and IKKε inhibitors 
In this study I have shown that IKKε is a potential druggable target for the treatment 
of metastatic triple negative breast cancer in the 20% of breast cancer patients whose 
tumours harbour CNVs of IKKε. These patients have a significantly shorter overall 
survival and these data suggests that targeting IKKε may provide life prolonging 
benefit.  With this in mind, future pre-clinical studies should aim to  optimise  the 
scheduling and dosing of   IKKε inhibitors with Docetaxel in order to reduce adverse 
side-effects and enhance the efficacy of the combination at reducing metastatic spread 
of breast cancers and improving patient survival. Furthermore, future studies could also 
address if inhibition of IKKε can be combined with targeted treatments. ER+ and 
HER2-enriched breast cancers are often treated with therapies such as tamoxifen and 
Herceptin respectively. Activation of NFκB has been shown to play a role in response 
to both tamoxifen and Herceptin resistance (Guo et al., 2010, Zhou et al., 2007, Kanzaki 
et al., 2016) therefore it may be pertinent to explore whether IKKε inhibition in 
combination with these and other chemotherapies may be of value in overcoming 
resistance and enhancing patient survival.  
In this study I have demonstrated that Amlexanox acts synergistically with rapamycin 
in triple negative breast cancer cells. Everolimus, a derivative of Sirolimus 
(Rapamycin) is approved for the treatment of metastatic ER+ breast cancers in 
combination with hormone-therapy (Baselga et al., 2012). The BOLERO-2 trial 
indicated that everolimus reduced the incidence of breast cancer progression in bone 
(i.e., development of new skeletal metastases) in the overall patient population (Gnant 
et al., 2013).  Furthermore, the combination of everolimus and hormone therapy 
(exemestane) reduced progressive bone disease in patients with bone metastases at 
baseline (Gnant et al., 2013). The reduction in skeletal lesion progression is postulated 
to be due the effects of everolimus on bone remodelling. Everolimus and Rapamycin 
have both been shown to inhibit osteoclast formation and resorption in pre-clinical 
models (Kneissel et al., 2004). Therefore, it would be interesting to test the added 
effects of Amlexanox in this combination as Amlexanox similarly reduces osteoclast 
formation and activity whilst inhibiting breast cancer skeletal growth.  
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6.2.3 Combined administration of immunotherapies and IKKε inhibitors 
The remarkable success of immunotherapies in cancers such as lung and melanoma, 
revealed the suppressive power of T-cell anti-tumour immunity (CiRen et al., 2016, 
Gandhi et al., 2018). Immunotherapies are treatments that aim to enhance the patient’s 
own immune system to eliminate cancer cells. Often in tumours, cancer cells have 
developed mechanisms to evade the innate and adaptive immune system. Tumour cells  
upregulate molecules like programmed death receptor ligand-1 (PDL-1) and others 
which bind to inhibitory receptors on the surface of T-cells such as programmed death 
receptor-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). These 
receptors function to induce T-cell anergy and apoptosis thus inhibiting an anti-tumour 
response. The most trialled and successful immunotherapies so far in breast cancer 
have been PD1 blockade with around 20% of patients exhibiting a significant 
improvement (Nanda et al., 2016), thus there is still a need to enhance the efficacy of 
immunotherapies for the treatment of breast cancer.  
Recently, it was demonstrated that IKKε acts as a negative regulator of CD8+ 
(cytotoxic) T-cell activity (Zhang et al., 2016). IKKε phosphorylates the transcription 
factor NFATc1 upon T-cell activation to inhibit prolonged activation of T-cells. Zhang 
and colleagues went on to demonstrate that knockout of IKKε in CD8+ reduces 
metastatic tumour burden and significantly improves survival in a mouse model of 
melanoma. In this study we demonstrated that IKKε inhibition reduces skeletal and 
primary tumour growth of breast cancer cells. Our unpublished data indicates that 
Amlexanox inhibits macrophage- and TNFα-induced expression of PDL1 by cancer 
cells (Gkanatsiou, Bishop and Idris, unpublished data) and thus, it would be interesting 
to assess how pharmacological inhibition of IKKε in combination with 
immunotherapies such as PD-1/CTLA-4 inhibitors affects primary and metastatic 
tumour growth of breast cancer cells in mouse models. Current work in our own 
laboratory is investigating the link between IKK/NFκB activity and anti-tumour T-cell 
responses. 
6.2.4 The role of IKKε inhibitors in obesity-driven breast cancers 
Obesity has become pandemic and studies suggest that a high-fat diet and obesity 
enhance the incidence of cancers including breast cancer (Meldrum et al., 2017). 
Current studies suggest that obese breast cancer patients have a significantly poorer 
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prognosis than their healthy counterparts (Protani et al., 2010).  In addition, it has been 
suggested that obesity enhances the development of metastasis via production of 
proinflammatory cytokines that alter the metastatic niche (Quail et al., 2017) 
In recent years, a number of studies have demonstrated that IKKε and TBK-1 are both 
upregulated in adipose tissue in response to a high-fat diet (Chiang et al., 2009). In 
addition, they demonstrated that targeted deletion of adipose IKKε prevented diet-
induced obesity and reduced adipose inflammation. Furthermore, in a follow-up study 
by Reilly and colleagues, it was shown that Amlexanox causes reversible weight loss 
and reduction of adipose inflammation in obese mice. In this study I have demonstrated 
that IKKε is overexpressed in ~20% of breast cancer patients. Therefore one could 
postulate that pharmacological inhibition of IKKε in obese patients may serve to reduce 
adipose inflammation and resultant metastatic spread. Future studies should assess the 
role of obesity in breast cancer growth and metastasis and whether pharmacological 
inhibition of IKKε can reduce or even prevent obesity driven breast cancers.  
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Appendices 
Appendix 1. List of reagents and manufacturers. 
Materials and reagents Supplier Experiment 
1.5ml Eppendorf tubes with cap 
Starlab, Milton Keynes, 
UK 
Western blot/TC 
12% Criterion™ TGX™ Precast Midi 
Protein Gel, 12+2 well 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
4-Nitrophenyl phosphate disodium salt 
hexahydrate powder 
Scientific laboratory 
supplies (SLS), 
Nottingham UK 
ALP 
Acetic Acid Glacial 
Sigma Aldrich, Dorset, 
UK 
TRAcP 
Agar powder 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
AlamarBlueTM reagent Invitrogen, Paisley, UK Viability 
Alizarin Red S 
Sigma Aldrich, Dorset, 
UK 
Mineralization 
Amlexanox 
Tocris Bioscience, 
Bristol, UK 
Drug treatments 
Anti-CD14 microbeads human 
Miltenyi Biotech, 
Gladbach, Germany 
Human OC 
BD microlance needles (19, 21 and 
25G) 
Fisher Scientific, 
Leicestershire, UK 
Isolation  
Bicinchoninic acid (BCA) solution 
Sigma Aldrich, Dorset, 
UK 
BCA assay 
Blasticidin 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Bovine serum albumin 
Sigma Aldrich, Dorset, 
UK 
Antibodies 
Carbenicillin 
Fisher Scientific, 
Leicestershire, UK 
Transfection protocol  
CAY10575 
Cambridge Bioscience, 
Cambridge, UK 
Drug treatments 
CAY10576 
Cambridge Bioscience, 
Cambridge, UK 
Drug treatments 
Centrifuge tubes 15ml 
Scientific laboratory 
supplies (SLS), 
Nottingham UK 
TC 
Centrifuge tubes 50ml 
Fisher Scientific, 
Leicestershire, UK 
TC/WB 
Cetyl pyridinium chloride monohydrate 
Sigma Aldrich, Dorset, 
UK 
Destain 
Clarity Western ECL Substrate 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
Collagenase (type 1A) 
Sigma Aldrich, Dorset, 
UK 
Primary OB 
Copper (II)-sulfate 
Sigma Aldrich, Dorset, 
UK 
BCA assay 
Corning™ Transwell™ Multiple Well 
Plate with Permeable Polycarbonate 
Membrane Inserts 
Corning, Flintshire, UK Invasion assay 
Cover slips 
Fisher Scientific, 
Leicestershire, UK 
Any histology 
DAKO 
Sigma Aldrich, Dorset, 
UK 
Invasion assay 
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Diethanolamin 
Sigma Aldrich, Dorset, 
UK 
TRAcP staining 
DL-Dithiothreitol (DTT) 
Sigma Aldrich, Dorset, 
UK 
Strip WB/ Sample 
buffer 
DMSO 
Sigma Aldrich, Dorset, 
UK 
Freezing 
DPX mounting medium 
Sigma Aldrich, Dorset, 
UK 
Slide mounting 
(TRAcP) 
Dulbecco's Minimum Essential 
Medium (DMEM) 
Fisher Scientific, 
Leicestershire, UK 
TC 
ECL solution 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
EDTA 
Sigma Aldrich, Dorset, 
UK 
Lysis 
EDTA Buffer, sterile` 
Sigma Aldrich, Dorset, 
UK 
OC 
Electrophoresis power supply 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
Ethanol Absolute 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Fetal calf serum (FCS) 
Fisher Scientific, 
Leicestershire, UK 
TC 
Filter Tips any size 
Starlab, Milton Keynes, 
UK 
General 
Glycine 
Acros organics, Geel, 
Belgium 
Sample buffer 
Histopaque 
Sigma Aldrich, Dorset, 
UK 
Isolation of PBMCs 
Human recombinant RANKL 
Gift from Dr. Patrick 
Mollat (Proskelia SASU) 
Osteoclast assays 
Hygromycin 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Jackson ImmunoResearch Anti-rabbit 
secondary ab  
Stratech Scientific Unit, 
Newmarket Suffolk, UK 
WB 
Kaleidoscope Pre-stained standards 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
L-Ascorbic acid 
Sigma Aldrich, Dorset, 
UK 
Mineralization 
Luria-Bertani (LB) Broth 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Magic Marker Invitrogen, Paisley, UK WB 
Magnesium chloride 
Sigma Aldrich, Dorset, 
UK 
ALP 
Matrigel, Growth Factor Reduced Corning, Flintshire, UK TC/Invivo 
M-CSF mouse recombinant 
R & D Systems, 
Abingdon, UK 
OC 
Methanol 
VWR International LTD, 
Leicestershire, UK 
WB 
Minimum Essential Medium (αMEM) 
Fisher Scientific, 
Leicestershire, UK 
TC 
MS Columns 
Miltenyi Biotech, 
Gladbach, Germany 
Human OC 
N,N-Dimethylformamide 
Sigma Aldrich, Dorset, 
UK 
TRAcP 
Napthol-AS-BI-phosphate 
Sigma Aldrich, Dorset, 
UK 
TRAcP 
Neubauer Haemocytometer Hawksley, Lancing, UK General/TC 
Paraformaldehyde Taab Lab, Berkshire, UK Fixation 
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Pararosanilin 
Sigma Aldrich, Dorset, 
UK 
TRAcP 
Penicillin/Streptomycin 
Fisher Scientific, 
Leicestershire, UK 
TC 
Phosphatase inhibitor cocktail  
Fisher Scientific, 
Leicestershire, UK 
WB 
Phosphate buffered saline 
Fisher Scientific, 
Leicestershire, UK 
TC 
Pierce™ Bovine Serum Albumin 
Standard Pre-Diluted Set 
Fisher Scientific, 
Leicestershire, UK 
BSA 
Pipette tips (all sizes) 
Starlab, Milton Keynes, 
UK 
General 
Polybrene 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Polyethylenimine  
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Protease inhibitor cocktail  
Sigma Aldrich, Dorset, 
UK 
WB 
Proteome Profiler XL Cytokine Array 
Kit 
R & D Systems, 
Abingdon, UK 
WB 
Puromycin 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Roswell Park Memorial Institute 
(RPMI) 
Sigma Aldrich, Dorset, 
UK 
TC 
Scalpel, disposable 
VWR International LTD, 
Leicestershire, UK 
TC 
Scissors (fine points and spring bow 
handles) 
S Murray & Co Ltd, 
Surrey, UK 
TC 
Sodium acetate trihydrate  
VWR International LTD, 
Leicestershire, UK 
TRAcP  
Sodium barbiturate 
Sigma Aldrich, Dorset, 
UK 
TRAcP  
Sodium chloride 
Sigma Aldrich, Dorset, 
UK 
General 
Sodium dodecyl sulphate (SDS) 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
Sodium hydroxide 
VWR International LTD, 
Leicestershire, UK 
Decalcification 
Sodium phosphate 
Sigma Aldrich, Dorset, 
UK 
Destain 
Sodium tartrate dibasic dihydrate 
Sigma Aldrich, Dorset, 
UK 
TRAcP  
Starguard® laboratory gloves 
Starlab, Milton Keynes, 
UK 
General 
Sterile filter (0.2 and 0.45μm) 
Pall lifesciences, 
Portsmouth, UK 
TC 
Stripettes (5, 10, 25 and 50ml)  
Fisher Scientific, 
Leicestershire, UK 
General 
Superfrost Plus™ Adhesion 
Microscope Slides 
Fisher Scientific, 
Leicestershire, UK 
Histo 
Syringes (all sizes) 
Fisher Scientific, 
Leicestershire, UK 
In vivo 
Tissue culture 25, 75, 175cm2 flasks 
Fisher Scientific, 
Leicestershire, UK 
TC 
Tissue culture microplates (6, 12, 24, 
48 and 96-well plates) 
Corning, Flintshire, UK TC 
Transblot Turbo midi Size PVDF 
membrane 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
Transblot Turbo midi Size Transfer 
stacks 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
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Tris 
Sigma Aldrich, Dorset, 
UK 
WB 
Tris-Base 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Tris-EDTA buffer 
Sigma Aldrich, Dorset, 
UK 
WB 
Tris-Glycine buffer 10x 
Bio-Rad Laboratories, 
Hertfordshire, UK 
WB 
Tris-HCl 
Sigma Aldrich, Dorset, 
UK 
Transfection protocol  
Triton X-100TM 
Sigma Aldrich, Dorset, 
UK 
RIPA 
Trizma® base 
Sigma Aldrich, Dorset, 
UK 
WB 
Trizma® hydrochloride 
Sigma Aldrich, Dorset, 
UK 
WB 
Trypan Blue 
Fisher Scientific, 
Leicestershire, UK 
TC/In vivo 
Trypsin/EDTA 
Sigma Aldrich, Dorset, 
UK 
TC 
Tween-20 
Acros organics, Geel, 
Belgium 
WB 
Western blot tips 
Starlab, Milton Keynes, 
UK 
WB 
Xylene 
Sigma Aldrich, Dorset, 
UK 
Histology 
β-glycerophosphate disodium 
Sigma Aldrich, Dorset, 
UK 
Mineralization 
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Appendix 2. Solutions for TRAcP staining of osteoclasts in vitro. 
Solution Method 
Naphthol-AS-BI-phosphate 
10 mg/ml Naphthol-AS-BI-phosphate in 
Dimethylformamide 
Veronal buffer 
1.17 g sodium acetate anhydrous and 2.94g sodium 
barbiturate both dissolved in 100 ml of dH2O 
Acetate buffer 
0.82 g sodium acetate anhydrous dissolved in 100 ml 
of dH2O and pH adjusted to 5.2 with 0.6 ml glacial 
acetic acid made up to 100 ml with dH2O 
Pararosanilin 
1 g Pararosanilin dissolved in 20 ml of dH2O and 5 ml 
of 5M HCl added to it 
The solution was heated carefully whilst stirring and 
filtered after cooling. 
TRAcP Staining Solution 
 
The TRAcP staining solution was freshly prepared by 
mixing solution A and B as outlined below. 
Solution A 
150 ml of Napthol-AS-BI-phosphate 
750 ml of Veronal buffer 
900 ml Acetate buffer 
900 ml Acetate buffer with 100 mM Sodium Tartate 
Solution B 
120 ml of Pararosanilin 
120 ml of Sodium Nitrate (4% w/v) 
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Appendix 3. Solutions for Alkaline phosphatase detection in osteoblasts 
Solution Method 
Diethanolamine (DEA)/MgCl2 buffer 
1 M DEA and 1 M MgCl2 made up in 100 ml 
dH2O and pH adjusted to 9.8. Left at room 
temperature for 24 hours 
ALP Lysis buffer 
0.05% Triton X-100 added to DEA/MgCl2 
buffer 
p-Nitrophenol standard solution 
p-Nitrophenol standards (1.25 – 30 nM) 
prepared in lysis buffer 
Substrate solution 
20 mM p-nitrophenol-phopshate made up in 
DEA/MgCl2 buffer and pH adjusted to 9.8 
Appendix 4. Buffers for Western blotting 
 
  
Solution Method 
RIPA Lysis buffer 
1% Triton 100X, 0.5% (w/v) Sodium 
Deoxycholate, 0.1% (w/v) Sodium Dodecyl 
Sulphate (SDS), 50 mM Tris-HCl (pH 7.4) and 
150 mM Sodium Chloride were dissolved in 
dH2O. 
20X TBS 
60.5g TrisBASE  in 1L dH2O adjust pH to 7.9 
with 79g TrisHCl. Add 3M (175.32g) NaCl.  
1x TBS-Tween (TBST) wash buffer 
Dilute 20X TBS in  dH2O (1:19). Add 0.1% 
Tween-20. Shake well. 
5X Sample loading buffer 
0.63g of TrisHCl in 5.2ml of  dH2O (pH6.8; 
alter pH with TrisBase), 1g of  DL-
Dithiothreitol (DDT),  Add 1.3g 
SDS  and put at 37˚ degrees on the 
stirrer to dissolve 
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Appendix 5. Buffered Formalin for fixation 
 
Appendix 6. Solutions for decalcification of mouse hind limbs 
 
Appendix 7 . List of Antibodies 
 
Solution Method 
10% buffered formalin 
8g sodium dihydrogen orthophosphate 
dehydrate, disodium hydrogen orthophosphate 
dehydrate, 37% formaldehyde in 2L warmed  
dH2O.  
Solution Method 
EDTA-decal 
500g EDTA-disodium salt in 3.5L of   dH2O 
added gradually with continual stirring, 
followed by addition of 50g sodium hydroxide 
pellets. Store at 4°C 
Antibody Host Species Supplier 
anti-IKKα rabbit Cell Signalling Technologies 
anti-IKKβ rabbit Cell Signalling Technologies 
anti-IKKε rabbit Cell Signalling Technologies 
anti-TBK-1 rabbit Cell Signalling Technologies 
anti-IRF3 rabbit Cell Signalling Technologies 
anti-p65 rabbit Cell Signalling Technologies 
anti-Phospho-IκBα rabbit Cell Signalling Technologies 
anti-IκBα rabbit Cell Signalling Technologies 
Anti-actin rabbit Sigma Aldrich 
Anti-rabbit secondary goat Jackson Laboratories 
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 Figure 2. Schematic diagram of tumourigenesis and the metastatic process. 
 Figure 3. Patterns of breast cancer metastatic dissemination. 
 Figure 5. The bone metastatic process. 
 Figure 6. Canonical and non-canonical NFκB activation.  
 Figure 7. IKKε/TBK-1 signalling pathways in innate immunity. 
 Figure 8. Existing mechanisms of IKK  oncogenic activity. 
 
